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1. BACKGROUND 
Bicuspid aortic valve (BAV) is the most common congenital heart defect, being 
present in almost 1% of the general population (1-3). The prevalence of BAV 
depends on ethnicity and gender, as BAV is more common in Caucasians and 
males, however these factors have not always been considered in analyses 
of BAV prevalence (4;5). The male to female ratio of BAV is estimated to be 
approximately 2:1 (3;6).  
BAV is associated with an increased risk of aortic valve stenosis, aortic 
regurgitation, as well as thoracic aortic dilation, occurring in approximately 
40-60%, and aortic dissection, as compared to patients with a tricuspid 
aortic valve (TAV) (7;8). Aortic dilation was long thought to be secondary 
to the valve disease itself, but increasing evidence points to a common 
origin for both sites of pathology (3;6;9;10). Although the relative risk of 
aortic dissection is lower than in patients with Marfan syndrome (MFS), 
there are likely as many, if not more, dissections in patients with BAV 
given the significantly greater prevalence of this disease (11). Hence, BAV-
associated aortic wall pathology has important public health implications and 
has therefore long been a subject of intensive clinical and basic research. 
Optimal management of patients with BAV and associated ascending aortic 
dilation requires an approach, carefully assessing various risk factors of 
the aortic valve and wall and discerning individual indications for ongoing 
surveillance, medical management, and surgical intervention.
Operative management of aortic dilation presents a complicated clinical 
problem given the unpredictable lifetime risk of morbidity and mortality 
related to aortic wall pathology in BAV and major surgical intervention 
required to address these risks (11-13). This is not a new clinical issue; the 
complexities of aortic wall disease have long been appreciated (14;15) but 
our understanding and ability to diagnose and intervene have also evolved 
considerably. Recommendations on when to intervene surgically for thoracic 
aortic dilation for BAV patients have been progressively expanded over the 
past 15 years. BAV is now widely considered to be an independent risk factor 
for an acute aortic event, which has led surgeons to consider whether an 
additional concomitant aortic procedure should be performed at the time of 
aortic valve replacement. 
The fact that some BAV patients can present with severe forms of aortic wall 
pathology (16), with an early onset in life (17), and clear familiar inheritance 
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for aortic complications (10) has led to greater general aggressiveness 
towards all BAV-related vascular wall pathology. With some arguing that 
aortic dimensions indicating surgical intervention in BAV should be similar 
to those used for other genetic diagnosis with an increased risk for aortic 
complications, such as MFS (18-20). Absolute aortic diameter remains 
the most used clinical parameter to guide intervention, although indexed 
and non-size predictors have also been proposed (21-23). Guideline 
recommendations for surgical intervention based on the ascending aortic 
diameter have decreased from ≥5 cm (24-27) to ≥4.5 cm for patients 
with BAV undergoing concomitant aortic valve replacement, with others 
proposing even lower thresholds for intervention (21;28-30). However, these 
recommendations remain controversial (13;31;32) as there is still no clear 
understanding of how the dimensions of the ascending aorta change over 
long term in patients with BAV. A great number of BAV patients show a less 
severe natural clinical course (12). The debate will only calm down when our 
ability to stratify BAV patients will improve, so that indications will be less 
subjective and more individualized. Therefore among the most important 
tasks at hand for the research in this field is to define and validate tools 
and criteria for risk stratification, in order to more rationally guide surgical 
management. 
To reach this, a detailed knowledge of the pathophysiology of aortic wall 
pathology in BAV and the clinical and genetic factors increasing the risk of 
aortic complications is necessary. 
As an introduction to this thesis, an overview of the current status of knowledge 
of aortic wall pathology in bicuspidy will be provided. First, the cardiac 
anatomy will be described, along with the embryologic development of the 
cardiac valves. Furthermore, the two most discussed possible pathogenetic 
mechanisms of aortic wall pathology in BAV: haemodynamics and intrinsic 
wall abnormalities will be discussed and compared. Finally, the aims of this 
thesis and the chapter outline are presented. 
2. CARDIAC ANATOMY 
The main function of the cardiovascular system is to transport nutrients and 
oxygen to the entire body. The heart can be thought of as two pumps in 
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series that send a fluid (blood) through tubes (vessels) that eventually return 
to the pump. 
Each ‘pump’ in the heart is made up of two chambers; an atrium and a 
ventricle, giving the heart a total of four chambers. The atria receive blood 
returning from the circulation and pass it to the ventricles. The ventricles 
make up most of the heart’s volume, with the left ventricle being the larger 
of the two. The ventricles receive blood from the atria and pump it through 
arteries to the body. 
The heart uses a series of valves to ensure that blood flows in one direction 
into and out of the heart. Heart valves are made of tough, flexible fibrous 
tissue that are oriented in such a way that blood can only go through the 
valve in one direction. A valve only opens when the blood exerts enough 
pressure on it, forcing it to open for blood to flow through. When this pressure 
drops, the valve returns to its originally closed position, preventing blood 
from flowing in the wrong direction. A pressure gradient is developed as 
blood flows through the body, and blood only flows from a high pressure to 
a lower one. 
Like the heart chambers there are four heart valves, two atrioventricular valves 
and two semilunar valves. An AV valve is located between each atrium and 
ventricle, with the tricuspid valve on the right and the mitral valve on the left. 
The valve opens when the atrial pressure is greater than ventricular pressure. 
When ventricular pressure exceeds atrial pressure, the valve closes again. 
The area of the valve cusps are about twice that of the passageway they 
cover, creating a large overlap of the cusps when they close. This overlap 
helps to prevent the backflow of blood (regurgitation) into the atrium. 
A semilunar valve is located between the right ventricle and pulmonary trunk 
(pulmonary valve) and the left ventricle and the ascending aorta (aortic valve). 
Similar to the AV valves, when left or right ventricular pressure exceeds aortic 
or pulmonary artery pressure, the valve opens. When ventricular pressure 
decreases, the three cusps of the valves close, preventing blood from flowing 
back into the ventricle. 
The heart has two atria and two ventricles because there are two different 
blood flow circulation paths. The circulation path controlled by the right side 
of the heart is a low-pressure system known as the pulmonary circulation. 
Oxygen depleted blood enters the right atrium through the caval veins and 
coronary sinus and is pumped to the lungs by the right ventricle through the 
pulmonary trunk. The blood receives oxygen in the lungs and is sent back to 
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the left side of the heart through the pulmonary veins and is returned to the 
left ventricle through the left atrium. The left ventricle pumps the oxygen-rich 
blood through the aorta to the rest of the body. As the blood flows farther 
from the body, oxygen concentration is diminished by exchange with CO2 
in the body tissues and organs. The blood returns to the heart through the 
caval veins in the right atrium, depleted of oxygen, completing the cycle. 
This circulation path is known as the systemic circulation. Due to the large 
distance the blood travels, this is a high-pressure system. After entering the 
right atrium, the blood repeats the two circulatory paths. 
Figure 1. Schematic overview of the heart. 
AA: ascending aorta; AoV: aortic valve, LA: left atrium; lPA: left pulmonary artery; LV: left 
ventricle; MV: mitral valve; PT: pulmonary trunk; PV: pulmonary valve; Pv: pulmonary vein; 
RA: right atrium; rPA: right pulmonary artery; RV: right ventricle; TV: tricuspid valve; VCI: vena 
cava inferior; VCS: vena cava superior.
Pv
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Throughout the cardiac cycle, blood pressure increases and decreases. 
The aorta is an elastic artery (with a large number of collagen and elastin 
filaments in the tunica media), which gives it the ability to stretch in response 
to each pulse to maintain a relatively constant pressure in the aorta despite 
the pulsating nature of the blood flow. This is called the ‘Windkessel effect’ 
of the elastic artery. 
3. CARDIAC EMBRYOLOGY
a. Semilunar valves
The heart is derived from the anterior splanchnic mesoderm. It forms from two 
crescent-like cardiogenic plates. After fusion of these plates in the midline, 
a primary heart tube is formed (33) that shows peristaltic contraction at 3 
weeks of development in a human embryo. The primary cardiac tube is lined 
on the inside by endocardium and on the outside by myocardium consisting 
of about two cell layers. A thick basement membrane is sandwiched in 
between referred to as cardiac jelly, containing water-binding extracellular 
matrix molecules including hyaluronic acid. At a later stage the cardiac 
jelly is restricted to endocardial cushions lining the myocardial outflow 
tract and the atrioventricular canal (34). The myocardium-lined primary 
heart tube initially consists of a small atrial component (connected to the 
sinus venosus), an atrioventricular canal, a ventricular inflow tract and a 
small outflow tract (connecting to the aortic sac). On the borderline of the 
ventricular inflow tract and the outflow tract a bulboventricular or primary 
fold is present. These cardiac components are derived from the mesoderm 
of the first heart field. The addition of dorsal cardiac mesoderm positioned 
between the primary heart tube and the primitive gut, the so-called second 
heart field (SHF) mesoderm, is essential for the subsequent development 
of all cardiac components. This SHF mesoderm can reach the heart tube 
at both the arterial (anterior SHF) and venous poles (posterior SHF). At the 
arterial pole the anterior SHF-derived mesoderm supplies the myocardium 
of the right ventricle up to the right side of the ventricular septum. The SHF 
also contributes to the semilunar valves and the walls of the great arteries.
For subsequent remodeling, septation, valve formation and coronary 
vascular development two other cell populations are added to the heart, 
being the neural crest cells and the epicardium. Semilunar valve formation 
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includes remodeling of the distal end of the endocardial outflow tract 
cushions that derive from the cardiac jelly and receive mesenchymal cells 
from the overlying endocardium. During normal development, separation of 
the arterial orifice level results in three semilunar valve cusps in the aortic 
and pulmonary orifices. Abnormal development includes both the occurrence 
of deficient numbers (as well as excessive numbers) of valve cusps (35). 
Several gene mutations have now been reported in the human population to 
play a role in the development of BAV, which will be further discussed in the 
paragraph ‘Genes related to BAV in animal models and human population’. 
However, the exact cause of BAV has not been elucidated, there are even 
indications that the anterior SHF is involved and that not only the aortic valve 
is abnormal but the wall of the ascending aorta is also included (35).
The mature cusps of the aortic valve are usually less than 1 mm thick and 
consist of three layers: the collagen-rich fibrosa located at the aortic side of 
the valve, the ventricularis with an abundance of elastin and located at the 
ventricular side of the valve, and, in between these, the spongiosa, which 
rich in proteoglycans.   
b. Ascending aorta
Recent lineage tracing studies in transgenic mice with Nkx2.5 (5) have shown 
that SHF progenitor cells give origin to three specific cell lines: (1) outflow 
tract and right ventricular myocardium, (2) endothelial-derived endocardial 
cushion cells, which are in part derived from the endothelium and (3) vascular 
smooth muscle cells (VSMCs) of the great arteries (36). Recently, Harmon et 
al presented data on the boundary where SHF-derived VSMCs meet neural 
crest cell-derived VSMCs at the base of the aorta (5). The SHF contribution to 
the aortic media then forms a vertical seam complementary with neural crest-
derived VSMCs (36). Next to contributing to the vascular wall, a population 
of neural crest cells migrates to the outflow tract cushions where they are 
important for semilunar valve formation and outflow tract septation (37;38). 
Preliminary data show a contribution of the arterial epicardium to the VSMCs 
of the ascending aorta (39).
The wall of the ascending aorta consists of three basic layers: the internal 
layer, tunica intima, which contains a single layer of endothelial cells and a 
subendothelial thin layer of connective tissue and VSMCs; the middle layer, 
tunica media, which mainly contains VSMCs, elastic fibers and collagen; 
and the outer layer, tunica adventitia, which predominantly contains loosely 
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organized collagen fibers, small blood vessels and fatty tissue. The intima 
and the media are separated by the lamina elastica interna and the media is 
separated from the adventitia by the lamina elastic externa.   
The aortic media is arranged in lamellar units where two elastic lamellae 
enclose VSMCs, which are surrounded by extracellular matrix that contains 
microfibrils, small elastic fibers, collagen, and proteoglycans. The extracellular 
matrix interconnects the two elastic lamellae as well as connecting the 
elastic lamellae with the VSMCs (40-42). Elastin fibers from the lamellae 
protrude between thick collagen fibers (containing collagen I, III, and V) and 
together with microfibrils of fibrillin-1 and collagen VI (also containing some 
fibronectin) facilitate the VSMCs-elastin interaction (43).
4. GENETIC BASIS OF BAV 
In 1866 it was already suggested by Peacock that BAV is congenital in origin 
(44). It has since then been confirmed that BAV is indeed related to other 









Figure 2. Transverse sections of the aortic wall stained with hematoxylin-eosin (HE) and 
resorcin fuchsin (RF).
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aortic coarctation (45). BAV further is found co-existing with hypoplastic left 
heart syndrome and these two conditions are to some extent genetically 
linked (46). Shone’s syndrome is characterized by a supravalvular mitral ring, 
parachute mitral valve, subaortic stenosis, and aortic coarctation. Bolling et 
al. reported that 63% (19/30) of their patients with Shone’s syndrome had a 
BAV (47). William’s syndrome is a neurodevelopmental disorder that is also 
associated with cardiovascular conditions such as supravalvular stenosis, 
peripheral pulmonary artery stenosis, aortic coarctation, and BAV (48). BAV 
is found in about 25% of individuals with Turner’s syndrome and is present 
in 95% of patient with Turner’s syndrome who suffer from aortic dissection 
(49;50). BAV has been noted in conjunction with ventricular septal defects 
(51), patent ductus arteriosus, (52;53) and atrial septal defects. BAV is also 
associated with left coronary artery dominance (54;55).
Heritability of BAV formation is suggested to be as high as 89% (56). BAV has 
an inheritance consistent with an autosomal dominant pattern with reduced 
penetrance (57;58) and about 9% of first-degree relatives of BAV individuals 
will also have the malformation (56;59). BAV formation has been linked to 
several different chromosomes and gene mutations, which suggests complex 
inheritance (57;60-62).   
5. GENES RELATED TO BAV IN ANIMAL MODELS AND HUMAN 
POPULATION 
Since BAV is a congenital malformation, it is reasonable to expect that 
mutations in genes encoding transcription factors, extracellular matrix 
components, and proteins of signaling pathways that are implicated in 
valvulogenesis are important in BAV formation (Table 1) (63-67).  
Linkage analyses revealed an association between BAV and chromosome 
9q34-35 and subsequently NOTCH1 in humans (60). NOTCH1 encodes 
a transmembrane receptor and its signaling pathway is important in 
developmental processes and organogenesis. NOTCH signaling is highly 
conserved in evolution and, regardless of what animal model is used, 
perturbations in the pathway inevitably lead to developmental abnormalities 
(review (68). NOTCH1 is expressed in endocardial cells found in the common 
outflow tract in mouse embryos (69) and NOTCH signaling is suggested to 
have a role in BAV formation and valve calcification (60). Smad6 (SMAD 
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Gene Description Function 
Acvr1 Activin A receptor, Type 1 (Alk2) Member of the TGFβ 
superfamily 
EGF superfamily Epidermal growth factor Signaling pathway 
eNOS Endothelial nitric oxide, NOS3 Signaling pathway 
ErbB V-erb-b2 erythroblastic leukemia 
viral oncogene homolog 
Epidermal growth factor 
receptor signaling 
pathway/family of receptor 
tyrosine kinases 
GATA5 GATA binding protein 5 Transcription factor 
KCNJ2 Inward- rectifying potassium 
channel Kir2.1 
Voltage-gated potassium 
channel activity involved in 
cardiac muscle action potential 
repolarization 
NF-1 Neurofibromin 1 Ras signaling pathway 
NFATc1 Nuclear factor of T cells 
cytoplasmic 1 
Transcription factor 
Nkx2-5 NK2 homeobox 5 Transcription factor 
NOTCH1 Family of transmembrane 
receptors  
Signaling pathway 
Smad6 SMAD family member 6 Signal transducer and 
transcriptional modulator in 
BMP signaling 
Sox9  SRY (sex determining region Y)-
box 9 
Transcription factor 
TGF-β superfamily  Transforming growth factor beta Signaling pathway 
Tbx20  T-box 20 Transcription factor 
Twist-1 Twist homolog 1 Transcription factor 
VEGF  Vascular endothelial growth 
factor   
Signaling pathway 
Wnt/β-catenin Canonical 
Wnt signalling pathway.  
Wingless type MMTV integration 
site family/cadherin-associated 
protein beta 
Wnt, growth factor; β-catenin, 
co- activator of transcription 
factors 
 
Table 1 Genes related to valvulogenesis in BAV formation
family member 6) encodes a protein that functions as a signal transducer 
and transcriptional modulator in BMP signaling (bone morphogenetic protein, 
a member of the TGF-β superfamily). Smad6 is expressed in the embryonic 
outflow tract in mice and genetic variants of Smad6 predispose for BAV in 
humans (70). BAV has also been linked to chromosomes 18q22, 5q21 and 
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13q34; however which specific genes within these loci are associated with 
BAV is unknown (61). The empirical association of BAV and hypoplastic left 
heart syndrome has also been confirmed genetically (46).The mutation of 
the inward-rectifying potassium channel Kir2.1 (KCNJ2) found in patients 
with Andersen’s syndrome (a combination of characteristic physical features 
and arrhythmias) has also been suggested in BAV disease (62).
A number of other genes are implicated in BAV formation in mice but their 
relevance in humans remains to be shown. These include Nkx2-5 (NK2 
homeobox 5, transcription factor) (71), eNOS (endothelial nitric oxide, Nos3) 
(72), GATA5 (GATA binding protein 5, transcription factor) (73), and Acvr1 
(activin A receptor, Type 1, alias Alk2, member of the TGF-β superfamily) 
(74). There is a marked phenotypic variability in individuals with BAV; it is 
not always familial and/or associated with other cardiac malformations. 
Furthermore, not all individuals with BAV develop valve and/or aortic disease 
and therefore might remain unidentified (75-77).
6. BAV PHENOTYPE  
It is now recognized that BAV should not be considered as one single entity, 
but that distinct morphological phenotypes are distinguishable based on 
the presence and number of raphe, as classified by Sievers et al. (6) Most 
BAVs consist of one free and two cusps that are conjoined (or have failed 
to separate during embryonic development). The term ‘raphe’ defines the 
conjoined area of the two underdeveloped cusp turning into a malformed 
commissure between both cusps (6). Variable orientation of the raphe/ fused 
commissure in relation to the sinus are seen: fusion of the right (RCC) and 
left coronary cusp (LCC) with a raphe (RCC/LCC), fusion of the right and non-
coronary (NCC) cusp with a raphe (RCC/NCC), fusion of the left and non-
coronary cusp with a raphe (LCC/NCC). This orientation of the raphe defines 
the subcategory in the classification of Sievers et al. referring to three types: 
type 0, valve with no raphe; type 1, valves with one raphe; and type 2, valves 
with two raphe. In our pathology papers we used a modified classification: 
type 1: RCC/LCC, type 2: RCC/NCC, type 3: LCC/NCC (Fig. 3). 
BAV phenotype is suggested to have an incomplete heritability (78) i.e. 
families with several BAV individuals will not all have the same BAV 
phenotype. The etiology of the different BAV phenotypes seems to differ. Mice 
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deficient in eNOS or Gata5 develop RCC/NCC BAVs (72;73;79).The RCC/
NCC phenotype is thought to be the result of perturbations in the formation 
of endocardial cushions of the common outflow tract that occurs before 
septation of the outflow tract (79). By contrast, the RCC/LCC phenotype is 
suggested to be the result of an abnormal septation of the common outflow 
tract and to be linked to neural crest cell function on the basis of studies in 
inbred Syrian hamsters (79).
7. BAV AND AORTIC WALL PATHOLOGY 
a. General introduction
BAV is usually asymptomatic in children and young adults and is commonly an 
incidental finding. Symptoms and physical findings associated with BAV are 
mainly related to the associated valvular dysfunction, being aortic stenosis, 
aortic regurgitation or a combination of both conditions. Ascending aortic 
dilation is rarely symptomatic whereas aortic dissection is usually associated 
with an acute onset of severe chest and/or back pain and is accompanied by 
signs of organ dysfunction and shock.
Some BAVs have an accelerated progression of valve thickening and 
calcification which is generally evident in the fourth decade of life (77;80) 
Figure 3. Schematic overview of BAV morphologies. 
Drawings are oriented in echocardiographic, i.e. inferior, view of the aortic valve. The three 
major valve morphologies observed in BAV patients are described as three different types 
based on the valve cusp orientation: fusion of the right (RCC) and left coronary cusp (LCC) 
with a raphe (RCC/LCC) (type 1), fusion of the right and non-coronary (NCC) cusp with a 








150119_versie 3.indd   21 19-1-2015   22:56:24
22 chapter 1
1
(5;81;82). The valvular changes frequently progress into clinically significant 
valve stenosis (83). Excessive folding and creasing as well as asymmetrical 
and turbulent flow patterns due to a morphological ‘stenosis’ are thought 
to cause increased stress and subsequently early regurgitation, (not 
secondary to infective endocarditis) (77;80) Furthermore, BAV individuals 
are predisposed to infective endocarditis (77;80). The risk of bacterial 
colonization is greater owing to increased shear stress and subsequent 
endothelial damage which in turn leads to platelet aggregation and fibrin 
deposition. Microorganisms tend to adhere to and multiply in these platelet-
fibrin vegetations (84-86) (review (87)). BAV phenotype has been proposed 
to affect the susceptibility for valve disease; BAV individuals with a RCC/
NCC configuration are prone to develop valve disease in childhood, whereas 
BAV individuals with a RCC/LCC configuration tend to develop valve disease 
in adulthood (78). All together approximately 50% of individuals with BAV will 
have to undergo aortic valve surgery (12).
BAV individuals have an age-adjusted relative risk of aneurysm formation 
of approximately 86% in comparison with the general population, and 
about 25% of BAV individuals will develop indication for ascending aortic 
replacement (12).  
Aortic dissection is caused by disruption of the intimal layer of the aortic 
wall, which results in bleeding between the aortic wall layers and creation of 
a dissection plane (88;89). The condition is associated with malperfusion of 
vital organs and predisposes for aortic rupture. The risk of aortic dissection is 
eight-fold higher in BAV individuals than in the general population (12).
b. Aortic valve stenosis 
Aortic valve stenosis is the most frequent valvular dysfunction associated 
with BAV (80). The underlying mechanisms of aortic valve stenosis formation 
are believed to be similar to those of atherosclerosis (for review see (90)). A 
number of risk factors that are associated with aortic valve calcification have 
been identified and these are similar to those of atherosclerotic disease; 
however, a distinction between BAV and TAV has not been made (91;92). 
Even though BAV patients present with significant valve stenosis earlier in 
life than patients with TAV, the pathogenesis of the valve lesion is thought 
to be similar, however not identical (93-95). eNOS deficiency and signaling 
pathways such as NOTCH and Wnt/β- Catenin, which are implicated in BAV 
formation, have also been suggested to be important in valve calcification, 
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possibly providing a link between the malformation and its most frequent 
valvular pathology (60;96;97). 
An association between aortic valve disease and BAV phenotype has been 
proposed; however there are conflicting results. Beppu et al. found a more 
rapid progression of valve stenosis in BAVs with a RCC/LCC BAV (82). 
Fernandes et al. found an association between valve disease (both stenosis 
and regurgitation) and RCC/NCC BAVs (98). Conversely, Tzemos et al 
concluded that BAV phenotype is not an independent predictor of cardiac 
events (including aortic valve disease) (80).
c. Aortic valve regurgitation 
Aortic valve regurgitation is the second most common valvular lesion 
associated with BAV and is often secondary to valve calcification. BAV 
patients with isolated valve regurgitation are in general younger than 
those with combined valve stenosis/regurgitation. Further mechanisms of 
incompetence include incomplete closure of cusps, redundancy of the fused 
cusps leading to prolapse, infective endocarditis, dilation of the aortic root, 
and aortic dissection (5;86;99-102). 
d. Aortic dilation: structural wall abnormalities or shear stress?
In patients with a normal TAV histological changes of the aortic wall related 
to age as well as aortic pathology (dilation/dissection) are associated with 
medial degeneration (focal loss of smooth muscle cell nuclei), regardless 
of aortic location (i.e., ascending, descending, or abdominal) (103;104). 
Histologic changes in BAV patients are controversial in the current literature. 
More severe histopathological features have been described in BAV patients 
as compared to TAV patients (105;106). Furthermore, elastic fragmentation 
is more pronounced in BAV patients than in TAV patients with isolated valve 
pathology (107) and an association of BAV phenotype and the severity of 
medial degeneration has been reported (108). Whereas others have shown 
that BAV exhibits less histopathologic features (109).
The pathogenesis of aortic dilation and aneurysm formation of the ascending, 
descending, and abdominal aorta differs (110;111). Experimental studies 
have shown that the embryonic origin of the cells populating the aorta in 
mammals differs with the aortic location. Neural crest cells give rise to the 
ascending aorta, aortic arch, pulmonary trunk, and ductus arteriosus. By 
contrast, cells originating from the mesoderm populate the descending 
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aorta and subclavian artery (112;113). Whether developmental differences 
have an impact on differences in the underlying pathogenesis of aortic 
dilation related to aortic location (i.e., ascending, descending, abdominal) 
is not known. Furthermore, ascending aortic dilation in TAV, but not BAV, is 
associated with inflammation and immune response (114).    
In addition to differences in the severity of medial degeneration and 
inflammatory profile between BAV and TAV patients with aortic dilation, 
several other factors related to BAV-associated aortic dilation have been 
reported as follows: 1) dilation of the ascending aorta is more progressive in 
BAV, as compared to TAV, even after aortic valve replacement (30;115); 2) 
children (and young adults) with BAV have larger dimensions of the aortic 
root/ascending aorta and impaired aortic elastic properties compared with 
children with TAV (116-118) 3) approximately one third of first degree relatives 
of BAV patients (with normally functioning TAVs) have dilated aortic roots 
and abnormal elastic properties of the aorta (10) 4) there are differences in 
signaling pathways involved in extracellular matrix homeostasis between 
BAV and TAV patients with dilated aortas (119-125) 5) eNOS expression is 
lower in BAV patients than in TAV patients and is inversely correlated with 
aortic diameter (126) and 6) mutations in genes encoding components of the 
extracellular matrix are linked to aortic dilation and BAV (FBN-1(124;127), 
TGFBR-2 (127), ACTA-2 (128)). 
Many aspects of what causes BAV formation and subsequent BAV disease 
are not known, but there are two predominating theories, i.e., genetics 
and haemodynamics. The description above entails the genetic theory; 
haemodynamics will now further be discussed. 
The morphology of a BAV is evidently different from that of a normal TAV with 
the consequence of altered flow across the valve (129). A bileaflet valve causes 
a turbulent flow compared to a normal tricuspid valve, due to asymmetric 
movement of valve cusps. A turbulent flow, along with other haemodynamic 
factors, as an increased stroke volume (i.e. aortic regurgitation) and aortic 
curvature, could play a facilitative role in developing aortic complications, 
such as dilation in BAV individuals (6;130-132). In regions of turbulent flow 
matrix degrading enzymes are expressed and smooth muscle cells (SMCs) 
go into apoptosis (133). In response to degradation of the extracellular 
matrix local fibroblasts and SMC are considered to synthesize new 
connective tissue components. This progressive remodeling presumably 
results in a new extracellular matrix of a different structure. The combination 
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of remodeling and loss of SMCs, due to apoptosis, weakens the integrity of 
the vessel wall, which could lead to subsequent aortic dilation (134).   
Though, on the other hand, several studies have confirmed that ascending 
aortic aneurysms can develop in the absence of valvular abnormality 
(7;106;135-142). Moreover, Yasuda et al. have reported development of 
aortic dilation after (an isolated) surgical repair of the diseased bicuspid aortic 
valve (115). These studies suggest that structural abnormalities occur at the 
cellular level. Haemodynamic factors alone seem therefore not sufficient to 
explain the pathogenesis of cardiovascular malformations associated with 
bicuspid aortic valves. Suggesting that genetically determined abnormalities 
of the aortic wall lead to a defect in the cellular microenvironment, causing, 
or at least contributing to the aortic pathology associated with BAV. 
Although, besides a strictly genetic or haemodynamic theory, a combination 
of both is plausible as an alternative hypothesis. We postulate that 
the structurally altered vascular wall, might be prone for secondary 
haemodynamic changes observed in BAV.
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AIM OF THIS THESIS
The aim of this thesis is to determine clinical, histological, molecular biologic 
and morphological factors that may predict the clinical course and explain 
the increased susceptibility for aortic wall pathology seen in the majority of 
patients with BAV. We also intended to compare the pathobiology of aortic 
wall pathology in BAV with MFS.
In Chapter 2 we approach our hypothesis that aortic wall pathology 
associated with BAV could be the result of a shared development defect 
during embryogenesis. To address this hypothesis we provided an overview 
of embryonic cell lines involved in the normal development of the semilunar 
valves and the ascending aortic dilation, being neural crest cells, second 
heart field (SHF) progenitors and endocardial cushion derived cells. Genes 
involved in abnormal development of the aortic valve (BAV) are further 
discussed. To understand whether thoracic aortic dilation, not necessarily 
accompanied by BAV, is related to defects in neural crest signaling or SHF-
derived cells. The genetic origin of syndromes associated with aortic dilation 
(including MFS, Ehlers-Danlos, Smad3 mutations and Loeys-Dietz) was 
reviewed in the view of a central role for TGFβ and linked to embryonic 
development.
In Chapter 3 we approach our hypothesis that the aortic wall is structurally 
different in BAV as compared to the TAV. By studying the dilated and 
also particularly the non-dilated aortic wall specimen, we investigated the 
expression of smooth muscle cells markers of diverse differentiation states. 
Further Lamin A/C, with a pivotal role in myoblasts differentiation and 
progerin, a marker for cardiovascular aging, were studied.  
In Chapter 4 valve phenotype and aortic dimensions of 255 BAV patients 
were evaluated retrospectively. Patient characteristics, the clinical course 
and echocardiographic parameters including morphology of the valve were 
obtained. The aim of this study was to more definitively characterize whether 
an association exists between the morphology of the BAV and the degree of 
aortic dilation. And to provide a risk profile for clinical complications based 
patient characteristics and echocardiographic measurements. 
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In Chapter 5 we further investigated a panel of vascular wall markers that 
might distinguish within the non-dilated BAV group a susceptible and non-
susceptible group for future aortic wall complications. 
In Chapter 6 we investigated the aortic wall composition in patients with 
BAV, MFS and TAV. Recent studies suggest that in BAV patients the risk 
of aortic catastrophes, although higher than in the general population, 
remains low (12;80) as compared to the MFS. Controversies regarding aortic 
similarities and differences between various types of aortic wall pathology 
(BAV, MFS, TAV) in regard to aortic dilation and dissection of the aorta are 
as yet unresolved. Therefore the aim of this study was to shed light on the 
pathogenetic mechanism of aortic wall complications seen in both syndromes 
and compare those to the aortic wall pathology in dilated TAV patients. 
Findings were correlated to the effectiveness of clinical treatment modalities. 
In Chapter 7 the activity of the arterial epicardium covering the ascending 
aorta is investigated in both non- and dilated aortic wall specimen of BAV, 
TAV and MFS. In chapter 5 a signaling cascade is presented consisting 
of markers which can aid in distinguishing BAV patients with an increased 
susceptibility for future aortic complications. However, the link between 2 
markers in the cascade: eNOS and MMP9, could not be substantiated. In 
this paper we aimed to identify how these markers are associated with each 
other.  
Chapter 8 provides a summary of this thesis and discusses future 
persepectives
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Dilation of the wall of the thoracic aorta can be found in patients with a 
tricuspid (TAV) as well as a bicuspid aortic valve (BAV) with and without a 
syndromic component. BAV is the most common congenital cardiovascular 
malformation, with a population prevalence of 0.5–2%. The clinical course is 
often characterised by aneurysm formation and in some cases dissection. The 
non-dilated aortic wall is less well differentiated in all BAV as compared with 
TAV, thereby conferring inherent developmental susceptibility. Furthermore, 
a turbulent flow, caused by the inappropriate opening of the bicuspid valve, 
could accelerate the degenerative process in the aortic wall. However, not 
all patients with bicuspidy develop clinical complications during their life. We 
postulate that the increased vulnerability for aortic complications in a subset 
of patients with BAV is caused by a defect in the early development of the 
aorta and aortic valve. This review discusses histological and molecular 
genetic aspects of the normal and abnormal development of the aortic wall 
and semilunar valves. Aortopathy associated with BAV could be the result of 
a shared developmental defect during embryogenesis.
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Aortic dilation is a pathological widening of the aorta, which can be found in a 
thoracic and abdominal form according to its location. In contrast to abdominal 
aortic dilation, thoracic aortic dilation is usually not related to atheroma and 
often occurs at a younger age (1). Different aetiologies have been described 
which predispose individuals for thoracic aortic dilation, involving monogenic 
syndromes, such as Marfan (MFS), Ehlers-Danlos, Smad3 mutations and 
Loeys-Dietz syndromes, sometimes accompanied by bicuspid aortic valve 
(BAV) as well as idiopathic causes (2), while BAV is also found as an isolated 
anomaly. 
Although patients with isolated BAV may remain asymptomatic, in a 
significant proportion of the patients the clinical course is accompanied by 
aortic stenosis, aortic regurgitation, infective endocarditis, and thoracic aortic 
dilation which has a prevalence as high as 50–60 % (3). Particularly, thoracic 
aortic dilation forms a critical complication, as it carries a risk of dissection 
and rupture, making it a potentially lethal disease. 
Considering these clinical complications, understanding of the development 
of the ascending aorta and both normal and abnormal aortic valves is 
mandatory. By sharing a number of embryonic cell types, the development of 
the ascending aorta is narrowly related to the development of the aortic valve. 
Hence, aortopathy associated with BAV could be the result of a combined 
developmental defect in early embryogenesis. It has to be kept in mind, 
however, that not all individuals with BAV develop thoracic aortic dilation. 
In search of the pathogenesis of aortic complications in BAV, the focus has 
recently shifted towards defining patients susceptible for aortopathy needing 
aortic intervention. 
This review discusses several aspects of normal and abnormal development 
of the aortic wall and aortic semilunar valves. We hypothesise that the 
increased vulnerability for aortic complications in BAV is caused by a defect 
in the early development of the aorta and aortic valve. 
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GENERAL OVERVIEW OF NORMAL AND ABNORMAL AORTIC 
VALVE AND AORTA DEVELOPMENT
During organogenesis the first functional organ to form is the heart. The 
first sign of valvulogenesis is the formation of endocardial cushions in 
the atrioventricular canal and outflow tract. The atrioventricular cushions 
contribute to the atrioventricular (mitral and tricuspid) valve leaflets, whereas 
the outflow tract cushions contribute to the semilunar (aortic and pulmonary) 
valve leaflets (4). Development of semilunar valves is a complex process in 
which neural crest cells, second heart field (SHF) progenitors and endocardial 
cushion derived cells play a role (Fig. 1). The developmental origin of the 
endocardial cushion cells themselves has been a matter of debate in the 
past years. Recent lineage tracing studies with Nkx2.5 (5) have shown that 
SHF progenitor cells give origin to three specific cell lines: 1. VSMCs of the 
great arteries, 2. outflow tract and right ventricular myocardium, and to 3. the 
much discussed endothelial-derived endocardial cushion cells, which are in 
part derived from the endothelium (5). Recently, Harmon et al. presented 
data on the boundary where SHF-derived VSMCs meet neural crest cell-
derived VSMCs at the base of the aorta (5). The SHF contribution to the 
aortic media then forms a vertical seam complementary with neural crest 
derived VSMCs (5). Next to contributing to the vascular wall, a population 
of neural crest cells migrates to the outflow tract cushions where they are 
important for semilunar valve formation and outflow tract septation (6, 7). 
Preliminary data show a contribution of the arterial epicardium to the VSMCs 
of the ascending aorta (8). 
During valvulogenesis several signalling pathways such as Wnt/β-catenin, 
NOTCH, transforming growth factor β (TGF-β), bone morphogenetic protein 
(BMP), vascular endothelial growth factor, NFATc1 and MAPK, as well 
as transcription factors, including Twist1, Tbx20, Msx1/2, and Sox9, are 
necessary for the regulation of cell migration, proliferation, and extracellular 
matrix deposition in the developing valves (9–12). As a consequence, more 
than one cell population that contributes to both aortic wall and semilunar 
valve formation may be involved in the development of bicuspidy. Clinically, 
several BAV subtypes are distinguished on the basis of the fused commissure 
or raphe position. Type 1: raphe between right coronary cusp (RCC) and left 
coronary cusp (LCC), type 2: between RCC and non-coronary cusp (NCC) 
and type 3: raphe between LCC and NCC (Fig. 2). Clinical outcome differs 
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Figure 1. Schematic overview of the developing heart tube. 
The second heart field (SHF) is indicated contributing to the arterial pole of the heart including 
the great vessels and the right ventricle by the anterior population (AHF). At the venous 
pole SHF cells are entering from the posterior population (PHF). Both at the venous (vPEO) 
and arterial (aPEO) pole a proepicardial organ provides the epicardial cells that cover the 
myocardium and the intrapericardiac part of the great vessels. Neural crest cells migrate from 
the neural tube primarily to the arterial pole of the heart.
between the valve types, supporting a different developmental background 
as underlying cause. Recent support for the role of deficient neural crest 
cell contribution in development of type 1 BAV was seen in the Rock 1,2 
deficient mouse (6). Fernandez et al. argued that type 1 and type 2 BAVs 
have a different pathogenesis (13). An altered neural crest cell behaviour 
was suggested to be responsible for the development of type 1 BAVs and the 
endothelial nitric oxide (eNOS) mutation for type 2 BAV. eNOS is expressed 
by endocardial cells (14), cardiomyocytes (14) and VSMCs (Grewal et al. 
unpublished data), all SHF-derived cell types/populations, indicating a role 
for SHF progenitors in the development of type 2 BAV. Another role for SHF 
in the development of type 2 BAV was demonstrated by endocardial specific 
deletion of the gene encoding for the activin type I receptor (ALK2) (15). Other 
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Figure 2. Overview of our hypothesis on the developmental origin of the bicuspid aortic valve 
and aortic wall abnormalities. 
Figure 2 provides a schematic presentation of the aortic bicuspidy valve types based on the 
valve cusp orientation and the position of the raphe. Type 1: with fusion between the right 
coronary cusp (RCC) and left coronary cusp (LCC). Type 2: with fusion between the RCC 
and non-coronary cusp (NCC). Type 3 with fusion between the LCC and NCC. Furthermore 
an overview of our hypothesis on the developmental origin of the bicuspid aortic valve and 
aortic wall abnormalities is provided. Previously identified genetic mutations in mice (Nkx2.5, 
Alk2, eNOS, GATA5, NOTCH, Fgf8, Rock1,2 and Pax3) and in human (NOTCH) resulting 
in bicuspid aortic valves (BAV) are indicated in this figure. These genetic defects can be 
subdivided in either second heart field (SHF) or neural crest cell related. SHF and neural crest 
cells both contribute to the vascular smooth muscle cells in the ascending aorta as well as to 
the cells involved in semilunar valve formation. The SHF most probably also contributes to 
the endocardial cells of the cardiac outflow tract. Therefore these early developmental defects 
can cause bicuspidy, but also explain the less well differentiated aortic wall seen in all patients 
with a BAV. However, not every patientwith BAV has increased susceptibility for aortopathy. 
Therefore an additional factor needs to be identified to recognise patients with increased 
vulnerability for aortic complications.
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genetic defects leading to BAV have been identified with selective knockout 
of genes in murine models but have not focused on the differentiation in type 
1 or type 2 BAVs. From the recognised genes, Pax3 is a marker of neural 
crest cells (16). Furthermore, the identified SHF markers Nkx2.5 and GATA5 
(endocardial cell-specific) are associated with the development of BAV (17). 
Abnormalities of NOTCH signalling in the neural crest (18) or SHF can 
also contribute to the development of abnormal semilunar valves (16, 19). 
Interestingly, inhibition of NOTCH in SHF impairs fibroblast growth factor 8 
(Fgf8) signalling, which results in the development of BAV, but also in VSMCs 
abnormalities of the great arteries (20). Therefore, we postulate that a 
developmental defect of various progenitor cell lines may provide a common 
mechanism underlying aortic valvulopathy (BAV), as well as aortopathy. The 
next section focuses on genetic defects described in BAV and thoracic aortic 
dilation in human and their origin in embryogenesis. 
GENETIC BASIS OF BAV AND THORACIC AORTIC DILATION 
Consistent data have suggested a genetic cause of BAV disease (21, 22). 
Despite high heritability it remains challenging to determine the underlying 
mechanism of BAV in the human population, supported by murine data, 
as it is probably due to interacting mutations in diverse genes encoding 
transcription factors, extracellular matrix proteins and signalling pathways 
that regulate cell proliferation, differentiation, adhesion or apoptosis.
Although a remarkable reduction in eNOS levels was seen in BAV patients, 
this could not be correlated to a mutation in the eNOS gene (23). Moreover, 
mutations in the NOTCH1 gene, which is expressed by both neural crest 
and SHF, and mapped to chromosome 9q34, have been associated with the 
development and progression of BAV (18, 24). Further genetic haplotypes 
within the AXIN1-PDIA2 locus have been recognised that strongly associate 
with BAV. AXIN1 (Axis Inhibitor 1) is a critical member of the Wnt pathway, 
which regulates both heart valve formation (25) and cardiac neural crest 
development (26). Another haplotype within the Endoglin gene (known as 
a co-receptor in the TGFβ pathway) is required for differentiation of neural 
crest cells into VSMCs that populate the aorta (27). 
From these genetic defects we conclude that there is a clear link to defects in 
neural crest as well as SHF-derived cell populations with elements for BAV. 
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Alterations in neural crest signalling are associated with the most common 
type 1 BAV (28), identified as the valve type with most severe aortic wall 
abnormalities as compared with the other valve types (13, 29, 30) while 
SHF-related genes seem to correlate more with BAV type 2.
This brings us to the next important question whether thoracic aortic dilation, 
not necessarily accompanied by BAV, is related to defects in neural crest 
signalling or alternatively, is there a more specific role for the SHF-derived 
cells? The following section concentrates on genetics of thoracic aortic 
dilation in syndromes including Marfan, Ehlers-Danlos, Smad3 mutations 
and Loeys-Dietz and their link to embryonic development.
Marfan syndrome (MFS) is a connective tissue disorder characterised 
by cardiovascular, skeletal and ocular manifestations. The progressive 
dilation of the aortic root culminating in dissection is a major cause of 
morbidity and mortality in MFS patients. This syndrome is the result of a 
defect in the fibrillin-1(FBN1) gene that localises on chromosome 15q21.1 
and is inherited in an autosomal dominant manner (31). A second locus for 
Marfan syndrome (MFS2) has been mapped to chromosome 3p25-24.2, 
and a heterozygous mutation in TGFΒR2 was subsequently identified as 
the genetic defect (32). The TGFBR2 mutations in MFS patients involve 
the serine-threonine kinase domain and reduce TGFβ-induced receptor 
signalling.
Loeys-Dietz is caused by another defect in the TGFβ signalling pathway. In 
this syndrome TGFBR1 and TGFBR2 mutations are mapped to chromosome 
9q33-34 and 3p24-25 respectively. Cardiovascular lesions in Loeys-
Dietz syndrome include aortic valve regurgitation and aortic root dilation, 
aneurysm formation and dissection. Other phenotypic characteristics 
include craniosynostosis, cleft palate, bifid uvula, congenital heart disease 
and mental retardation.
Another syndrome presenting with aneurysms, dissections and tortuosity 
throughout the arterial tree in association with mild craniofacial features 
and skeletal and cutaneous anomalies has recently been described by Van 
de Laar et al. (33). The genetic locus has been mapped to chromosome 
15q22.2-24.2 and shows that the disease is caused by mutations in SMAD3, 
essential for propagation of the TGF-β signal to the nucleus and activation 
of downstream gene transcription. 
An additional syndrome worth mentioning is Ehlers Danlos. Patients with 
vascular Ehlers-Danlos often present with dissection or rupture of the 
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thoracic aorta. Aortic dissections have been reported in at least 10 % of 
patients with Ehlers-Danlos (34). This syndrome is attributed to a mutation 
in the gene encoding type III procollagen (COL3A1), mapped to 2q24.3-q31 
(35). Type I and type III collagen are the most abundant collagen fibers 
found in the media and adventitia of the aortic wall. In addition to providing 
mechanical strength, collagen has other functional properties, including 
activation of intracellular signalling cascades, storage of soluble factors, 
such as IL-2, and regulation of their local activity (36). Recently, a collagen 
crosslinking disorder has been reported specifically for isolated BAV (37). 
Furthermore, thoracic aortic dilation occurs in association with an autosomal 
dominant disorder in the absence of syndromic features, termed familial 
thoracic aortic aneurysm and dissection (FTAAD). A variety of genetic loci 
have been identified in this regard, such as TAAD1 locus, on chromosome 
5q 13-14 (38) and TAAD2 locus on chromosome 3p24-25 (39), the mutant 
gene associated with this locus is TGFBR2. Only 5 % of investigated 
families have this mutation, suggesting a relatively rare cause (39). TAAD3 
locus on chromosome 15q24-26 (38, 39) and TAAD4 locus on chromosome 
10q23-24 are also related to the development of aortic dissection. In the 
latter ACTA2 encoding for VSMCs a-actin is identified (40). The mutations 
impair the function of the VSMCs and this affects the integrity of the vessel 
wall, making it prone to dilation. This mutation has also been associated 
with an increased activity of the TGFβ pathway in the aorta (41). In TAAD5 
the identified gene is TGFBR1, mapped to chromosome 9q33-34 (42). 
In most of the above thoracic aortic dilation cases an increased TGFβ 
activity has been identified. However, TGFβ is not specific for neural crest, 
as it is also clearly involved in the endothelium and the SHF-derived cell 
populations (43). In syndromes as MFS, Ehlers-Danlos and Loeys-Dietz 
syndrome, bicuspidy is not an obligatory clinical manifestation, indicating 
that a defective TGFβ signalling is at least not the main factor causing 
BAV formation. Neural crest defects seem to cause the most frequently 
occurring type 1 BAV which is associated with most marked complications 
of the aortic wall, and often with an increased TGFβ activity (44). However, 
the clinical course is not complicated with thoracic aortic dilation in all BAV 
patients. Thus, neural crest involvement and TGFβ activity together are 
not sufficient to explain the variability within the pathogenesis of BAV and 
associated aortopathy. Additional pathogenetic factors need to be taken 
into account such as haemodynamics or a contribution of SHF. 
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PATHOGENESIS OF THORACIC AORTIC DILATION IN BAV: ROLE 
OF HAEMODYNAMICS AND SHF 
The morphology of the bi-leaflet valve produces a nonaxial transvalvular 
turbulent flow jet within the aortic root (45). This turbulent flow, along with 
other haemodynamic factors, as an increased stroke volume (for instance 
aortic regurgitation), have been suggested to facilitate developing aortic 
complications, as the created abnormal biomechanics and helical flow 
alterations lead to an uneven wall stress distribution. However, several 
studies have confirmed that ascending aortic aneurysms can develop in the 
absence of valve abnormality (46). Moreover, Yasuda et al. have reported 
development of aortic dilation after surgical repair of the diseased bicuspid 
aortic valve (47). These studies suggest that structural wall abnormalities 
at the cellular level may be important for the onset of dilation. Therefore, 
haemodynamic factors alone are not sufficient to explain the pathogenesis 
of aortopathy associated with bicuspid aortic valves. 
The alternative hypothesis is that genetically determined abnormalities of 
the aortic wall lead to a defect in the cellular microenvironment, causing or 
at least contributing to the aortic pathology and render the wall vulnerable to 
haemodynamic stress.
Several studies have focused on differences between the dilated aortic 
wall in BAV and TAV. Histopathological features of the aortic wall in BAV 
show decreased medial inflammation, elastin fragmentation and cystic 
medial necrosis, when compared with TAV (48). In addition, the aortic wall 
has a different composition in BAV, with a significantly thicker tunica media 
but significantly thinner tunica intima (49). In recent years research on 
extracellular matrix composition mainly established differences in the aortic 
media of dilated aortic wall in BAV and TAV (24, 37). To take a step further 
in unravelling a possible different pathogenetic mechanism of thoracic aortic 
dilation in BAV and TAV, we investigated non-dilated aortic walls of both valve 
types. The aortic media was specifically studied for maturation of VSMCs 
and ageing characteristics. We concluded that thoracic aortic dilation in TAV 
has aspects of ageing, whereas in bicuspidy there is a defective smooth 
muscle cell differentiation (Fig. 3) unrelated to ageing. These results suggest 
that the fundamental difference in the aortic wall make-up of BAV is found in 
less differentiated VSMCs as compared with TAV while still both neural crest 
cells and SHF contribute to the VSMCs in the aortic wall. Haemodynamic 
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factors might play a role in the aortic complications, but superimposed on the 
already present structurally immature aortic wall seen in BAV. 
CONCLUSION AND FUTURE PERSPECTIVES 
From a clinical point of view, aortic complications vary between the different 
BAV types. Aortic root diameters for instance have been analysed between 
BAV type 1 and 2 in several studies, all of which found larger aortic root 
diameters in the type 1 (13, 29, 50), being more vulnerable for degradation 
(30). Type 2 BAVs are responsible for valve dysfunction at a younger age 
(29, 50). Aortopathy seems most outspoken in BAV type 1, probably being 
caused by a defect in neural crest. Despite these recent findings however, 
clinical parameters have not been conclusive in distinguishing patients with 
BAV susceptible for aortopathy, suggesting that an alternative, molecular 





Figure 3. Transverse histological 
sections of the media of the aortic 
wall stained for the smooth muscle 
cell marker alpha smooth muscle actin 
(αSMA). 
In patients with a tricuspid aortic valve 
and a dilated aortic wall (TAD) the 
expression of this marker is higher 
as compared with the expression 
in patients with a bicuspid aortic 
wall and dilated aortic wall (BAD). 
Furthermore the aortic media in TAD 
shows significantly more pathology as 
compared with BAD, with profoundly 
more cystic medial necrosis (CN) 
defined as loss of smooth muscle cell 
nuclei. Magnification bar: 500 μm.
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In this review we describe that altered neural crest cell and second heart 
field contribution, separately or in combination, can account for a structurally 
different aortic wall in combination with bicuspidy (Fig. 2). Figure 2 summarises 
that defects in neural crest cells are mostly associated with type 1 BAV and 
defects in SHF with type 2. These contributions alone, however, are not 
sufficient to explain the clinical heterogeneity seen in BAV patients, as not all 
individuals with BAV develop aortic complications during their life. Therefore, 
additional factors make the aorta susceptible for ensuing complications. 
It is important to determine which developmental defect accounts for the 
additional pathology making the aortic wall susceptible for thoracic aortic 
dilation. Future research, therefore, needs to focus on identifying molecular 
pathways related to neural crest and SHF. These factors are required to 
distinguish a susceptible and a non-susceptible group for suspected aortic 
complications.
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Objective: Patients with a bicuspid aortic valve have increased susceptibility 
to the development of ascending aortic dilation and dissection compared with 
persons with a tricuspid valve. To unravel a possible different mechanism 
underlying dilation in bicuspidy and tricuspidy, a comparison of the structure 
of the aortic wall was made.
Methods: Ascending aortic wall biopsies were divided into 4 groups: bicuspid 
(n = 36) and tricuspid (n = 23) without and with dilation. The expression of 
vascular smooth muscle cell maturation markers including lamin A/C, which 
plays a pivotal role in smooth muscle cell differentiation, and its splicing 
variant progerin indicative of aging, were studied immunohistochemically. 
Attention was also paid to the inflammatory status.
Results: There is a significant difference in the structure and maturation of 
the aortic wall in bicuspidy, persisting in the dilated aortic wall, presenting with 
a thinner intima, lower expression of a smooth muscle actin, smooth muscle 
22a, calponin, and almost absent expression of smoothelin. We show for the 
first time significantly lowered lamin A/C expression in bicuspidy. Progerin 
was found to be significantly increased in the media of the dilated wall in 
tricuspidy, also showing increased periaortic inflammation.
Conclusions: The structure of the non-dilated and dilated aortic wall in 
bicuspidy and tricuspidy are intrinsically different, with the latter having 
more aspects of aging. In bicuspidy there is a defective smooth muscle cell 
differentiation possibly linked to lowered lamin A/C expression. Based on 
this vessel wall immaturity and increased susceptibility to dilation, different 
diagnostic and therapeutic approaches are warranted. 
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INTRODUCTION
A bicuspid aortic valve (BAV) is characterized by an aortic valve with 2 
semilunar leaflets. BAV is the most common congenital cardiovascular 
malformation with a prevalence of 0.5% to 2% (1). The incidence of thoracic 
aortic dilation or aneurysm formation and dissection in patients with BAV is 
considered to be 50% to 70% (2). Compared with patients with a tricuspid 
aortic valve (TAV), patients with BAV have larger aortic root dimensions 
and a higher progression rate of dilation (3,4) suggesting that the process 
of dilation of the thoracic aorta is different in BAV compared with TAV. The 
terms aneurysm and dilation for the aortopathy are used interchangeably. 
We have chosen to use the term dilation for clarity. Turbulent flow, as a result 
of asymmetric movement of valve leaflets in BAV, has been postulated as an 
essential determinant for the development of aortic dilation (5). An alternative 
hypothesis, that aortic dilation in BAV is mainly based on the intrinsic 
structure of the aortic wall, (6) is supported by a high incidence of dilation 
in asymptomatic patients with BAV as well as dilation observed after aortic 
valve replacement (7). The latter hypothesis is further supported by reported 
altered molecular and/or metabolic characteristics in the aortic wall and valve 
leaflets in BAV, differences in elastic lamellae, loose attachment of VSMCs 
to their surrounding elastic lamellae, and precocious VSMCs apoptosis 
(8-17). Most studies have focused on the differences between the dilated 
TAV and BAV wall. The exact mechanisms underlying the development and 
progression of an aorta with normal dimensions into dilation in patients with 
TAV versus BAV, however, have not been delineated. 
In this study, we used a unique opportunity to compare non-dilated ascending 
aortic wall specimens from patients with BAV, representative of a specific 
architecture and possible early lesions rather than of end-stage disease, with 
the normal aortic wall in TAV.
Furthermore, these data could be compared with the histopathology of the 
dilated vessel wall in BAV and TAV. Histologic procedures using hematoxylin-
eosin and resorcin fuchsin were applied to assess the general vessel wall 
architecture, that is, inflammation, vessel wall thickness, elastic lamellae, and 
cystic medial necrosis (focal loss of VSMC nuclei in the media). Expression of 
markers of differentiated VSMCs was investigated to determine differences 
in vessel wall maturation or differentiation between patients with BAV and 
TAV. Smooth muscle 22α (SM22α), smoothelin, and calponin were used 
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as markers for fully differentiated contractile VSMCs (18) and a smooth 
muscle actin (αSMA) was used as a marker for differentiation of VSMCs 
and myofibroblasts (19). Lamin A/C, was investigated to explain possible 
differences between VSMC differentiation in BAV and TAV, because it has a 
pivotal role in the differentiation of myoblasts (20). Progerin, a splice variant 
of lamin A/C, was studied to further elucidate differences in the pathogenesis 
of aortopathy between the 2 valve types, because it has been suggested that 
progerin not only plays a role in Hutchinson-Gilford progeria syndrome but 
also in cardiovascular aging (21-23). We hypothesize that the BAV vessel 
wall has a maturation defect that underlies a more aggressive form of dilation.
MATERIALS AND METHODS
Ethical Approval
Sample collection and handling was carried out according to the official 
guidelines of the Medical Ethical Committee of Leiden University Medical 
Center (LUMC), Leiden, and the code of conduct of the Dutch Federation of 
Biomedical Scientific Societies www.FMWV.nl). Six cryopreserved bicuspid 
human aortic valves were obtained from the Heart Valve Bank in Rotterdam 
(Erasmus University Medical Center, Rotterdam) originating from postmortem 
donors. These valves were declared unfit for implantation because of the 
bicuspid nature of the valves. The Advisory Board of the Heart Valve Bank 
allowed these valves to be included in the present project because the 
research was in line with the permission of the donation. 
Tissue Samples 
Samples of the ascending aorta were collected from individuals with BAV 
and TAV, with and without dilation. Material from patients with BAV without 
dilation was available in cases of stentless root replacement, the preferred 
technique for stentless valve implantation in LUMC. Dilation was clinically 
defined by reaching an ascending aortic wall diameter of 45 mm or more 
(24). The patients were divided into 4 groups: (1) TAV without dilation (TA, 
n = 11, mean age 64.5 ±  9.0 years) obtained post mortem; (2) TAV with 
dilation (TAD, n = 12, mean age 72.3 ± 11.2 years) collected during elective 
repair; (3) BAV without dilation (BA, n = 17, mean age 55.8 ±  9.8 years); (4) 
BAV with dilation (BAD, n = 19, mean age 60.7 ± 7.8 years) obtained during 
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elective repair. Patients with a proven genetic disorder (eg, Marfan disease) 
were excluded.
After excision, specimens were fixed in 4% formalin (24 hours), decalcified in a 
formic acid-formate buffer (120 hours), and embedded in paraffin. Transverse 
sections (5 µm) were mounted on precoated Starfrost slides (Klinipath BV, 
Duiven, The Netherlands). Histologic Parameters Sections stained with 
hematoxylin-eosin and resorcin fuchsin were analyzed quantitatively for (1) 
periaortic inflammation (presence of a cellular infiltrate in the adventitia), 
indexed from 0 (no inflammatory cells), 2 (a few cells), 4 (groups of cells) 
to 6 (large clusters of cells); (2) maximum intimal thickness in micrometers 
(the distance between the endothelial layer and the first major internal elastic 
lamella, excluding atherosclerotic areas; (3) maximum medial thickness in 
micrometers (the distance between the first and last elastic lamella on the 
borderline with the adventitia. Furthermore, the organization of the elastic 
content was studied qualitatively. All specimens were reevaluated by an 
independent, experienced histopathologist who was blinded to the clinical 
data.
Immunohistochemistry
After deparaffinization, antigen retrieval was performed in a microwave 
oven in citrate buffer (pH 6.0, 12 minutes), followed by treatment with 0.3% 
H2O2 in phosphate buffered saline (PBS, pH 7.3, 20 minutes) to extinguish 
endogenous peroxidase activity. Subsequently, sections were rinsed briefly 
twice in PBS and once in PBS with 0.05% Tween-20 (PBS-T). Sections were 
incubated overnight at room temperature with the primary antibodies diluted 
in PBS-T and 1% bovine serum albumin (BSA, Sigma, St. Louis, Mo) (Table 
1). Between the incubation steps, the slides were rinsed in PBS (23) and 
PBS-T (13). Bound antibodies were detected using 1-hour incubation with 
a secondary antibody diluted in PBS-T (Table 1). Subsequently, all slides, 
except for αSMA, were incubated with ABC reagent (Vector Laboratories, 
Burlingame, Calif; PK 6100) for 45 minutes. Control stainings were performed 
using PBS-T and BSA as the first incubation step. Slides were incubated with 
400 mg/mL 3,30-diaminobenzidine tetrachloride (Sigma-Aldrich Chemie, 
Buchs, Switzerland; D5637) dissolved in Tris-maleate buffer to which 20 
mL of H2O2 were added (pH 7.6, 10 minutes). After rinsing, counterstaining 
was performed with 0.1% hematoxylin (Merck, Darmstadt, Germany) (5 
seconds), followed by rinsing in tap water (10 minutes). After dehydration, 
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sections were mounted in Entellan (Merck, Darmstadt, Germany). Sections 
used for (semi)quantitative and morphometric analysis were stained in the 
same batch.
Double Immunofluorescence Staining
Deparaffinization, rehydration, and antigen retrieval were performed in the 
manner described earlier. Sections were incubated with the primary antibodies, 
progerin and lamin A/C (overnight, 4°C) (Table 1). The secondary antibodies 
used were 1:500 Cy3 donkey antimouse IgG (Jackson Immunoresearch, 
Table 1 Immunohistochemistry reagents
GAR (goat-anti-rabbit-biotin), NGS (normal goat serum), HAM (horse-anti-mouse-biotin), 
NHS (normal horse serum) and  RAM-PO (peroxidase-conjugated rabbit anti-mouse). 
Primary antibody Vendor, order number Concentration               Secondary antibody 
 
Anti-lamin A/C                    Chemicon 
(MAB3211)                                       






Anti-progerin Kindly provided by K. 
Djabali (dpt. Of 
Dermatology,                                             
Colombia University, 
NY, USA) 
1:50                                 GAR (1:200) & NGS 
(1:66) 
(Vector Laboratories, 
USA, BA-1000 and 
S1000) 
Anti-αSMA                          Sigma-Aldrich Chemie 
(A2547)                   
1: 5000                            RAM-PO (1:250) 
(DAKO p0260) 
Anti-SM22α                        Abcam 
(-)                                            





1:6000                             HAM & NHS 
Anti-Smoothelin                 Progen Biotechnik 
(d4816101) 
1:200                               HAM & NHS 
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Newmarket, England; 715-165-150) and 1:500 Alexa Fluor 647 donkey 
antirabbit IgG (Invitrogen, Grand Island,NY; A-31573) (1 hour, 20°C). 
The nuclei were counterstained for visualization with 4,6-diamidino-2-
phenylindole (Sigma-Aldrich). All slides were mounted with ProlonGold 
(Invitrogen, P36930).
Immunohistochemical and Morphometric Analyses
Sections were studied with a Leica BM5000 microscope equipped with 
plan achromatic objectives (Leica Microsystems, Wetzlar, Germany). The 
cytoplasmic level of expression of αSMA, SM22α, calponin, and smoothelin 
was indexed at 3 predetermined locations (left, middle, and right) of 
every tissue section, referred to as the microscopic field (MF), from 0 (no 
expression in VSMCs), 2 (expression in less than one-third of all VSMCs), 
4 (expression in two-thirds of all VSMCs) to 6 (expression in all VSMCs). 
This was maintained for all stainings. 
To determine the lamin-progerin balance, in each stained section the 
number of positively stained nuclei was counted using ImageJ in the 3 
MFs. A threshold was applied to filter background noise. The total number 
of nuclei (positively stained and negative) was equal in all specimens. In 
each MF, the number of lamin- and progerin-positive nuclei was therefore 
normalized to the total number of nuclei per 100,000 μm2. The number of 
normalized lamin- and progerin-positive nuclei was averaged between the 
3 MFs.
Western Blot
Aortic tissue (60 mg) was homogenized in 300 mL of lysis buffer (Cell 
Signalling Technology,Beverly, Mass). Whole protein concentration in the 
cell lysate was measured using the BCA protein assay (ThermoFisher 
Scientific, Rockford, Ill). Lamin A/C expression was quantified following 
procedures described previously (25), by using lamin A/C rabbit polyclonal 
antibody (sc-20681) together with bovine antirabbit IgG AP (sc-2372) 
secondary antibody (Santa Cruz Biotechnology, Santa Cruz, Calif) to detect 
lamin A/C protein. Band intensity was analyzed using ImageJ software. To 
compare band intensity between different blots, an internal control sample 
(Rest) was run on every blot. Glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) antibody (sc-47724; Santa Cruz Biotechnology) was used as 
loading control and with the calibration sample.




All numerical data are presented as the mean ± standard deviation of 3 MFs 
on each stained slide. Statistical differences were evaluated with the Mann-
Whitney U test for comparison between the groups. SPSS 20.0 (SPSS Inc. 
Chicago, Ill) was used for the statistical analyses.
An additional 1-, 2- and 3-way analysis of variance test was performed 
to correct for age and gender and it was found that both factors were not 
confounding in this study. GraphPad software (GraphPad Software, Inc, San 
Diego, Calif) was used to create graphics of the statistical analyses.
RESULTS
Histopathology
The ascending aorta consists of a tunica intima, media, and adventitia, with 
endothelium lining the lumen (Fig. 1, A, D, H, and K). The border between 
the fine elastic fibers in the tunica intima and more regular thick elastic 
lamellae in the tunica media is delineated by an internal elastic lamella (Fig. 
1, B and I). The media to adventitia border is marked by the last elastic 
lamella of the media. The absolute intimal thickness was significantly 
smaller in BA compared with TA and BAD compared with TAD (P<0.001, 
P<0.0001, respectively) (Fig. 1, B, I, and O). The media, however, was 
significantly thicker in all specimens in the BAV groups (BA and BAD) 
compared with the TAV groups (TA and TAD) (P < .01 and P<0.001, 
respectively) (Fig. 1, A, H, and P). Differences in the organization of the 
elastic lamellae were also observed. In the TA group, the elastic lamellae 
had a dense regular distribution (Fig. 1, C), whereas in the TAD group the 
lamellae appeared fragmented and the distance between the lamellae was 
enlarged (Fig. 1, E). The BA group contained well-organized lamellae, even 
more neatly regulated compared with the TA group (Fig. 1, J). In the BAD 
group, the architecture of the elastic lamellae remained regular (Fig. 1, L). 
Specimens from the BAD group also showed less cystic medial necrosis 
(focal loss of VSMC nuclei in the media) compared with specimen from the 
TAD group (Fig. 1, G and N). The adventitia in all specimens harbours fat 
cells, fibroblasts, nerve fibers, a few quiescent resident inflammatory cells, 
and vasa vasorum. The amount of adventitial fat cells (Fig. 1, M) was not 
different between the 4 groups (data not shown). Periaortic inflammation 
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Figure 1. Transverse sections of the aortic wall (A-N). 
The aorta consists of an intima (i), media (m), and adventitia (a) indicated in A and H. The media 
and intima are separated by the internal elastic lamella (arrows in B and I).A very compact 
layering of medial elastic lamellae is seen in TA (C) compared with the somewhat more loosely 
organized yet regular lamellae in BA (J). The latter is maintained in the BAD group (L), in 
contrast to the TAD where the lamellae become fragmented and disorganized after dilation 
(E). Medial thickness is significantly increased in BA and BAD compared with TA and TAD (P). 
The reverse is seen for the intimal thickness, which is significantly thinner in BA and BAD (O). 
αSMA staining (G, N) exhibits more severe cystic medial necrosis (CN) in TAD compared with 
BAD (G). Periaortic inflammation (box in D, indexed as 6) is significantly more severe in TAD 
compared with BAD (D, F, K, M,and Q). TA, Tricuspid valve, without dilation; TAD, tricuspid 
valve, with dilation; BA, bicuspid valve, without dilation; BAD, bicuspid valve, with dilation; RF, 
resorcin fuchsin; HE, hematoxylin-eosin; αSMA, a smooth muscle actin. Scale bars: A, D, G, 
H, K, and N, 500 μm; B, C, E, F, I, J, L, and M, 50 μm.
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was significantly more profound in the TAD group compared with the TA 
and BAD groups (P<0.001 and P<0.0001, respectively) (Fig. 1, D, F, K, M, 
and Q).
Altered Pattern of Smooth Muscle Cell Expression in the Aorta of 
Patients With BAV Compared With TAV
Differences in the expression of actin-positive VSMCs were noted between 
the groups. The ascending aorta from BAV showed less αSMA expressing 
VSMCs compared with TAV, in both dilated and non-dilated specimens 
(P<0.05) (Fig. 2, A, B, and C). Less expression in BAV was not due to focal 
vessel wall degeneration, rather individual cells expressed less αSMA. 
The results obtained for αSMA were mirrored by the expression pattern 
of SM22α (P <0.01) (Fig. 2, D, E, and F) and calponin (data not shown). 
The intima of the aortic wall stained positive for SM22α, but not for αSMA 
(Fig. 2, A, B, D, and E). Smoothelin expression in the TA group was seen 
mainly in the outer media compared with the middle and inner media, with a 
significant degenerative loss of expression in the middle media of the TAD 
group (P<0.001) (Fig. 2, G, J, and I). Smoothelin expression in the BA and 
BAD groups was nearly absent (P<0.0001 and P<0.001, respectively) (Fig. 
2, H, K, and I). 
Lamin A/C and Progerin Expression
The expression of the nuclear protein lamin A/C was seen in the intima and 
media. Significantly less lamin A/C positive nuclei were observed in the BA 
group compared with the TA group (P <0.01) (Fig. 3, A, E, and G). We also 
investigated the expression of progerin. Confocal microscopy revealed 
progerin expression at the nuclear lamina (Fig. 3, C and F), whereas lamin 
A/C was also distributed in the nucleoplasm (Figure 3, B and D), confirming 
that the 2 antibodies recognize different proteins. Morphologic analyses 
of progerin expression patterns revealed a significant increase in the 
TAD group compared with the TA group (P<0.05) (Fig. 3, H), whereas no 
such increase was seen between the BAD and BA groups. Moreover, the 
expression in the BAD group was significantly lower than in the TAD group 
(P<0.05) (Fig. 3, H). Lamin A/C expression in the BA and TA groups was 
quantified by performing a Western blot. The level of GAPDH was used as 
calibration of the samples. The results of lamin A/C quantification showed 
the same trend as the immunohistochemistry data (Fig. 4). 
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Figure 2. Transverse sections of the aortic wall (A, B, D, E, G, H, J, K). 
Cytoplasmic 3,30-diaminobenzidine tetrachloride vascular smooth muscle cell (VSMC) staining, 
with positivity depicted by an arrow in A, D, and G. The number of αSMA expressing VSMCs is 
significantly lower in BA (B, indexed as 0) than TA (A, indexed as 6), which is maintained after 
dilation (BAD and TAD, respectively) (C). The number of SM22α expressing VSMCs is also 
significantly lower in BA (E, indexed as 2) than TA (D, indexed as 6) and in BAD compared 
with TAD (F). VSMCs expressing smoothelin were only seen in the TA, mainly in the outer (om) 
compared with the middle (mm) and inner media (im) (G, indexed as 4) and nearly absent in the 
other groups (H, J, and K, indexed as 0) (I). TA, Tricuspid valve, without dilation; TAD, tricuspid 
valve, with dilation; BA, bicuspid valve, without dilation; BAD, bicuspid valve, with dilation; 
αSMA, a smooth muscle cell actin; SM22α, smooth muscle cell 22a. Scale bars: 200 μm.




Previous studies demonstrated that patients with BAV have more severe 
aortic wall abnormalities than patients with TAV (14). The results of our 
study provide evidence that the aortic wall in BAV is intrinsically different 
and presents with a maturation defect compared with the aortic wall in TAV. 
This maturation defect is maintained in the dilated aortic wall, which also 
has a different basic architecture in BAV compared with TAV. The significant 
difference observed remained after correcting for age and gender. 
Most literature data refer to comparison of the dilated wall in patients with 
TAV and BAV (11,12,14). We had the opportunity to compare the wall in 4 
groups, including a unique non-dilated BA population, which allowed us to 
define its basic structural differences. Our observation that the inflammatory 
component is minimal in BAD compared with TAD, despite the presence of 
a similar degree of aortic dilation, confirms the findings of Matthias Bechtel 
and colleagues (26). The significantly thinner intima in all our BAV specimens 
compared with the TAV specimens is a novel finding and might explain the 
less frequent observation of atherosclerosis in the BAV aortic wall (26). The 
aortic media appeared significantly thicker in all patients with BAV compared 
with TAV, which was not found earlier (12). Specimens in the BA and BAD 
groups showed relatively well-organized, albeit thinner, elastic lamellae, with 
a larger interlamellar distance compared with those from patients with TAV, 
a finding previously described for the BAD group, but not for the non-dilated 
BA group (11,12,14). 
We propose that the finer elastic lamellae observed combined with an 
increase in extracellular matrix in the non-dilated BA group might add to the 
increased susceptibility for dilation of the media as has been suggested in 
Literature (27). 
VSMCs have the ability to undergo a phenotypic switch from a quiescent 
contractile state to a less mature, proliferative synthetic state. Disability of 
this switch has been shown to play a critical role in a variety of cardiovascular 
diseases (18,28). By using differentiation markers of contractile VSMCs, we 
showed less maturation in patients with BAV compared with TAV in both 
dilated and non-dilated specimens. This was particularly prominent for 
smoothelin, a specific marker of highly differentiated VSMCs, which was 
significantly less in the TAD group compared with the TA group, and, as we 
show for the first time, nearly absent in all BAVs. These findings correlate 
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Figure 3. Transverse histologic sections of the aortic wall (A-F). 
Nuclear 3,30-diaminobenzidine tetrachloride (DAB) staining of lamin A/C (A, brown, see arrow; 
E, absent staining, see arrow). The number of lamin A/C-expressing nuclei is significantly 
lower in the BA group compared with the TA group (G). Nuclear DAB staining of progerin is 
shown in C (brown, see arrow) and F (absent staining, see arrow). The number of progerin-
expressing nuclei significantly increases with wall dilation in TAD (H), which is not seen in BAD. 
The number of progerin-expressing nuclei is significantly lower in BAD compared with TAD (H). 
Confocal images of consecutive sections (B and D). Nuclei are counterstained with diamidino 
phenylindole (B and D, blue). Immunofluorescence shows nuclear distribution of lamin A/C 
(red, B) and nuclear envelope localization of progerin (green, D). TA, Tricuspid valve, without 
dilation; TAD, tricuspid valve, with dilation; BA, bicuspid valve, without dilation; BAD, bicuspid 
valve, with dilation. Scale bars: A, C, E, and F, 20 μm; B and D, 1 μm.
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with the structurally less well-differentiated BA wall compared with the normal 
TA wall, which could explain aortic wall vulnerability in bicuspidy.
This hypothesis is further supported by the novel finding that lamin A/C is 
significantly less expressed in all patients with BAV. The nuclear intermediate 
filament lamin A and C proteins are expressed from the same LMNA gene 
by alternative splicing. Lamin A/C are of utmost importance in regulating 
transcription, organizing the chromatin, and protecting the nucleus from 
mechanical stress during cell development (29). The role of lamin A/C in 
normal VSMC differentiation has not been reported so far, however mice with 
reduced expression show nuclear deformation and impaired transcription 
response to mechanical stress (30). Low expression and an altered lamin 
A/C ratio in the BA group, which is maintained in the BAD group, suggest 
that the lamins might also play a role in VSMC differentiation and maturation, 
and thereby affect the aortic dilation process. In line with these data is the 
remarkably increased progerin expression in the degenerated TAD group, 
which can be linked to normal cardiovascular aging (21-23). The relative lack 
of progerin in the BA group and the non-significant increase subsequently 
Figure 4. Western blot of cell lysate from 8 samples of non-dilated aortic wall with a bicuspid 
aortic valve (BA, 1-4) and tricuspid valve (TA, 5-8) and glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) used as an internal control sample (Rest). 
The lamin A/C protein level in each sample was determined by densitometry, performed using 
ImageJ software, and normalized. The band intensity of the Rest was used as calibrator. The 
Coomassie Blue stained gel showed equal loading of proteins with a molecular mass of 69 
kDa (lamin A), and 62 kDa (lamin C). Bar diagram in white, lamin A level in %; and in black, 
lamin C level in %.
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in the BAD group indicate that in the immature wall of patients with BAV, 
the degenerative changes are of a different nature compared with TAV and 
do not involve so much accelerated aging, emphasizing that BAV and TAV 
are clearly different entities. Although, in general, reduced levels of lamin 
A/C and associated proteins affect the transcription of genes (31) by, for 
example, histone modifications, (32) it is of utmost importance to understand 
its role in cell type-specific differentiation and dedifferentiation processes. 
Future studies should focus on the regulation of lamin A and C in VSMCs 
and the role of these lamins in vessel wall pathology. In conclusion, our data 
show that the aortic wall in patients with BAV is intrinsically different from 
patients with TAV, in whom inflammation and accelerated aging lead to aortic 
pathology. A maturation defect of the aortic wall in BAV, showing less well-
differentiated VSMCs and low lamin A/C expression, might be the cause of 
the increased risk of aortic wall dilation. We have thereby shown with the 
amended markers that there is clearly a different substrate for aortopathy, 
seen more frequently and at a younger age, in BAV compared with TAV. As 
the non-dilated aortic wall has already been found to be different, there is a 
need for re-evaluation of the role of haemodynamics as a possible primary 
cause for the dilation in BAV. Future experimental research should focus on 
whether pharmacologic interventions can influence maturation in the aortic 
wall, which would be valuable in limiting clinical disease progression in the 
immature BAV wall.
STUDY LIMITATIONS
A limitation of our study is that we did not have aortic wall specimens from 
control patients (children and adolescents) to indicate whether the observed 
immaturity in BAV is the result of a maturation defect or a matter of non-
progression of normal maturation. This can only be studied in the various 
existing BAV mouse models. 
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Editorial: The aortic wall with bicuspid 
aortic valve: immature or prematurely 
ageing?
Commenting on the paper by Grewal N et al. “Ascending 
aorta dilation in association with bicuspid aortic valve: a 
maturation defect of the aortic wall”
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We read with interest the study (1) by Grewal and co-workers, suggesting 
a maturation defect of the aortic wall in patients with bicuspid aortic valve 
(BAV). A number of recent publications have addressed the pathobiology of 
BAV-associated aortopathy, however most of them just vaguely concluded 
that BAV and tricuspid aortic valve (TAV) must have different mechanisms 
driving aortic dilatation. Grewal et al. are commendable for their effort to 
define the nature of this difference.
However, their data are partially in contrast with previous studies, with 
which they failed to perform a critical comparison. We have reported (2) 
increased α-smooth muscle actin (α-SMA) mRNA expression and only mildly 
and non-homogenously increased overall protein levels, with sub-intimal 
areas of α-SMA-positive cell loss. This relative stability of the amount of 
α-SMA (in contrast with Grewal’s data) coupled with smoothelin decrease 
(not absence, unlike in Grewal’s results) was consistent with other studies 
both on samples from patients and on experimental models of aneurysm 
(discussed in our paper (2)), and suggests a loss of contractile-phenotype 
SMCs and the emergence of a differentiated myofibroblast line.
In our abovementioned study (2), to minimize confounding factors, we 
selected BAV and TAV aortic stenosis patients with maximal diameter <4 
cm, and analysed both the concavity and the convexity of the vessel, to 
distinguish constitutive from stress-induced changes. Some of Grewal’s co-
Authors have previously borrowed in their studies this protocol of sample 
retrieval from different sites of each aorta, first introduced by us (3), and 
confirmed that aortic wall changes are asymmetrically expressed with BAV, 
suggesting a role for longstanding flow and stress pattern alterations in 
their development. The change of SMC orientation from circumferential to 
longitudinal direction we observed in the convexity (2) is known to occur in 
vessels submitted to altered tensile strain. The undefined site of sampling 
in the present study (1), conversely, could explain the above discrepancies. 
Similarly, the authors stated that the aortic wall specimens were obtained 
during full-root stentless implantation in non-dilated BAV patients (1), 
suggesting that the BAV specimens were taken from the root (sinuses of 
Valsalva) instead of the ascending tubular tract proper.
Where were the aortic specimens taken in the other patients, also 
considering that BAV aortopathy usually affects the ascending tract? 
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How was valve function in the four groups? Also, the mean diameters per 
subgroup were not acknowledged (1). Intimal thickness data (1) were at 
odds with previous investigations (2,4): could different diameters between 
BAV and TAV subgroups explain this?
The paradigms of flow-induced remodeling share many mechanisms 
with the vascular ageing process, including increased TGF-β receptor-II 
signalling (5), which has been evidenced in both BAV-associated and non-
BAV-associated aortopathies (2). Functionally, one of the early signs of 
arterial ageing is impaired wall distensibility, which is known to occur in the 
BAV aorta, even before overt dilation. Thus, with the currently available 
data, an hypothesis of defective wall maturation is hardly sustainable, 
without ruling out the contribution of flow induced remodeling: a conceptually 
opposite theory of premature ageing of the aortic wall, prompted by altered 
biomechanical environment, could be drawn as well.
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We thank dr. Della Corte for his insightful comments and the opportunity to 
clarify a number of points from our work and you as an Editor to give us this 
opportunity. We agree with authors of the letter that the mechanisms driving 
aortic dilation in bicuspid aortic valve (BAV) and tricuspid aortic valve (TAV) 
are different but not explained as yet. Following that line, also based on 
the expertise of most of our authors, we hypothesized that a developmental 
background linking BAV and the accompanying aortic wall might provide 
new insights into the matter. Haemodynamic differences could still play a 
role in the developing pathobiology but might not be the primary insult. This 
approach led to different selection criteria for our patient population. We did 
not primarily take into account the presence of aortic stenosis/regurgitation 
but focused on non-dilation (< 45 mm) and dilation of the aortic wall within the 
BAV and TAV groups. Additional characteristics of our study population are 
presented in Table 1, which also provides answers to a number of questions 
with regard to the material studied. The aortic valve pathology in non- and 
dilated BAV and dilated TAV varied from either stenosis or no stenosis, with 
or without regurgitation. In dilated BAV and TAV in some cases only an 
ascending aorta replacement was performed as there was no aortic root 
pathology that needed surgical correction. All biopsy specimen were taken 
from the ascending aortic wall adjoining the surgical transverse aortotomy 
site. In case of post-mortem or transplantation material the tissue was taken 
at identical sites. The results of the Forte paper (1) and our publication 
(2) can in part be appreciated as complementary. Some differences need 
an additional explanation from our side as provided below. The described 
results in expression of alpha-smooth muscle actin in the Forte paper 
(1) and our study do indeed not correlate. This is most probably due to a 
difference of technique in which mRNA expression based on RT-PCR 
analysis of the vascular wall (1) was compared to our immunohistochemistry 
of the three vessel wall layers (2). In case of increased mRNA detection 
a lowered translation into protein cannot be excluded. Dr Della Corte is 
correct that almost absent smoothelin expression cannot be detected 
by immunohistochemistry, so we agree with their results that smoothelin 
expression is lowered, which correlates with an immature smooth muscle cell 
(SMC) phenotype (3, 4). With regard to the cellular composition of the media 
and intima of the aortic wall we do not postulate a few resident fibroblasts to 
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be present that, under experimental development of thoracic aortic dilation, 
replace the disappearing SMC population by myofibroblasts as indicated by 
Jones et al (5) and adopted by the Della Corte group (1). In our studies it 
suffices to have a mature contractile SMC phenotype that can switch to a 
synthetic (immature) phenotype that expresses most of the markers also 
attributed to the myofibroblast phenotype, including the fibronectin splice 
variants (6). Our assumption is supported by less apoptosis (caspase-3) in 
the wall of the non-dilated as well as the dilated BAV (data unpublished). 
Apoptosis was however detected (not shown) in the media of the dilated TAV 
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and was in our study (2) linked to the increased expression of progerin. On 
this aspect we will have further comments when discussing the aspect of 
ageing. As described above, our study population was primarily not selected 
on the valve pathology or on the difference in architecture of the convex 
versus concave site. The fact that our group consisted of patients with a 
non- and dilated aortic wall, variable aortic valve pathology and commissure 
position, underlines that the observed differences between all BAVs and 
TAVS are intrinsic to the BAV wall morphology. This is further supported 
in a recently accepted paper (7) in which we did address the differences 
between the convex and concave aortic sites of patients with a dilated aortic 
wall, provided by our German co-authors that have adopted the selection 
technique as described before (8). We did not disclaim the earlier published 
differences (8, 9) in the structure of the wall and the expression of markers 
between the convex and concave site of the aorta. We performed, however, 
an additional analysis on these specimen with Transforming-Growth-Factorβ 
and endothelial nitric oxide and found no difference in expression between 
the convex and concave sites (7).  Haemodynamic influences are therefore 
not excluded from having an important influence but according to our studies 
cannot be considered as the primary source for the observed differences in 
dilation formation between BAV and TAV.
On basis of the above observations and additional arguments provided below 
we cannot endorse the concluding remarks of Dr Della Corte: ‘Functionally, 
one of the early signs of arterial ageing is impaired wall distensibility, which 
is known to occur in the BAV even before overt dilation. Thus, with the 
currently available data, an hypothesis of defective wall maturation is hardly 
sustainable, without ruling out the contribution of flow induced remodeling: a 
conceptually opposite theory of premature ageing of the aortic wall, prompted 
by altered biomechanical environment could be drawn as well’. In this respect 
the definition and detection of ageing of the vascular wall is an issue. Loss of 
aortic wall distensibility, based on the increase of collagen and loss of elastin 
is adapted by some as a measure of vascular wall ageing (5) and used not 
only for the TAV models but also for BAV (1). We have not specifically studied 
the collagen content but confirm the diminished elastin structure in BAV (2). 
Additionally we have introduced a new set of ageing markers being the 
balance between lamin A/C and progerin (2, 10). Even physiologic ageing with 
increasing age has been correlated with the increased expression of progerin 
(10-12). We are excited about the fact that in this way we could differentiate 
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between TAV and BAV, showing increased physiologic ageing in TAV based 
on an increase of progerin and accompanying apoptosis resulting in cytolytic 
necrosis, while this was lacking in BAV. The decrease of distensibility as 
described (1, 5) might still hold for the aortopathy in both BAV and TAV but 
should in our opinion not be translated as an indication of premature ageing 
in BAV. In our study we had the relatively unique opportunity to show that the 
structural immaturity was present in both non- and dilated BAVs independent 
of the degree and type of underlying aortic valve pathology. 
In conclusion we demonstrated that a different mechanism underlies aortic 
dilation in BAV and TAV patients. We postulate that secondarily haemodynamic 
influences, additionally triggered by the specific BAV aortic valve pathology, 
might have a different impact on the immature BAV wall as compared to the 
ageing TAV aortic wall.
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Background: The clinical course of bicuspid aortic valve (BAV) disease is 
variable. Data on predictors of aortopathy and valve dysfunction are limited. 
This study sought to define a risk profile for BAV patients based on clinical 
patient characteristics.
Methods: Valve morphology and aortic dimensions of 255 BAV patients (179 
men
(70.2%), 48±15 years) were evaluated retrospectively from the center’s 
echocardiography database. Patient characteristics, clinical course and 
echocardiographic parameters including morphology were obtained.
Results: Type 1A BAV patients (n = 151, fusion right and left coronary 
cusps) showed significantly larger sinuses than type 2A BAV patients (n = 
37, fusion right coronary and non-coronary cusps) (p= 0.001). Regurgitation 
was most apparent in type 1A BAVs with a complete raphe (p=0.017). All 
regurgitant valves showed larger sinuses (p=0.023) and patients with valve 
regurgitation had a larger LV mass (p<0.001). Male gender was associated 
with aortic valve regurgitation (p<0.001), larger aortic diameters and a larger 
LV mass (p=0.01). Patients with a history of aortic coarctation showed less 
valve regurgitation (p=0.048) and smaller diameters of the ascending aorta 
and arch (p<0.001). Patients with hypertension had faster dilation of the 
ascending aorta (p=0.049), statin use was associated with a smaller diameter 
of the ascending aorta (p=0.017).
Conclusions: This study provides a working model showing that males with 
a type 1A BAV with a complete raphe, hypertension and no statin use exhibit 
the highest risk of complications such as progressive aortic and valvular 
dysfunction necessitating  intervention.
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INTRODUCTION
Bicuspid aortic valve (BAV) is the most common congenital cardiac 
malformation, with a clear male predominance and an estimated prevalence 
of 0.5-1% (1-3). BAV can occur in an isolated form or in association with 
other congenital malformations, such as coarctation of the aorta (CoA). The 
prevalence of BAV in CoA patients is reported to be as high as 40-50% (4).
Although some patients with isolated BAV remain asymptomatic throughout 
their lifetime, others develop severe cardiac complications from an early 
age onwards, such as aortic valve stenosis, aortic insufficiency and/or 
endocarditis. However, the first presentation can also be a clinically relevant 
aortic wall abnormality, including ascending aortic dilation (reported to occur 
in 45% of patients (5)), aneurysm formation or rupture of the ascending 
aorta. Identifying patients who are prone to develop complications is a major, 
clinically relevant, challenge.
It is now recognized that BAV should not be considered as one single entity, 
but that distinct morphological phenotypes are distinguishable based on 
the presence and number of raphe, as classified by Sievers et al. (6) Most 
BAVs consist of one free cusp and two cusps that are conjoined (or have 
failed to separate during embryonic development). The term ‘raphe’ defines 
the conjoined area of the two underdeveloped cusps turning into a malformed 
commissure between both cusps (6). 
There is discussion in the literature about the relationship between BAV 
morphology and long term clinical outcome. Several studies reported that 
BAVs with fusion of the right coronary cusp and left coronary cusp (Type 
1A in this study) are associated with more aortic dilation in adults, whereas 
BAVs with fusion of the right and non-coronary cusp (Type 2A in this study) 
are responsible for valve dysfunction at a younger age (7-12). The third 
phenotype resulting from fusion between the left and non-coronary cusp 
(Type 3A in this study) is rare compared to the other two types (8). Some 
studies reported that type 1A BAVs are more stenotic than type 2A and 3A, 
whereas other studies described that the latter types are more stenotic and 
type 1 BAVs are more regurgitant (13-15). When no raphe is present, the 
valve is called strictly bicuspid (subtype B in our study). The raphe position 
has been linked to the area of dilation, type 2A BAVs are for instance 
responsible for dilation of the aortic sinus, whereas type 1A BAVs are related 
to dilation of the ascending aorta (16,17). In contrast, other studies reported 
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valve regurgitation as the main cause of sinus dilation, whereas stenosis 
causes a much milder ascending aortic dilation and valve morphology is 
proposed to be of little influence (18-21). The extent of the raphe (i.e. the 
extent to which the cusps are conjoined) however, has not been taken into 
account in the mentioned studies.
The purpose of this study was to determine whether valve morphology is 
associated with the degree of aortopathy and valvular dysfunction. By also 
taking the extent of the raphe and individual patient characteristics into 
account, a tailored risk stratification was developed.
METHODS
Study population
Consecutive patients who had undergone transthoracic echo-cardiography 
between 2005 and 2010 and had been diagnosed with BAV disease were 
identified retrospectively from the Leiden University Medical Center (LUMC) 
echocardiography database. Clinical and echocardiographic data were 
collected and analyzed from the departmental Cardiology Information System 
(EPD-Vision®, LUMC) and the echocardiography database respectively. 
For this analysis of clinically acquired data, the Institutional Review Board 
waived the need of patient written informed consent. A total of 255 patients 
was selected, all had situs solitus of the atria and concordant AV and VA 
connections. Other patient characteristics recorded included date of birth, 
height, weight, body surface area (calculated using the Du Bois formula (22)), 
other congenital malformations, genetic syndromes, history of arrhythmias, 
ischemic procedures, cardiovascular risk factors, use of medication, known 
valve dysfunction, history of valve surgeries and age at time of surgery 
(Table 1).
Classification of valve morphology
As from a developmental point of view a morphological spectrum may exist in 
which the extent of the raphe can be regarded as a continuum, in the current 
study we chose to describe the major valve morphologies observed in BAV 
patients as 3 different types (Type 1A, 2A and 3A, based on valve cusp 
orientation), in which the extent of the raphe can vary (Fig. 1). In this study, 
fusion of the right and left coronary cusp is defined as type 1A BAV, fusion 
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Table 1 Patient Characteristics 
 Variable n (%) 
Gender 
- Male 




Bicuspid aortic valve  
- Type 1A 
- Type 2A 
- Type 3A 
- Strictly bicuspid (type B) 
o  Type 1B 








Extent of the raphe  
- Complete 




Valve surgery  
- Mitral valve replacement 
- Pulmonary valve stenosis 






- Atrial fibrillation 
- Supraventricular tachycardia 
- Ventricular tachycardia 
- Pacemaker 
- Implantable cardioverter defibrillator 
o Secondary prevention 










- Angiotensin converting enzyme 
inhibitors  
- Statins 
- Carbasalate calcium 
- Oral anticoagulants 










- Mitral valve repair 
- Aortic valve replacement 
- Aortic valve repair 
- Bentall 
- Tricuspid valve repair 










- Aortic coarctation 
- Atrial septal defect 
- Ventricular septal defect 
- Marfan 
- Common truncus 









- Aortic valve stenosis 
- Aortic valve regurgitation 
- Mitral valve regurgitation 






Smoking  54 (21.2) 
Diabetes 11 (4.3) 
Cerebrovascular accident 14 (5.5) 
Hypercholesterolemia 33 (12.9) 
Peripheral arterial disease 7 (2.7) 
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of the right and non-coronary cusp as type 2A BAV and fusion of the left and 
non-coronary cusp as type 3A BAV. As at this time there is no consensus on 
whether or not a strictly bicuspid valve (i.e. a valve without a raphe) should 
truly be regarded as a separate group, strictly bicuspid valves were defined 
as a subgroup B to facilitate analysis of data (Fig. 1).
Echocardiography
Transthoracic echocardiography was performed using a GE Vivid7 or E9 
(GE-Vingmed, Horten, Norway) ultrasound machine with standard views 
from the parasternal, subcostal, suprasternal and apical windows. The aortic 
valve was examined in the two dimensional parasternal short-axis view and 
classified as bicuspid when two cusps could be clearly identified and the 
Figure 1. Schematic overview of BAV morphologies. 
Drawings are oriented in echocardiographic, i.e. inferior, view of the aortic valve. Upper panel: 
The three major valve morphologies observed in BAV patients are described as three different 
types based on the valve cusp orientation: type 1,2 and 3. The extent of the raphe is indicated 
as analyzed in this study (<0.5, >0.5, complete). Lower panel: Strictly bicuspid valves (without 
a raphe) are defined as a subgroup B. BAV: bicuspid aortic valve
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typical ‘fish-mouth opening’ of the valve was observed (Fig. 2). Diameters of 
the aortic root and ascending aorta were determined in the parasternal long 
axis view.
Echocardiographic analysis
All echocardiographs were evaluated by one experienced observer, using 
GE Medical Systems’s EchoPac, Version 7 (110.0.0, GE-Vingmed, Horten, 
Norway). The aortic valve was evaluated in a cross-sectional view for 
the presence and extent of a raphe. For valves where a raphe could be 
distinguished (subgroup A), distinction was made between a complete raphe 
and an incomplete raphe. Cases where no raphe was detected (subgroup B) 
were defined as strictly bicuspid valves. Diameters of aortic sinus, ascending 
aorta and aortic arch were measured from leading edge to leading edge 
in end-diastole according to the European Association of Echocardiography 
recommendations (23). Aortic annular diameter was measured from inner 
edge to inner edge during systole. All measurements were made in mm, 
rounded to 2 significant figures. The ascending aorta was considered dilated 
at a diameter of >38mm. Subgroup analysis was performed in: 1) patients with 
pronounced dilation of the aortic wall, defined as an ascending aortic diameter 
>44 mm; 2) patients with a history of CoA; 3) patients who had undergone 
ascending aortic or aortic valve surgery. If a patient had undergone surgery 
of either the aortic valve or the ascending aorta, the last echocardiographic 
study before surgery was used to measure aortic diameters and to evaluate 
valve morphology.
Of 199/255 patients serial echocardiographic studies at least 6 months 
apart were available. Both the first and most recent studies were selected 
for quantitative evaluation of the dynamics of aortic dilation over time. To 
evaluate left ventricular hypertrophy, end-diastolic left ventricular mass was 
calculated by measuring the end diastolic outer and inner left ventricular wall 
thickness in the M-mode view using the Devereux formula (24).
Statistical Analysis
All collected data were registered in a Microsoft Office Access 2003 database. 
The database was exported into IBM SPSS Statistics Version 20 for computing 
variables and statistical analysis. Independent samples T-tests were used to 
compare means of numerical data in 2 categories. One-way ANOVA tests 
were used for comparing numerical data in more than 2 categories. Cross-
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Figure 2. Representative examples of different BAV types as seen from the short-axis 
parasternal view on echocardiography. 
The yellow arrow indicates the raphe. The orange star indicates the typical fish mouth 
opening of the valve. a: Type 1A in open position. b: Type 1A with complete raphe in closed 
position. c: Type 1A with incomplete raphe in closed position. d: Type 1B in open position. 
e: Type 1B in closed position. f: Type 2A in open position. g: Type 2A with complete raphe 
in closed position. h: Type 2A with incomplete raphe in closed position. i: Type 2B in open 
position. j: Type 2B in closed position.BAV: bicuspid aortic valve
Type 1 Type 2
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tabulations were made for binary categorical data, on which chi-square 
goodness-of-fit-tests were performed to test for independence. For sets of 
independent numerical data linear regression analysis was used to evaluate 
trends. Similarly, trends for binary categories were evaluated with binary 
logistic regression to correct for possible confounding factors such as age 
and gender. To evaluate surgery-free survival for different patient groups, 
Kaplan-Meier survival curves were made whereby the age of a patient at 
the time of a surgical intervention of the aortic valve or ascending aorta was 
considered an uncensored ‘event’ and the age of an un-operated patient at 
the end of the study was considered censored data. All statistical analyses 
were two-tailed and considered significant if p<0.05. 
RESULTS
Patient characteristics
A total of 255 patients with BAV (age 18-85 years, mean 48±15 years) were 
identified and analyzed. Of these, 179 were male (70.2%) and 76 female 
(29.8%). Patient characteristics and echocardiographic data are summarized 
in Table 1. The distribution of valve morphology is shown in figure 3.
Figure 3. Schematic overview of the distribution of valve morphologies in the study population.
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BAV morphology as related to valve function
120 patients were diagnosed with aortic stenosis, the same number of 
patients showed aortic regurgitation (Table 1). There were no significant 
differences in valve function between the different morphological subtypes. 
However, BAVs with a complete raphe had a significantly higher prevalence 
of valve dysfunction than BAVs with an incomplete raphe (82.9% vs. 66.7%, 
p=0.01, Table 2). When specifying this for type of valve dysfunction, this 
difference remained significant in patients with aortic regurgitation (56.8% 
vs. 42.3%, p= 0.05), whereas in patients with aortic stenosis there was no 
difference between patients with a complete or incomplete raphe (49.5% 
vs 43.6%, p=0.419, table 2). In type 1A BAVs with a complete raphe the 
difference in prevalence of aortic regurgitation was even more outspoken 
compared to the rest of the study population (57.6% vs. 41.8% p=0.017). 
Aortic valve regurgitation was a greater predisposing factor of valve surgery 
than aortic stenosis, as shown by the Kaplan-Meijer survival curves (Fig; 
4a, b). 
BAV function and left ventricular mass
In patients with valve regurgitation, left ventricular mass was larger 
compared to those without regurgitation (128g/m2 vs. 103g/m2, p<0.001). 
Both aortic valve regurgitation and a larger left ventricular mass were 
associated with male gender (53.6% in males vs. 31.6% in females, p= 
0.001; 122.2 in males vs. 94.2 g/m2 in females, p<0.001 respectively). This 
remained significant even after correcting for body surface area (p=0.01). 
Surprisingly, aortic stenosis was not associated with either left ventricular 
mass, nor with gender.
BAV morphology as related to aortic diameters
All type 1A BAVs, compared to type 2A BAVs, showed a significantly larger 
Table 2: Valve morphology as related to dysfunction





Valve dysfunction (n = 144)  92 (82.9%) 52 (66.7%) 0.01 
Aortic regurgitation (n = 96)  63 (56.8%) 33 (42.3%) 0.05 
Aortic stenosis (n = 89)  55 (49.5%) 34 (43.6%) Not significant 
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sinus (37.29 vs. 33.89mm, p=0.001, table 3a). Valves with a complete 
raphe had significantly larger aortic diameters at the level of the ascending 
aorta, as compared to valves with an incomplete raphe (p=0.041). At the 
level of the aortic sinus and aortic arch this difference was not significant 
(Table 3b). Type 1A BAVs and a complete raphe also showed a significant 
difference in sinus diameter (37.74 vs. 36.01 p=0.031) compared to the 
rest of the study population. Males had significantly larger absolute aortic 
diameters compared to females at all levels, but these gender differences 
became non-significant when corrected for body surface area. 
Regurgitant valves showed a significantly larger sinus (37.5mm vs. 35.8mm, 
p= 0.023) compared to non-regurgitant BAVs. Stenotic valves on the other 
hand had a significantly smaller sinus (38.1mm vs. 39.9mm p<0.001) and 
annulus (20.93mm vs. 22.96mm, p<0.01) compared to the rest of the study 
population, but a larger aortic arch (30.2mm vs. 28.7mm, p=0.036). 
When corrected for body surface area, age and gender, statin intake was 
associated with a significantly smaller diameter of the ascending aorta (p= 
0.017) and with a significantly longer surgery free survival compared to no 
statin use, apparent on the Kaplan-Meijer survival curve for intervention-
free lifespan and statin use (Fig. 4c). The latter finding corresponded with 
the mean age at the time of operation, BAV patients taking statins were 
almost 14 years older at the time of an intervention as compared to those 
who do not (56.0 vs. 42.2 years old, p<0.001) (Fig. 4c). 
Table 3 Valve morphology as related to aortic diameter
a: Type 1A versus type 2A
b: In all types BAV with complete raphe versus all types BAV with incomplete raphe
Aortic diameter  Type 1A Type 2A P value 
Sinus (mm)  37.29 ± 5.88 33.89 ± 4.84 0.001 
Ascendens (mm)  37.34 ± 6.75 36.33 ± 7.03 Not significant 
Arch (mm) 29.30 ± 5.45 30.94 ± 4.70 Not significant 
 
Aortic diameter  Complete raphe Incomplete raphe P value 
Ascendens (mm)  38.02 ± 6.53 35.91 ± 7.00 0.041 
Sinus (mm)  36.91 ± 5.82 36.13 ± 5.81 Not significant 
Arch (mm) 30.07 ± 5.16 29.21 ± 5.66 Not significant  
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Aortic dimensions over time
The interval between the evaluated echoes ranged from 1 to 17 years with 
an average of 5.6 (SD 4.1) years follow-up. Dilation was most pronounced at 
the ascending aorta followed by the sinus, arch and annulus.
Increase in diameter of the ascending aorta, occurred more often in males 
than in females (46.9% vs. 28.9%, p= 0.008). Evaluation of the subgroup 
with dilation of the ascending aorta >44 mm, showed that these patients were 
on average 10 years older than patients with smaller degrees of dilation, 
indicating a progression of dilation with age. These patients also had more 
rapid aortic dilation per year at all locations, except for the aortic arch.
Patients with isolated aortic dilation received valve/aortic surgery 10 years 
later in life than patients with isolated valve disease who underwent surgery 
Figure 4. Kaplan-Meijer curves of freedom from intervention with age in years amongst a) 
patients with aortic stenosis versus patients without; b) patients with valve regurgitation versus 
patients without; c) patients with statin use versus patients without.
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(p<0.05), probably reflecting the fact that the latter group became symptomatic 
earlier in life. When studying the progression of dilation of the ascending aorta 
over time, hypertension was found as a predisposing factor; 14.6% of patients 
with hypertension showed dilation of more than 1.5 mm/year, compared to 
only 5.7% of patients without hypertension (p= 0.049 when corrected for age 
and gender). 
BAV and Aortic coarctation
Patients with aortic coarctation constituted the largest group of patients 
with associated congenital cardiac malformations (n=39). Other congenital 
malformations included atrial or ventricular septal defect, and patent ductus 
arteriosus (numbers too small for sufficient power for analysis). Patients with 
a history of aortic coarctation were 9 years younger than those without (40.7 
vs. 49.3 years old, p<0.001) and there was no statistical difference in gender 
(p=0.47).
Distribution of BAV morphology in patients with aortic coarctation was 
identical to the rest of the study population, the majority having a type 1A BAV 
(56.4% in patients with versus 59.7% in patients without aortic coarctation, 
p=0.321). However, in the majority (72.7%) of aortic coarctation patients and 
type 1A BAV an incomplete raphe was seen as compared to only 38.8% in 
the population without aortic coarctation. A complete raphe was found in only 
27.3% of aortic coarctation patients, whereas 61.2% of the patients with type 
1A BAV without aortic coarctation, had a complete raphe (Table 4).
Patients with aortic coarctation and type 1A BAV had significantly less valve 
regurgitation (13.6% vs. 55.8%, p<0.001) and significantly smaller diameters 
of the ascending aorta (33.7mm vs. 37.8mm, p<0.001) and aortic arch 
(25.8mm vs. 30.2mm, p<0.001) than patients with isolated BAV. Figure 5 
shows a working model for the risk stratification of BAV patients, based on 
findings of this study.
DISCUSSION
Key findings of this study are 1) Patients with type 1A BAV and a complete 
raphe show more aortic regurgitation and root dilatation as compared to the 
rest of the study population 2) Patients with type 1A BAV have larger aortic 
sinuses than patients with type 2A BAV 3) aortic coarctation patients have 
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smaller aortic root diameters and less valve regurgitation 4) Males have 
a higher prevalence of aortic regurgitation, larger aortic diameters 5) Use 
of statins is correlated with smaller aortic diameters and a delay in valve 
intervention. 
Valve morphology and extent of the raphe as predictors of outcome.
The most important findings were related to the extent of the raphe. A complete 
raphe predisposed for larger aortic diameters and more valve regurgitation. 
However, the extent of the raphe could not explain the gender differences 
described above as the prevalence of complete raphe was the same in 
males and females. To our knowledge, the extent of a raphe in BAV disease 
has not been studied previously as a prognostic factor. The worse outcome 
observed in patients with a complete raphe is possibly due to the fact that 
BAVs with incomplete raphe have a more physiological, tricuspid-like opening 
and therefore function better. BAVs with complete raphe seem to have more 
uneven sized cusps and smaller openings which may predispose to valve 
dysfunction. With regard to the orientation of the raphe, type 2A BAVs showed 
a trend to more aortic valve stenosis and dilation of the ascending aorta over 
time than type 1A BAVs. The same is observed in patients with type B BAVs 
(no raphe), when comparing type 2B to type 1B, with about the same level 
of significance. This is supported by developmental findings of Fernandez 
et al, who state that the etiology underlying various BAV orientations is 
different (25). In this study eNOS knock-out mice developed only type 2 
BAVs with abnormal development of cardiac valve cushions, suggesting that 
Table 4: Characteristics of patients with type 1A BAVs with aortic coarctation versus without 
aortic coarctation
Variable  Aortic coarctation No aortic 
coarctation 
P value 
Type 1A BAV, n (%) 22 (56.4%) 129 (59.7%) Not significant 
Raphe 
- Incomplete 










Ascendens (mm)  33.3 ± 6.06 37.8 ± 6.78 <0.001 
Arch (mm)  25.5 ± 4.77 30.2 ± 4.98 <0.001 
Valve regurgitation  3 (13.6%) 72 (55.8%) < 0.001 
Valve stenosis 10 (45.5%) 56 (43.4% Not significant 
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the type 2 BAV may be a product of a developmental defect related to an 
exacerbated NO dependent epithelial-to-mesenchymal transformation. The 
Syrian hamster on the other hand develops only type 1 BAV, which seemed 
to be the product of an abnormal embryonic outflow tract septation and may 
therefore be related to alterations in neural crest cell behaviour (25).
Type 1A BAVs had a significantly larger sinus and these patients underwent 
10% more operations as compared to type 2A BAVs. These data are in line 
with previous studies (6,7,10). Patients with type 1A BAVs and a complete 
raphe showed significantly more regurgitation and root dilation as compared 
to the rest of the study population. As freedom from valve and aortic 
intervention is an important criterion for a better prognosis in BAV disease, 
type 1A BAVs can be regarded as the valve orientation with the highest risk, 
which is in line with the above mentioned studies. This indicates that type 
1A BAVs with a complete raphe are more susceptible for aortic dilation and 
should be monitored more closely for valve regurgitation and aortopathy. 
Figure 5. Working model for risk stratification of BAV patients. BAV: bicuspid aortic valve
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Aortic valve regurgitation versus stenosis as predictors of outcome
Aortic valve regurgitation was a stronger predictor for adverse outcome than 
stenosis. Patients with regurgitant BAVs had larger sinus diameters, showed 
more left ventricular hypertrophy and underwent surgery earlier in life than 
patients without aortic regurgitation. In contrast, stenosis has little effect on 
the age at time of operation (Fig. 4). This corresponds to the data reported 
by Cotrufo et al. and by Della Corte et al., who found BAV regurgitation 
responsible for root dilation, whereas stenotic BAVs had an unaffected root 
(18,19). Hence, the type of valve dysfunction is an important tool for the 
clinician when monitoring BAV patients.
Exponential dilation and aneurysm formation of the ascending aorta
Dilation was most apparent in the ascending aorta, with a progressive 
growth per year seen with increasing diameters. This stresses the indication 
for careful follow up of patients with larger diameters, as they may show 
more rapid progression in the course of their disease. The age at the time 
of operation of patients with dilation of >44mm however, was 10 years older 
than other BAV patients. This may be explained by the fact that patients 
with isolated dilation can remain asymptomatic for many years, whereas 
patients with valve disease develop symptoms and are referred for a surgical 
intervention. Concomitant aortic surgery can be performed then, also in 
cases with a non-critical aortic diameter.
BAV patients with hypertension showed a higher incidence of rapid dilation of 
the ascending aorta than those without. This again stresses the detrimental 
effects of strain on the aortic wall caused by high blood pressure, predisposing 
for dilation and the necessity for careful regulation of blood pressure (26). 
The use of statins was correlated with smaller aortic diameters and a delay 
in valve interventions. Based on these results the preventive use of statins 
could be considered in high risk patients with BAV. Statins are already known 
for limiting the progression of stenosis in BAV disease (27) as well as slowing 
aortic dilation in patients with BAV and stenosis (28). Further research is 
warranted to determine whether statins may also be used as preventive 
measure in patients with BAV without valve stenosis.
BAV and aortic coarctation
Subgroup analysis of the aortic coarctation group revealed that these patients 
are on average 9 years younger than the rest of the study population, which 
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may be explained by the fact that these patients usually show symptoms 
earlier and are often referred from the pediatric cardiologist as soon as they 
reach adulthood. The prevalence of BAV in aortic coarctation patients is an 
estimated 40-50%(4). The majority of patients in the current study had type 
1A BAV, which corresponds to reports in literature (29). Aortic coarctation 
patients had smaller aortic root diameters and less valve regurgitation, 
which may be explained by the fact that less aortic coarctation patients had 
a BAV with complete raphe. The prevalence of stenosis was similar in the 
aortic coarctation group compared to the rest of the study population. This 
in contrast to earlier research which found an association between aortic 
coarctation and valve dysfunction (29). 
Male gender and prognosis
Male patients with BAV had a higher prevalence of valve dysfunction, 
especially regurgitation. They also had larger absolute aortic diameters and 
more often increase in aortic diameter. More left ventricular hypertrophy 
was observed in male BAV patients as compared to females. These data 
indicate that male gender is a risk factor for a worse prognosis in patients 
with BAV, which is in line with previous studies (17,24). The larger degree of 
regurgitation may be a direct result of the larger aortic dimensions observed 
in male patients, although an opposite effect (regurgitation leading to dilation 
of the sinus and ascending aorta) may also be the case. The hypertrophy 
could be a result of chronic volume overload caused by aortic regurgitation, 
as reported previously (30). Why this is more pronounced in male patients, 
is not clear. Nistri and colleagues (31) have attributed aortic dilation, which 
was predominantly observed in young males, to a congenital weakness of 
the aorta, independent of valve dysfunction, age or body size. On the other 
hand, Della Corte and colleagues state that aortic dilation in young males 
should be attributed to varying degrees of regurgitation of the aortic valve 
(18). The current study indicates that this gender difference is not only seen 
in ‘young’ males, but remains significant at any age, indicating that males 
with BAV should be monitored more frequently than females throughout their 
lifetime. 




This was a retrospective analysis of clinically obtained patient data derived 
from a single center. A retrospective analysis is subjected to selection bias, 
as the investigator self-selects the cases. This bias was minimalized by 
including consecutive BAV patients who underwent an echocardiogram 
between 2005 and 2010.
CONCLUSIONS AND CLINICAL IMPLICATIONS
With regard to valve morphology in BAV patients, this study shows that the 
extent of the raphe is of clinical importance, as a complete raphe predisposes 
for more valve dysfunction and aortopathy.
This study provides a working model showing that males with a type 1A BAV 
with a complete raphe, hypertension and no statin use exhibit the highest 
risk of complications such as progressive aortic and valvular dysfunction 
necessitating intervention (Fig. 5).
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Objectives: The clinical course of many patients with a bicuspid aortic valve 
(BAV) is complicated by ascending aortic dilatation. Currently, the indication 
for aortic surgery is solely based on the aortic diameter and subsequently 
only a small proportion of BAV patients undergoing valve surgery require 
concomitant ascending aortic replacement based on these recommendations. 
Unfortunately, a substantial number of BAV patients still develop aortic 
dilatation in the future and would potentially benefit from a more aggressive 
approach towards ascending aortic replacement. We, therefore, designed 
this study to identify molecular biological markers in the aortic wall predictive 
of aortopathy in BAV. 
Methods: Ascending aortic wall specimen of BAV (n = 36) and tricuspid 
aortic valve (TAV) (n = 23), both without and with (>44 mm) dilatation were 
investigated histologically and immunohistochemically for the expression 
of markers for vascular remodeling (transforming growth factor (TGF)-β, 
phosphorylated Smad2, matrix metalloproteinase 9 (MMP9)), cellular 
differentiation (c-Kit, phosphorylated-c-Kit, hypoxia-inducable factor-1 alpha 
(HIF1α)) and haemodynamic influences on the aortic wall (endothelial nitric 
oxide (eNOS)). 
Results: All BAV patients showed significantly less inflammation (P < 0.001) 
and an altered intima/media ratio when compared with TAV patients. The 
expression of markers of a signalling pathway characteristic for cellular 
dedifferentiation, as exemplified by the marked expression of c-Kit, 
phosphorylated c-Kit and HIF1α; in the dilated BAV group was however 
completely comparable with only a subgroup of the non-dilated BAV (BAb), 
whereas the remainder of the non-dilated BAV group (BAa) was significantly 
distinct. This difference between the dilated BAV and BAa was further 
confirmed in the expression of TGF-β, phosphorylated Smad2, MMP9 and 
eNOS. Besides the expression pattern, similarity in the dilated BAV and BAb 
was also noted clinically in the most common variant of commissure position 
and conjoined raphe of the BAV. Based on these observations, we consider 
the BAb group a likely candidate for future dilatation as opposed to the BAa 
group. 
Conclusions: Using a panel of molecular tissue markers, the non-dilated 
BAV patients can be divided into groups susceptible and non-susceptible to 
aortopathy. 
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INTRODUCTION
Bicuspid aortic valve (BAV) is the most common congenital cardiac defect, 
with a prevalence in the general population in the range 0.5–2% (1). The 
clinical course of BAV is often complicated by aortic regurgitation and/or 
stenosis, infective endocarditis and aortic dilatation. In particular, the latter 
one forms a critical complication in individuals with BAV, as aortic dilatation 
carries an increased risk of dissection and rupture. Fifty-nine percent of 
patients with BAV, below the age of 30 have ascending aortic dilatation, which 
rises to 88% in people over 80 years old (2). Currently, guidelines recommend 
ascending aortic replacement in patients with BAV and an ascending aortic 
diameter ≥50 mm, and concomitant aortic surgery if the diameter exceeds 
45 mm (3). Unfortunately, aortic diameter alone as a selection criterion is not 
sufficient for identifying patients with inherent aortic weakness before a life-
threatening complication occurs (4, 5). On the one hand, patients with a non-
dilated aortic wall at the time of aortic valve surgery may still develop aortic 
dilatation in the future, while, on the other hand, some patients will never 
experience aortic wall dilatation. A preventive ascending aortic replacement 
would expose this last group of patients, not prone to develop dilatation of the 
aorta, unnecessarily to the risk of this procedure and ensuing postoperative 
complications. Therefore, there is an unmet need to identify genetic and/
or molecular markers to improve a patient-tailored risk stratification for BAV 
individuals, applicable prior to or during surgery. Although histological and 
biochemical differences have been shown between dilated aortic walls of BAV 
and tricuspid aortic valve (TAV) patients, little is known about the difference in 
non-dilated aortas. We have previously shown marked histological differences 
and maturation defects in non-dilated aortas of BAV patients (6). We were, 
however, not yet able to demonstrate differences within this group, as would 
be expected based on the fact that some patients with BAV never develop 
aortic dilatation. The aim of this study was therefore to identify patients with 
BAV and a non-dilated aorta who are susceptible for future aortopathy. To 
identify these patients, we compared dilated and non-dilated aortas of both 
BAV and TAV patients as controls with respect to biochemical markers of 
vascular remodeling, cellular differentiation and haemodynamic modifiers. 
Since developmental data (7) and recent clinical diagnostic data based on 
commissure position (8) suggest that the orientation of the conjoined raphe 
is of relevance, we also studied this aspect.





Ascending aortic wall biopsies were collected from individuals with BAV and 
TAV, with or without dilatation. Dilatation was clinically defined by surpassing 
an ascending aortic wall diameter of 44 mm, based on the American College 
of Cardiology/American Heart Association guidelines (3). The institutional 
ethics committee at the Leiden University Medical Centre (LUMC) approved 
this study. The Heart Valve Bank, Thoraxcenter, Erasmus Medical Center, 
Rotterdam, provided six BAV samples without aortic dilatation as these were 
not suitable for transplantation, as approved by their Scientific Advisory 
Board. Furthermore, we received five BAV aortic specimens from both the 
convex and concave side of the aortic wall of patients with dilatation, from the 
Universitätsklinikum Schleswig-Holstein, Lübeck, Germany. Patients were 
divided into four groups: (a) TAV without dilatation, termed TA (n = 11, mean 
age: 64.5 ± 9.0 years), obtained post-mortem, (b) TAV with dilatation, termed 
TAD (n = 12, mean age: 72.3 ± 11.2 years), collected during elective repair, 
(c) BAV without dilatation, termed BA (n = 17, mean age: 55.8 ± 9.8 years), 
representing the six BAV samples provided by the Heart Valve Bank Rotterdam 
and a group of patients who underwent elective stentless root replacement - 
our preferred technique - while they had no ascending aortic pathology and 
(d) BAV with dilatation, termed BAD (n = 19, mean age: 60.7 ± 7.8 years). 
A small subgroup of BAD (n = 5, mean age: 52.6 ± 7.9 years, BAD2 group) 
were selectively studied for differences in the protein expression patterns of 
the aortic wall between the convex and concave site, obtained during elective 
repair. We excluded patients with a proven genetic disorder identified by 
genetic tests (e.g. Marfan’s disease, familial thoracic aortic aneurysm and 
dissection). Characteristics of enrolled patients are presented in Table 1. 
All patients in BAV undergoing surgery had a stenotic valve with either mild 
or no regurgitation. The patients thus had comparable valve pathology. We 
also investigated the orientation of the conjoined cusps in BAVs: the raphe 
was noted either between the right to non-coronary (RCC/NCC), right to 
left coronary (RCC/LCC) and left to non-coronary (LCC/NCC) cusp or was 
defined as unicuspid, with fusion at two commissure sites. Following excision, 
all specimens were fixed in formalin for 24 h, decalcified in Kristensen’s 
solution (a formic acid–formate buffer) for 120h and subsequently embedded 
in paraffin. Transverse sections (5 μm) were mounted on precoated Starfrost 
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slides (Klinipath B.V., 3057-1, Duiven, The Netherlands) comparing different 
stainings on consecutive sections. 
 
Immunohistochemistry
In this article, we focused on the expression of proteins known to be 
involved in vascular remodeling (transforming growth factor (TGF)-β, 
phosphorylated Smad2 (pSmad2) and matrix metalloproteinase 9 (MMP9) 
and cellular differentiation (alpha smooth muscle actin (αSMA) and c-Kit 
(3, 9)) and possible haemodynamic influences on the convex and concave 
area of the dilated BAV aortic wall (endothelial nitric oxide (eNOS)). For 
immunohistochemical staining, sections were deparaffinated and rehydrated 
before antigen retrieval in citrate buffer (microwave, 92-98°C, 12 min). 
Inhibition of endogenous peroxidase was performed with 0.03% H2O2 in 
phosphate buffered saline (PBS) (20 min). Non-specific staining was reduced 
by blocking with PBS-Tween-20 (PBS-T) with 1% bovine serum albumin (1% 
BSA, Sigma-Aldrich, USA). Subsequently, the slides were incubated overnight 
at room temperature (20°C) with diluted primary antibodies against: eNOS 
1/100 (Thermo Scientific, PA1037), MMP9 1/100 (MCA2736), panTGF-β 
1/1000 (MO-C40009E), pSmad2 1/250 (Cell Signaling, 3108), fibulin-1 1/100 
(Santa Cruz, sc-20818), c-Kit 1/100 (DAKO, A4502) and phosphorylated 
c-Kit ( pc-Kit) 1/100 (Abcam ab62154). All primary antibodies were dissolved 
in PBS-T with 1% BSA. Control staining was performed using PBS-T and 1% 
BSA as the primary step. Between subsequent incubation steps, all slides 
were rinsed with PBS (2×) and PBS-T (1×). The slides were incubated with 
secondary antibodies (45 min): for eNOS, c-Kit and pc-Kit with goat anti-
rabbit biotin 1/200 (Vector Laboratories, USA, BA-1000) and goat serum 
1/66 (Vector Laboratories, USA, S1000) in PBS-T; for MMP9, panTGF-β 
and pSmad2 with horse anti-mouse biotin 1/200 (Santa Cruz Biotechnology, 
Inc., CA, USA, SC-9996-FITC) in horse serum 1/66 (Brunschwig Chemie, 
Switzerland, S-2000) in PBS-T. Subsequently, slides were incubated with 
ABC reagent (Vector Laboratories, USA, PK 6100) (45 min). The slides 
were incubated with 400 μg/ml 3–3’di-aminobenzidin tetrachloride (DAB, 
Sigma-Aldrich Chemie, USA, D5637) dissolved in Tris-maleate buffer 
(pH7.6) to which 20 μl of 30% H2O2 was added (10 min). Counterstaining 
was performed with 0.1% hematoxylin (Merck, Darmstadt, Germany) (5 s), 
followed by rinsing with tap water (10 min). Finally, slides were dehydrated 
and mounted with Entellan (Merck, Darmstadt, Germany). To differentiate 
150119_versie 3.indd   115 19-1-2015   22:57:18
116 chapter 5
5
c-Kit positive cells from mast cells expressing c-Kit, deparaffinated sections 
were stained with 0.1% toluidine blue (2 min), rinsed in distilled water, quickly 
dehydrated and cover-slipped. Toluidine blue staining excluded the possibility 
that the observed cells were mast cells, which appeared as metachromatic 
reaction granules containing heparin or histamine. The mast cells had a 
unique morphological appearance, and were rare among the c-Kit positive 
cells lining the adventitial–medial border.
Double immunofluorescence
To detect co-expression, we performed double immunofluorescent stainings. 
Sections were deparaffinated, rehydrated and subjected to antigen retrieval 
as described. Tissue sections were incubated with primary antibodies 
pc-Kit 1/100 and HIF1α 1/50 overnight (4°C), followed by incubation with 
secondary antibody Cy3 donkey anti-mouse immunoglobulin G (IgG) ( 
Jackson Immunoresearch, 715-165-150) for HIF1α and Alexa Fluor 647 
donkey anti-rabbit IgG (Invitrogen, A-31573) for pc-Kit (1 h, 20°C). Cy3 
and Alexa Fluor 647 were preferred secondary antibodies, because of 
green autofluorescence of the elastic lamellae. Nuclei were visualized with 
4’,6-diamidino-2-phenylindole (DAPI, Sigma-Aldrich). Finally, slides were 
mounted with ProlonGold (Invitrogen, P36930). 
Patient characteristics are shown in table 1. TA: tricuspid valve, without dilation; TAD: tricuspid 
valve, with dilation; BA: bicuspid valve, without dilation; BAD: bicuspid valve, with dilation. * 
data unavailable, clinically defined as non-dilated by pathologist. ** data unavailable for 5 
patients, clinically defined as non-dilated by pathologist. 
Table 1 Clinical characteristics of all patients
Characteristic TA TAD BA BAD BAD2 
 N=11 N=12 N=17 N=19 N=5 
Age (years) 64.5 ± 9.0 72.3 ± 11.2 55.8 ± 9.8 60.7 ± 7.8 52.6 ± 7.9 
Males (%) 6 4 12 16 2 
Females (%) 5 8 5 3 3 
Ascending aorta 
diameter (mean) 
* 55.0 ± 10.7 36.5 ± 7.4** 52.7 ± 6.2 56.2 ± 10.5 
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Histological parameters, immunohistochemical analyses and 
morphometry
To provide a basis for histopathological characteristics, we followed the 
techniques as previously described in our study on the differentiation 
differences between the aortic wall of BAV and TAV patients (6). In addition, 
cytoplasmic expression levels of MMP9 and c-Kit, nuclear expression of 
pSmad2, pc-Kit and HIF1α, cytoplasmic and extracellular expression of 
TGF-β, and cytoplasmic and nuclear expression of eNOS were analyzed 
using a BM500 microscope with plan achromatic objectives (Leica 
Microsystems, Wetzlar, Germany) on three predetermined locations (left, 
middle and right) of every section, which we refer to as ‘microscopic fields’ 
(MFs), and preserved in the evaluation of all stainings. In each MF, the level 
of expression was indexed on the three anatomical layers of the aortic wall 
(tunica intima, media and adventitia) as 0 (no expression in the respective 
layer), 2 (expression in less than one-third of the layer), 4 (expression in 
two-thirds of the layer) and 6 (expression in the whole layer). To determine 
the level of eNOS expression, the number of positively stained nuclei and 
cytoplasm was counted and analyzed using ImageJ in the three fields for 
each stained section. A threshold was applied to filter background noise. The 
total number of cells (positively and negatively stained nuclei and cytoplasm) 
was not different between specimens. Therefore, in each MF the number 
of eNOS-positive cells was normalized to the total number of cells per 105 
μm2. Finally, the number of normalized positive cells for each staining was 
averaged between the three MFs. All specimens were re-evaluated by an 
independent, experienced histopathologist who was blinded to the clinical 
data.
Statistical analyses
All numerical data are presented as mean ± standard deviation of 3 fixed 
MFs on each stained slide. Statistical differences were evaluated with the 
Mann-Whitney U-test for comparison between the groups. Significance was 
assumed when P < 0.05 using the SPSS 20.0 software program (SPSS, Inc., 
Chicago, IL, USA). We have performed a one-, two- and three-way analysis 
of covariance test to correct for age and gender. The Graphpad software was 
used to create graphics of statistical analysis.





The normal aortic wall is made up of three layers, the tunica intima, media 
and adventitia (Fig. 1A, B, F and G). The internal elastic membrane forms 
a border separating the fine elastic fibers in the tunica intima and lamellae 
in the tunica media, which are more regular and thick. The sometimes ill-
defined border between the media and adventitia is delineated by the last 
elastic lamella of the media.
The adventitia consists of loose fibrous tissue containing nerve fibers, 
fibroblasts, adipocytes, a few quiescent resident inflammatory cells and 
vasa vasorum, lined by endothelial cells and vascular smooth muscle cells 
(VSMCs). Characteristics of the differences in histopathology between the 
TAV and BAV groups which we recently reported (6) are summarized in Fig. 
1A, B, F, G, K–M. 
Transforming growth factor-β, pSmad2 and endothelial nitric oxide
We examined two components of the TGF-β pathway, TGF-β and pSmad2, 
involved in vascular remodeling. TGF-β expression spread out from the 
intima to the inner media (Fig. 1A and B). Intimal expression was significantly 
lower in all specimens of the BAV (BA and BAD) when compared with all TAV 
groups (TA and TAD) (P = 0.0058 and P = 0.0076, respectively) (Fig. 1A, B, 
F, G and N). The middle media was completely devoid of TGF-β expression 
in both groups, but in the outer media, on the adjacent adventitial side, 
expression was visible as a gradient (Fig. 1A, B, E–G). In the outer media 
Figure 1 Transverse histological sections of the aortic wall (A-J), consisting of an intima 
(i), media (m), further subdivided in an inner (im), middle (mm) and outer media (om), and 
adventitia (a). 
The significantly thinner intima in BA and BAD (L) is devoid of TGF-β (F (with a detailed view 
of the intima),G) and pSmad2 expression compared to TA and TAD (A,B) (N,O). In the outer 
media TGF-β and pSmad2 level of expression is significantly higher in TAD compared to BAD 
(P,Q), TGF-β expression shown in B and G with a detailed view of TGF-β in E and of pSmad2 
in J. No TGF-β expression is seen in the middle media of either group (A-C, F-H), whereas 
pSmad2 expression is present (D,I see arrow). In the significantly thicker media in TAD (M) 
significantly more severe inflammatory reaction is seen than BAD (K). TGF-β: Transforming 
Growth Factor-β, pSmad2: phosphorylated Smad2, TA: tricuspid valve without dilation, TAD: 
tricuspid valve with dilation, BA: bicuspid valve without dilatation, BAD: bicuspid valve with 
dilation.  Scale bars: A,B,F,G 500 µm; E,J 100 µm; C,D,H,I 50 µm
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TGF-β expression was significantly lower in the BAD when compared with 
TAD and BA groups (P = 0.026 and P = 0.0035, respectively) (Fig. 1B, E–G, 
J and P). 
The expression of the downstream mediator of the TGF-β signaling pathway, 
pSmad2, was in general comparable with its ligand TGF-β. PSmad2 
expression was seen in the intima, and significantly lower expressed in 
all BAV when compared with all TAV groups (P = 0.0020 and P = 0.0179) 
(Fig. 1O). Expression of pSmad2 in the outer media was lower in the BAD 
compared with the TAD group (P = 0.012) (Fig. 1J and Q). Unlike TGF-β, 
which was only seen in a gradient in the inner and outer media, pSmad2 was 
observed in the complete media, including the middle media (Fig. 1C, D, H 
and I). 
Pathological changes in the aortic wall during dilatation might be linked to 
haemodynamic changes, probably mainly acting on the endothelial cell layer, 
although no difference in endothelial eNOS localization was noted between 
the groups. A subset of VSMCs in the media, however, stained positive for 
eNOS (Fig. 2A and B). This media expression of eNOS was significantly 
less in all BAV (BA, BAD) when compared with TAV (TA, TAD) specimens 
(P = 0.023 and P = 0.035, respectively) (Fig. 2C). As shear stress plays 
an important role in the regulation of TGF-β and eNOS expression (10), 
we investigated whether TGF-β and eNOS levels were different between 
concave, with an increased turbulence of blood flow, and convex bicuspid 
aortic wall biopsies of the BAD group. No difference in expression was found 
between these two locations.
Vascular smooth muscle cells expression of c-Kit
To further elucidate the pathological changes in the aortic wall, we stained 
the sections for c-Kit (Fig. 2D and E), while c-Kit is well known as a stem cell 
marker. We observed staining solely in the cytoplasm of a subset of VSMCs 
in the media and no expression in the intima. The level of expression was 
significantly higher in the BA group when compared with the TA (P = 0.0024, 
(Fig. 2F), which was inverted in the dilated aortic walls where there was a 
significantly lower expression in the BAD compared with the BA group (P = 
0.028); whereas in the TAD compared with the TA group (P = 0.021) (Fig. 2F), 
a significant higher level was noted. Toluidine blue staining of consecutive 
sections excluded the possibility that the observed cells were mast cells. As 
we recently described that the aortic wall in all patients with BAV is less well 
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Figure 2  Transverse histological section of the aortic wall (A,D) with details (B,E). eNOS 
positivity, defined as brown colored DAB staining, in a subset of vascular smooth muscle cells 
in the media is shown in A (arrow) and B. Level of expression of eNOS was significantly lower 
in the dilated aortic wall of patients with a bicuspid valve (BAD) compared to the tricuspid valve 
(TAD) (C). C-Kit level expression (2D see arrow, E) is significantly lower in the non-dilated 
aortic wall of patients with a tricuspid aortic valve, TA, compared to bicuspid aortic valve, BA 
(F). Lowering of c-Kit level of expression is seen after dilation in bicuspid aortic valve (BAD) 
compared to BA, whereas an increase in the dilated aortic wall of patients with a tricuspid aortic 
valve (TAD) is seen as compared to TA (F). Scale bar A,D: 50 µm B,E 10 µm
differentiated compared with the TAV (6) and c-Kit was highly present in the 
less differentiated vascular wall when compared with the mature walls, we 
conclude that the c-Kit expressing cells are not stem cells but dedifferentiated 
VSMCs (9).
Bicuspid valve without dilatation variability and vascular wall remodeling
While analysing the expression of TGF-β and pSmad2 in the outer media 
of the BAD group (Fig. 3C and G), we found a striking segregation of the 
expression level pattern within the BA group. Eight (coded as the BAa 
group) of the total 17 specimens consistently showed significantly different 
expression patterns when compared with the BAD group (Fig. 3A and E), 
whereas the remaining 9 (BAb) completely resembled the BAD group (Fig. 
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3B and F) with a lower expression of both markers (Fig. 3D and H). This was 
not only obvious for TGF-β and pSmad2 expression but was noted for other 
markers expressed in the media. c-Kit expression in the media was also 
significantly higher in the BAa when compared with the BAD and BAb groups 
(Fig. 3I–L), whereas eNOS expression was almost absent in the media of 
the BAa when compared with the BAD and BAb groups (Fig. 3M–P). This 
variance in the BA group was not seen in the intima.
To further analyse whether the differences found between the BAa and BAb 
groups could be associated with differences in vascular wall remodeling, we 
analysed the expression of αSMA and MMP9. While αSMA expression was 
significantly lower in both dilated and non-dilated BAVs when compared with 
all TAVs (P = 0.015 and P = 0.044, respectively) (6), its expression pattern 
was not variable within the BA group. This is in contrast to the expression 
of MMP9, for which the two BA subgroups could be distinguished. The BAa 
group showed almost absent expression of MMP9, whereas significant 
expression was seen in the BAD, comparable with the BAb group (Fig. 3Q–T). 
Hollenbeck et al. (9) have shown that MMP9 regulates the phosphorylation 
of c-Kit, by releasing its ligand stem cell factor from the cell membrane, 
and therefore can also be considered as a marker for differentiation. Pc-Kit 
in turn controls expression of HIF1α. As the MMP9 level was significantly 
lower and c-Kit expression significantly higher in BAa (Fig. 3L and T), we 
eliminated a potential difference in pathobiology between the BAa and BAb 
groups by studying the expression of pc-Kit and HIF1α in specimens from 
the BA and BAD groups. Expression of pc-Kit was seen in the nucleus (Fig. 
4A, D and G) of a subset of VSMCs, while HIF1α was expressed at the cell 
membrane (Fig. 4B, E and H). Pc-Kit and HIF1α expression was abundantly 
present in the aortic media of patients with BAb and BAD (Fig. 4D–I). The 
BAa group, with the almost absent MMP9 expression, was nearly devoid 
of pc-Kit and HIF1α expression (Fig. 4A–C). Interestingly, HIF1α was only 
found coexpressed with pc-Kit in the BAb and BAD groups (Fig. 4A–I). In 
this cascade, however, the link of TGF-β with MMP9 could not be confirmed. 
The expression patterns of the discussed markers in the BAa, Bab and BAD 
groups are summarized in Fig. 4J.
Commissure position in bicuspid aortic valve
It has been reported that the commissure position is a predictor for future 
aortopathy (7). Provided that the presented similarities between the BAb 
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Figure 3 Subdivision of the group patients with a bicuspid aortic valve, without dilation (BA) 
in a BAa and BAb group.
Between the BAa, BAb and patients with a bicuspid aortic valve and dilated aorta (BAD) 
groups the stainings and level of expression of Transforming Growth Factor-β (TGF-β) (A-
D) and phosphorylated Smad2 (pSmad2) (E-H) in the outer media (om), further c-Kit (I-L), 
endothelial nitric oxide (eNOS) (M-P) and matrix metalloproteinase-9 (MMP9) (Q-T) in the 
middle media (mm) were compared. TGF-β, pSmad2, c-Kit expression was significantly 
higher in the BAa group as compared the BAD group. eNOS and MMP9 expression was 
significantly lower in the BAa than the BAD group. The Bab group showed marked similarity 
with the BAD for all markers. Whereas he BAb group was significantly different from BAa for 
all, except for pSMAD2 (E).  a: adventitia m: media Scale bar: 50 µm
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and the BAD group are valid, we expect that the commissure position would 
match between the two groups. Therefore, we assessed the commissure 
position in the BAa, BAb and the BAD groups. In the BAD group, of 4 patients 
the orientation was unknown and the remainder (n = 15) had an RCC/LCC-
type BAV. Although the groups are too small to obtain significant data, the 
RCC/NCC was most apparent in the BAa, while the RCC/LCC was most 
present in the BAb group, similar to the BAD group (Table 2 and Fig. 5).
DISCUSSION
In this study, we found two distinct expression patterns in patients with BAV 
without apparent dilatation. One pattern is completely comparable with the 
expression pattern seen in BAV patients with aortic dilatation, suggestive of a 
different state of vulnerability. To date, decision-making for preventive aortic 
root replacement in patients with BAV is solely based at the population level 
on the aortic diameter. However, although thoracic aortic dilatation forms 
the most critical complication, not all BAV patients are at risk for dissection 
and rupture. Additional criteria are needed to identify patients at risk as 
early as possible. Earlier, clinical parameters, such as the morphological 
appearance of the commissure position of BAV, have been considered (8, 
11); however, these tools are not conclusive. Therefore we searched for 
additional morphological features of the aortic wall, suggestive of vulnerability 
for future complications, which could either alone or in combination with the 
commissure position be applied as a patient-tailored risk stratification. 
When analysing the aortic wall histologically, we could not substantiate the 
observation made by many thoracic surgeons of a thinner aortic wall in 
BAV. Although this is a striking discrepancy with the clinical findings, other 
studies also reported that the total wall thickness, excluding the adventitia, 
is not different between BAV and TAV groups (12). The difference in the 
ratio between the intimal and medial thickness might therefore have been 
interpreted as difference in the wall thickness. 
We previously confirmed that inflammation was much more pronounced in 
the dilated TAV groups than in any other group (6). We also showed that the 
aortic wall in BAV patients is intrinsically different from those in TAV patients, 
as in TAV inflammation and accelerated ageing led to aortic pathology (6). 
In all cases with BAV, in both the dilated and non-dilated groups, there is a 
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Figure 4 Transverse histologic sections of the aortic wall (A-I). 
Immunofluorescent staining of pc-Kit (green), HIF1α (red) and DAPI (blue) is shown in the BAa 
(A-C), BAb (D-F) and BAD (G-I) groups. Expression of pc-Kit was seen in the nucleus (A,D,G) 
of a subset of VSMCs and HIF1α was expressed in the cellular membrane (B,E,H). Pc-Kit and 
HIF1α is richly expressed in the BAb and BAD group as compared to the BAa group which 
was nearly devoid of pc-Kit and HIF1α expression (C,F,I). VSMCs of only stained positive for 
HIF1α co-expressed with pc-Kit (A-I). The expression patterns of the discussed markers in 
the BAa, BAb and BAD group are shown in J. Expression patterns of TGFβ, pSmad2, c-Kit, 
eNOS, MMP9, pc-Kit and HIF1α in BAb and BAD resembled each other whereas BAa was 
significantly different. Scalebar: 25 µm
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maturation defect of the aortic wall, showing less well-differentiated VSMCs 
and a low lamin A/C and progerin expression (6). As the inflammatory 
status and the intima/medial thickness ratio are similar in all BAVs, these 
factors could not serve as a marker to identify the subset of BAV patients 
susceptible to future aortopathy. We, therefore, then focused on differences 
in the expression of markers/proteins involved in vascular remodeling 
(TGF-β, phosphorylated Smad2, MMP9), cellular differentiation (c-Kit (9), 
phosphorylated-c-Kit, MMP9, HIF1α) and eNOS as a marker of possible 
haemodynamic influences. We could distinguish a marked variability in 
the expression pattern of the above-indicated set of differentiation markers 
within the non-dilated BAV group. We see a comparable expression pattern 
in the BAD and BAb subgroups, different from that in the BAa group. We, 
therefore, postulate that the BAb is susceptible to dilatation, while the BAa 
group is non-susceptible to aortopathy. We hypothesize that the enhanced 
expression of the dedifferentiation markers and eNOS induces a cascade 
that will lead to a less stable aortic wall which is accompanied by a decrease 
in the expression of TGF β and pSmad2 correlating with (future) aortic wall 
dilatation. The precise mechanism causing the decrease in expression of 
the vascular remodeling markers in the BAb and BAD groups is not yet 
Table 2 Commissure position in BA
Commissure position in subdivided groups with bicuspid aortic valve, without dilation: BA-
susceptible and BA-non-susceptible. RCC/LCC right to left coronary cusp fusion. RCC/NCC 
right to non-coronary cusp fusion. LCC/NCC left to non-coronary cusp fusion. 
Commissure position  BA susceptible BA non-susceptible 
 N=9 N=8 
Unicuspid (n) (%)  1 (13%) 
RCC/LCC (n) (%) 6 (67%) 2 (25%) 
RCC/NCC (n) (%)  4 (50%) 
LCC/NCC (n) (%) 1 (11%)  
Unknown (n) (%) 2 (22%) 1 (13%) 
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Figure 5 The observed differences in expression of molecular biologic markers are presented 
in a cascade. 
The non-susceptible group (BAa) showed significant higher expression of c-Kit as compared 
to the susceptible group (BAb). MMP9, scarcely expressed in the non-susceptible group and 
abundantly in the susceptible, is involved in the phosphorylation of c-Kit. Lower expression 
of c-Kit in the susceptible group as shown in the cascade, could therefore be the result of its 
conversion to pc-Kit. Besides pc-Kit, HIF1α was richly expressed in the susceptible group, 
in contrast to the non-susceptible. HIF1α was only found co-expressed with pc-Kit. eNOS, 
regulated by HIF1α, showed a similar expression pattern of low expression in the non-
susceptible and significantly higher expression in the susceptible group.  
identified, and is a focus for future research. Further study also is necessary 
to determine the developmental and environmental factors that initiate the 
cascade and thus the distinction in a susceptible and non-susceptible group. 
The findings and hypothesis are summarized in Fig. 5.
Finally, we considered the morphological appearance of the commissure 
position as a determinant of susceptibility, since commissure position, which 
can clinically be analysed echocardiographically, is reported to be important 
in predicting future aortopathy (8, 11). Previously, several studies reported 
that BAVs with an RCC/LCC BAV, which is the most common variant, are 
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associated with more aortic dilatation in adults, whereas BAVs with fusion 
of the RCC/NCC are responsible for valve dysfunction at a younger age 
(13–18). Although the groups were small in our study, the orientation of the 
commissure and position of the raphe was in line with previous findings: RCC/
NCC was most apparent in the BAa (the considered non-susceptible group), 
while the RCC/LCC was seen more often in the BAb group (the considered 
susceptible group) and in BAD patients (Table 2). Recent preclinical studies 
showed that RCC/NCC and RCC/LCC likely have a different pathogenesis 
(19, 20). RCC/NCC BAVs are observed in eNOS −/− mouse embryos (19, 
21, 22), which is comparable with our BAa-non-susceptible group, as this 
group also shows almost absent expression of eNOS and has the RCC/
NCC BAV type as the most common variant. Although more research is 
needed, we suggest that identifying patients with an RCC/LCC commissure 
type could be the first step in selecting patients for a preventive aortic 
root replacement; however, as some variation in commissure position is 
apparent, patient selection could not solely be based on valve morphology. 
The proposed activation cascade should also be taken into account and the 
combination is a possible protocol for decisionmaking. To choose the best 
markers for clinical applications, we first need to question whether decision-
making for aortic replacement surgery will be possible before or only during 
surgery, as this influences the choice of markers. The clearest difference in 
expression level between the susceptible and non-susceptible BA group was 
seen for MMP9, phosphorylated c-Kit and Hif1α, and these would be most 
appropriate to serve as clinical biomarkers. Analysis of these markers would 
be relatively easy to perform using a quick histological frozen section during 
surgery. A disadvantage is that a biopsy from the aortic wall is only possible 
after the patient is on extracorporeal circulation and the aorta is clamped. 
Immunohistochemical analyses are time consuming and increases the time 
the patient is on bypass. Preoperative decision making would be preferable, 
and we will therefore be concentrating in future studies on factors detectable 
in blood. Not only will the decision be formed preoperatively, a blood test is 
also less invasive. Therefore, we will explore if any of the markers identified in 
this study can be measured, is sensitive enough to distinguish the susceptible 
patients and specific enough to recognize patients without expression and 
thus being non-susceptible.
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STUDY LIMITATIONS
We designed our study by comparing the expression of a panel of markers 
distinguishing cases of non-dilated aorta of BAV with BAV that will progress 
to dilatation over time. A limitation of our study is that we did not have frozen 
tissue samples of all the aortic wall specimens we received fixed in formalin 
from the various groups.Therefore, we could not perform a western blot to 
correlate this to our findings of immunohistochemistry. To secure greater 
confidence in the obtained results, an animal model that recapitulates the 
c-Kit phosphorylation and downstream HIF1α biology, using knock-down or 
c-Kit inhibition strategies is needed. 
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Background: Patients with bicuspid aortic valve (BAV) and patients with 
Marfan syndrome (MFS) are more prone to develop aortic dilation and 
dissection compared to patients with a tricuspid aortic valve (TAV). To 
elucidate potential common as well as distinct pathways of clinical relevance, 
we compared the histopathological substrates of aortic pathology. 
Methods and results: Ascending aortic wall biopsies were divided in five 
groups: BAV (n=36) and TAV (n=23) without and with dilation and non-dilated 
MFS (n=8). General histologic features, apoptosis, and the expression of 
markers for VSMCs maturation, markers predictive for ascending aortic 
dilation in BAV and expression of fibrillin-1 were investigated. Both MFS and 
BAV showed an altered distribution and decreased fibrillin-1 expression in 
the aorta and a significantly lower level of differentiated VSMCs markers. 
Interestingly, markers predictive for aortic dilation in BAV were not expressed 
in the MFS aorta. The aorta in MFS was similar to the aorta in dilated TAV 
with regard to the presence of medial degeneration and apoptosis, while 
other markers for degeneration and ageing like inflammation and progerin 
expression were low in MFS, comparable to BAV.
Conclusions: Both MFS and BAV aortas have immature VSMCs, while 
MFS and TAV patients have a similar increased rate of medial degeneration. 
However, the mechanism leading to apoptosis is different, being fibrillin-1 
mutation induced increased angiotensin-receptor-pathway signaling in MFS 
and cardiovascular ageing and increased progerin in TAV. Our findings could 
explain why angiotensin inhibition is successful in MFS and less effective in 
TAV and BAV patients. 
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INTRODUCTION
Bicuspid aortic valve (BAV) is the most common congenital cardiac 
malformation, with a prevalence of 1% in the general population (1). 
This anomaly is associated with complications as aortic stenosis and/
or regurgitation as well as critical aortic dilation, with an increased risk of 
dissection and rupture. Aortic dilation is also a key feature of the clinical 
presentation in patients with Marfan syndrome (MFS). In MFS, mutations in the 
fibrillin-1 gene, encoding for the fibrillin-1 protein, account for approximately 
70-93% of patients who meet the diagnostic criteria (2). Due to the fibrillin-1 
mutation, the aorta in MFS exhibits markedly abnormal elastic properties 
which are assumed to lead to a decrease in compliance and progressive 
increase in dilation (3). 
Both patients with MFS and BAV show aortic dilation but the anatomic site 
of vulnerability is distinct in both conditions. While maximal aortic dilation is 
observed above the sinotubular junction in BAV, in the MFS population it is 
mainly found at the level of the sinuses of Valsalva, also referred to as aortic 
root (4). 
To unravel the pathogenetic mechanism leading to aortic wall pathology 
in BAV, differences between the diseased aortic wall of patients with BAV 
and patients with a tricuspid aortic valve (TAV) were studied previously 
(5). We found that the ascending aorta in BAV is intrinsically different from 
TAV patients. The vascular smooth muscle (VSMC) cell layer is less well 
differentiated in BAV while inflammation and accelerated ageing attribute to 
the aortic pathology in TAV (5).
Despite the VSMC immaturity, not all patients with BAV carry an increased 
risk for aortic dilation. In a previous study we defined a panel of markers 
which could differentiate the non-dilated BAV patients, in a susceptible 
and non-susceptible subgroup for future dilation, being c-Kit, a marker for 
dedifferentiated VSMCs, and its phosphorylated state (pc-Kit) triggered by 
the presence of matrix metalloproteinase-9 (MMP9) influencing Hypoxia-
Inducible-Factor-1alpha (HIF1α) and endothelial nitric oxide synthase 
(eNOS) (6). 
The aortic wall in MFS and BAV has been described to have similarities, like an 
increased MMP activity and decreased fibrillin-1 expression (7,8). However, 
cytolytic necrosis, (also termed medial degeneration), defined as VSMC 
dropout, apoptosis and elastic fiber degeneration, highly characteristic for 
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MFS and the dilated aorta in TAV, are far less obvious in BAV (5,7). Although 
clinically, symptoms of aortic wall pathology in MFS and BAV overlap, still 
some striking differences remain less well understood. For instance, BAV 
patients rarely possess Marfanoid characteristics, conversely in patients with 
MFS the risk of concomitant BAV syndrome is only slightly increased (4.7%) 
(9).  Furthermore, the risk for aortic dilation in BAV, although higher than 
in the general population, remains low when compared to MFS where the 
majority of patients is prone to severe aortic wall disease. In MFS moreover, 
not only aortic dilation is a critical aortic complication, but also dissections 
in a non-dilated aortic wall and at a younger age, as compared to the BAV, 
have been reported (10,11). In MFS furthermore, angiotensin-receptor-
blockers (ARBs) as Losartan have been identified as a potentially therapeutic 
agent to prevent progressive dilation of the ascending aorta in (12-18). A 
similar positive effect in preventing aortic complications, by reducing the 
angiotensin pathway signaling is however not seen in the BAV population 
(19).  It is therefore interesting to study which similarities are actually present 
immunohistochemically between the ascending aortic wall in both diseases 
and the dilated aortic wall in the TAV, despite possible different clinical 
sequelae in future. What factors cause increased weakness of the aortic wall 
in MFS and are these similar in BAV? Why is aortic wall pathology seen in 
BAV and MFS not comparable to the aortic dilation complications in patients 
with TAV? 
To study this we compared the aortic wall between MFS, BAV and TAV, 
starting with the investigation of general histopathological features, including 
cytolytic necrosis, inflammation, elastin lamellae degradation and VSMC 
apoptosis. The level of expression of fibrillin-1 was also studied in these 
groups. As VSMCs play a role in the synthesis and assembly of fibrillin-1, 
we compared our findings of fibrillin-1 expression to that of differentiation 
and maturation of the vascular wall, being the VSMC differentiation markers 
lamin A/C and progerin (5). We further studied the expression of the pc-Kit 
pathway (c-Kit, pc-Kit, MMP9, HIF1α and  eNOS)  to investigate whether 
these markers, indicative of BAV aortic dilation (6) are also applicable in the 
MFS group.
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The institutional ethics committee at the Leiden University Medical Centre, 
Leiden approved this study. The Academic Medical Center (AMC), Amsterdam 
provided us with eight MFS biopsy aorta specimen, with approval of the 
Medical Ethical Committee. The Heart Valve Bank, Thoraxcenter, Erasmus 
Medical Center (EMC), Rotterdam, provided six non-dilated BAV aortic 
wall samples which were not suitable for transplantation, approved by their 
Scientific Advisory Board.
Patients and tissue samples 
Ascending aortic wall samples were collected from non-MFS individuals with 
TAV and BAV, with and without dilation. Based on the ACC/AHA guidelines, 
dilation was clinically defined by surpassing an ascending aortic wall 
diameter of 44 mm (20). The study population was divided in five groups: 1) 
TAV without dilation, termed TA (n = 11, mean age 64.5 ± 9.0 years) obtained 
post mortem, 2) TAV with dilation, termed TAD (n = 12, mean age 72.3 ± 11.2 
years) collected during elective replacement, 3) BAV without dilation, termed 
BA (n = 17, mean age 55.8 ± 9.8 years) representing a unique group from 
patients with stentless root replacement (the biopsy material was collected 
as residue waste material from the proximal anastomosis), and the 6 biopsies 
received from the EMC, 4) BAV with dilation, termed BAD (n = 19, mean 
age 60.7 ± 7.8 years), collected during elective replacement and 5) MFS 
aortic wall without ascending aorta dilation, termed MFS (n = 8, mean age 
34.2 ± 11.0 years), derived after elective replacement of the dilated root (the 
biopsy material was collected as residue waste material from the proximal 
anastomosis). Group one to four have been reported previously (5,6) and 
in the current study additional staining with fibrillin-1 and apoptosis markers 
were performed for comparison with the newly described MFS group. In this 
study we paid additional attention to the underlying aortic valve pathology of 
the study population. The TA group showed no valve pathology and the TAD 
group showed variably either no valve pathology or aortic valve stenosis or 
regurgitation. In the non-dilated BAVs six patients had a non-pathologic aortic 
valve, these were the specimen we received from the EMC, the remainder 
of the BA group showed aortic valve stenosis, aortic valve regurgitation 
or a combination of both. In the dilated BAV group 3 patients had a non-
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pathologic aortic valve. All MFS patients had a non-pathologic valve and a 
dilated aortic root, specimen were hence obtained during a valve sparing 
root replacement, which was performed in this patient group. 
Sample processing and routine histology 
Specimens were sectioned and stained as described previously (5,6). 
Briefly, following excision, all specimens were fixed, decalcified and paraffin 
embedded. Transverse sections (5 µm) of the paraffin-embedded tissue 
were deparaffinated and rehydrated after which they were stained with 
hematoxylin-eosin (HE) and resorcin fuchsin (RF) to study the morphology 
of the vessel wall. Aortic inflammation was quantified using the HE stained 
sections, indexed from zero (no inflammatory cells) to 6 (large clusters of 
cells). In RF stained sections the maximum intimal thickness was quantified 
in µm and the organization of the elastic lamellae in the media was evaluated. 
Immunohistochemistry 
Sections were stained following the protocol described previously (5,6). An 
overview of the primary and secondary antibodies used is given in Table 1.
Histologic parameters, immunohistochemical analyses and 
morphometry
Sections were studied with a Leica BM500 microscope equipped with 
plan achromatic objectives (Leica Microsystems, Wetzlar, Germany). 
Cytolytic necrosis and elastic fiber degeneration were defined qualitatively, 
in alpha-smooth muscle actin (αSMA) and Resorcin Fuchsin (RF) stained 
sections respectively. The cytoplasmatic level of expression of αSMA, 
smooth-muscle22-alpha (SM22alpha), smoothelin and MMP-9, intra- and 
extracellular expression of fibrillin-1, cytoplasmatic and extracellular matrix 
expression of Transforming Growth Factor- beta (TGFβ), nuclear expression 
of lamin A/C, progerin, cleaved-caspase-3, eNOS, pc-Kit and Hif1α were 
analyzed on three predetermined locations (left, middle and right) of every 
section, that we refer to as ‘microscopic fields’ maintained in evaluation of all 
staining on sister sections. In each microscopic field the level of expression 
was indexed on the three anatomical layers of the aortic wall (tunica intima, 
media, adventitia) as 0 (no expression in the respective layer), 2 (expression 
in less than one third of the layer), 4 (expression in two thirds of the layer) 
and 6 (expression in the whole layer). To determine the level of lamin 
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αSMA: alpha smooth muscle actin, SM22α: smooth-muscle-22-alpha,eNOS: endothelial 
nitric oxide, TGFβ: transforming growth factor-beta, MMP9: matrix metalloproteinase-9, pc-
Kit: phosphorylated c-Kit, HIF1α: Hypoxia-Inducible-Factor-1-alpha, FBN1: fibrillin-1, GAR: 
goat-anti-rabbit-biotin, NGS: normal goat serum, HAM: horse-anti-mouse-biotin, NHS: normal 
horse serum and  RAM-PO: peroxidase-conjugated rabbit anti-mouse
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BAV 
Anti-c-Kit A4502, Dako, 
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1:00 GAR & NGS Susceptibility for 
aortopahty in 
BAV 
Anti-pc-Kit ab62154, Abcam, 
Cambridge, United 
Kingdom 
1:100 GAR & NGS Susceptibility for 
aortopahty in 
BAV 
Anti-HIF1α SC-53546, Santa 
Cruz Biotechnology, 
Texas, USA 
1:500 HAM  Susceptibility for 
aortopahty in 
BAV 
Anti-FBN1 MAB1919, Millipore, 
Billerica, Germany 
1:100 HAM & NHS Fibrillin-1 
expression 
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A/C, progerin, cleaved-caspase-3, eNOS, pc-Kit and Hif1α expression, 
the number of positively stained nuclei was counted following previously 
described methods (6). All specimens were re-evaluated by an independent, 
experienced histopathologist who was blinded to the clinical data.
Statistical analyses 
All numerical data are presented as mean ±SD of three microscopic fields 
on each stained slide. Statistical differences were evaluated with the Mann-
Whitney U-test for comparison between the groups. We also performed a one, 
two and three way ANCOVA test to correct for age and gender. Significance 
was assumed when p<0.05 using SPSS 20.0 software program (SPSS Inc. 
Chicago, USA). Graphpad software was used to create graphics of statistical 
analysis.
 
Characteristics  TA TAD BA BAD  MFS 
 N=11 N=12 N=17 N=19 N=8 








Males (%) 54.5% 33.3% 70.1% 84.2% 62.5% 
Females (%) 45.5% 66.7% 29.4% 15.8% 37.5% 
Ascending aorta 
diameter (mean) 










*** *** *** *** 48.1 ± 3.0 
Aortic valve pathology       
-No valve pathology N=11 N=6 N=6 N=3 N=7 
-Aortic stenosis N=0 N=1 N=4 N=8 N=0 
-Aortic regurgitation N=0 N=5 N=1 N=5 N=1 
-Aortic stenosis and 
regurgitation 
N=0 N=0 N=5 N=3  N=0 
Table 2 Clinical characteristics of all patients
* data unavailable, clinically defined as non-dilated by pathologist. ** data unavailable for 5 
patients, clinically defined as non-dilated by pathologist. *** aortic root diameters unavailable
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Patient characteristics of all five groups are shown in Table 2. The MFS 
patients were evidently the youngest, followed by the BAV patients. In MFS, 
male and female were almost equally affected, the BAVs, however, showed 
a marked male predominance. There was thus a noticeable variance in age 
and gender distribution in our study. Statistically, both age and gender were 
not found confounding in our study. All MFS patients showed typical aortic 
root dilation (diameter 48.1 ± 3.0 mm), with a non-dilated ascending aorta 
(diameter 28.4 ± 12.8 mm). Marked root dilation was not present in the other 
four groups (TA, BA, TAD, BAD). 
General histopathologic features in aortic walls of MFS, BAV and TAV
The ascending aortic wall, consisting of a tunica intima, media and adventitia, 
was compared between the MFS, BAV (BA, BAD) and TAV (TA, TAD) groups. 
The total vessel wall thickness, excluding the highly variable adventitia, was 
not different between the 5 groups. 
Intima: Similar to BAV (5), in MFS the intima was significantly thinner as 
compared to the TAV groups (MFS vs TAD p<0.001) (Fig1A,B, graph 1F). 
Previously we described that in all specimens from BAV patients, the intima 
also showed a significantly lower intimal expression of TGFβ as compared 
to TAV (6). When analyzed in the MFS group, we found that in this group the 
intima also had a very low TGFβ expression (Fig1C). 
Media: Of all groups only the aortic wall of MFS and TAD showed significant 
pathology in the media, with more profound cytoclytic necrosis (Fig 1D) and 
a more fragmented pattern of the elastic lamellae in which the inter-lamellar 
distance was enlarged (Fig 1E). These signs of pathology were not observed 
in the TA, BA, and BAD group (not shown). Expression of the apoptosis 
marker cleaved-caspase-3 was markedly elevated in the media of MFS and 
TAD as compared to the BAD (p=0.033 and p=0.0286 respectively) (Graph 
1H). 
Adventitia: The adventitia consisted of loose fibrous tissue containing nerve 
fibers, fibroblasts, adipocytes and vasa vasorum, lined by endothelium and 
VSMCs in all groups. Adventitial inflammatory cells were most outspoken in 
the TAD group as compared to the MFS and BAD group (p<0.0001, p<0.001 
respectively) (Fig1A, graph 1G). 
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Figure 1 Transverse histologic sections (5µm) stained with Resorcin Fuchsin (RF), 
Hematoxylin-Eosin (HE) and alpha Smooth Muscle Actin (αSMA) in Marfan syndrome (MFS). 
HE stained overview section (A) shows the tunica intima (i), which was signifi cantly thinner 
(B), (graph F) and lacked TGF-β expression in all MFS (C) and BAV patients as compared 
to the TAV groups, tunica media (m) and tunica adventitia (a). The aortic media of MFS and 
TAD showed signifi cant pathology in the media, with more profound cytolytic necrosis (CN) 
(D) and a more fragmented pattern of the elastic lamellae in which the inter-lamellar distance 
(arrow) was enlarged (E). Adventitial infl ammatory cells were absent in the MFS (A) and 
most outspoken in the TAD group (graph G). Expression of the apoptosis marker cleaved-
caspase-3 was signifi cantly elevated in the media of MFS and TAD as compared to the BAD 
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In conclusion intimal thickness and lack of adventitial inflammation were 
similar between BAV and MFS. Aortic media pathology was comparable 
between the non-dilated MFS and dilated TAV.
Fibrillin-1, differentiating and mature VSMCs, lamin A/C, progerin and the 
pc-Kit pathway
To further understand the pathobiology we focused on the differentiation 
state of the aortic wall and the expression of the pc-Kit pathway and fibrillin-1 
in all patient groups.
Fibrillin-1 expression was identified in the aortic media of all groups. The 
level of expression was significantly lower in all patients with MFS and BAV 
(BA, BAD) as compared to TAV (TA, TAD) (p<0.05) (Fig. 2A-E, graph 2F). 
The localization of the staining was different between the groups. In the TAV 
(TA and TAD) the staining was mainly seen extracellular, whereas in the MFS 
and BAV besides being decreased, the expression was mainly observed 
intracellular (cytoplasmic) in the VSMCs (Fig. 2A-E). 
We further observed that in MFS the expression of αSMA (Graph 3E), SM22α 
(Fig. 3A, graph 3F) and smoothelin (Fig. 3B) was similar to the BAVs and 
significantly lower as compared to the TAVs group. Expression of lamin A/C 
(Fig. 3C, graph 3G) and progerin (Fig. 3D, graph 3H) in MFS was as seen 
in BAV, being lower as compared to the TAVs. Thus the aortic wall in MFS 
shows features of less differentiation comparable with the BAV group. The 
results are summarized in Table 3. We further investigated markers predictive 
for ascending aortic dilation in BAV, including pc-Kit (6). We found that these 
markers were not expressed in the MFS group (data not shown).  
DISCUSSION
Our study describes an in-depth effort to compare the ascending aortic wall 
of patients with MFS (non-dilated), BAV (non- and dilated) and TAV (non- 
and dilated) in one study. A specific aortic wall architecture associated with 
aortic wall pathology in both MFS and BAV is an extensively discussed, yet 
controversial, subject. Previous studies compared the aortic wall of MFS and 
BAV histologically and found that the media was characterized by cytolytic 
necrosis and elastic fiber degeneration in both diseases (21). An increased 
MMP activity and decreased fibrillin-1 in the aortic wall, without comparable 
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Figure 2 Transverse histologic sections (5µm) stained with fibrillin-1. TA (tricuspidy without 
dilation), TAD (tricuspidy with dilation), BA (bicuspidy without dilation), BAD (bicuspidy with 
dilation), MFS (Marfan syndrome without dilation). 
FBN-1 expression was observed in the aortic media (M) of all groups, with each picture (A-E) 
showing an insert with magnification 100x to illustrate the expression on cellular level. The 
level of expression was significantly lower in all patients with MFS (E), BA (C) and BAD (D) 
as compared to  TA (A) and TAD (B) (Graph F). Staining was mainly extracellular in the TA 
and TAD, whereas in the MFS and BAV, the decreased expression, was mainly observed 
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reduction in matrix components elastin and collagen was further noticed 
(4,7,8). Similarities have thus been noted, though without getting grip on a 
possible common defect. In this study we attempted to shed light on intrinsic 
defects of the aortic wall leading to the observed similarities by comparing the 
ascending aortic wall of both diseases with each other and with patients with 
TAV without MFS. As recently several publications focused on a difference in 
dilation progress after aortic valve repair dependent on whether the diseased 
aortic valve was stenotic or regurgitant with concomitant root dilation (22) 
in the latter, we also paid additional attention to the underlying aortic valve 
pathology besides structural histopathologic features in the patient groups. 
In the literature it is argued that the aortic dilation in the stenotic type 
is a functional haemodynamic induced problem, while the aortic wall problem 
in the root phenotype is genetically determined. Therefore, an isolated 
aortic valve replacement in stenotic BAV patients is believed to halt the 
aortic wall dilation. Girdauskas et al further state that BAV patients with 
root dilation require a more aggressive surgical approach, being a genetic, 
connective tissue disorder–like form of aortic disease which is independent 
of transvalvular flow perturbations (22). We however do not agree on this 
differentiation into two main groups for a several reasons. Firstly, all BAVs 
are intrinsically a congenital malformation and most probably also involve the 
wall of the ascending aorta independent of a stenotic or a root phenotype (23). 
Secondly, as shown in table 2, in our study population aortic valve pathology 
in non- and dilated BAV and dilated TAV was highly variable showing either 
stenosis or no stenosis, with or without regurgitation. The dilated BAV 
and MFS group even consisted of patients without valve pathology, which 
indicates that even in the absence of specific aortic valve pathology aortic 
complications can occur. We can however not completely refute the influence 
of haemodynamics on the development of aortic wall complications, as we 
do not have follow up data of the operated patients. This is a limitation of our 
study and an important aspect which should be taken into account in future 
research. 
Histopathologically, in our study patients in the BAV group did not show 
marked degenerative features in the aortic media (5), which has also 
been reported by Bechtel et al (24). The media of the ascending aorta in 
MFS however showed resemblance with the TAD with significant cytolytic 
necrosis, VSMC apoptosis and degradation of the elastic lamellae, which 
could predispose the aortic wall for dissection. The MFS group thus showed 
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Figure 3 Transverse histologic sections (5µm) stained with smooth muscle 22 alpha (SM22α), 
smoothelin, lamin A/C and progerin, markers for differentiation state of VSMCs. 
SM22α (A, graph 3F), αSMA (Graph E), and smoothelin (B) expression  in MFS was similar 
to  BAD and significantly lower as compared to  TAD. Expression of lamin A/C (C, graph 3G) 
and progerin (D, graph 3H) in MFS was also significantly lower than in TAD. Magnification: 
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characteristics of a weak aortic wall, although strikingly the pathologic aorta 
was not even markedly dilated in the MFS study population as compared to 
the TAD (Table 2). 
In order to further elucidate the high incidence of aortic wall pathology in MFS 
and BAV, we studied the level of fibrillin-1 expression. The immature aortic 
wall of BAV and MFS shared a marked resemblance in the level of expression 
of fibrillin-1. Decreased fibrillin-1 mRNA and fibrillin-1 protein have been 
demonstrated before in BAV individuals (8) and can lead to dissociation of 
VSMCs from medial matrix components (25). The diagnosis of MFS is however 
clinical and relies on a set of defined clinical criteria (the Ghent nosology) (2). 
The new diagnostic criteria emphasize cardiovascular manifestations of the 
disorder, in which aortic root aneurysm is one of the prime features. Recently 
Pape et al. (26) identified two fibrillin-1 mutations in a population of eight BAV 
patients. These mutations had never been detected in MFS patients before. 
Moreover, these BAV patients did not meet the clinical MFS criteria; therefore 
they were not diagnosed with MFS (26). We can conclude that in the present 
study and previous studies a decrease in fibrillin-1 has been reported in four 
conditions: patients with BAV without a fibrillin-1 mutation (8) (current study), 
patients with BAV and a fibrillin-1 mutation with (9) or without (26) clinical MFS 
features and finally patients with clinically MFS and a fibrillin-1 mutation but no 
BAV (27). 
 
 TA TAD MFS BA  BAD 
Intimal thickness +++ +++ +/- +/- +/- 
TGFβ intima expression ++ ++ - - - 
Inflammation  +/- +++ +/- +/- +/- 
Cytolytic necrosis - + + - - 
Apoptosis  ++ +++ ++ + + 
Elastic lamellae degeneration - + + - - 
Fibrillin-1  +++ +++ + + + 
Smooth muscle cell expression 
(αSMA, SM22α, smoothelin) 
+++ +++ +/- +/- +/- 
Lamin A/C +++ +++ + + + 
Progerin + +++ + + + 
Table 3 Summary of the results
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Figure 4 Schematic overview of our hypothesis regarding similarities and differences in aortic 
wall pathology between bicuspid aortic valve (BAV), tricuspid aortic valve (TAV) and Marfan 
syndrome (MFS). 
According to this schematic overview the ascending aortic wall can be classified as being 
either mature or less well differentiated. Patients with a TAV have a differentiated/ mature 
vascular wall (differentiated vascular smooth muscle cells (VSMCs) and lamin A/C) in 
which cardiovascular ageing (increased expression of progerin with increased apoptosis, 
atherosclerose and inflammation) accompanies degeneration with features of cytolytic 
necrosis (CN) This progressive aortic wall pathology in TAV thus leads to a weakened aortic 
media causing complications as aortic dilation and dissection.  
In BAV and MFS weakness of the aorta is however caused by immaturity of the aortic wall 
(deficient differentiated VSMCs and lamin A/C expression) instead of ageing. Fibrillin-1, pivotal 
for structural stability of the vessel wall is produced by VSMCs. Immaturity of the vessel thus 
leads to a quantitative decrease of fibrillin-1 in both BAV and MFS. In MFS additionally the FBN1 
(fibrillin-1) mutation leads to VSMC apoptosis through an increased signaling of Angiotensin II 
receptors (AT2 receptor). CN, caused by VSMC apoptosis, in combination with the immature 
state of the aortic media renders the vascular wall extremely weak. Most probably presenting a 
different pathogenesis of aortic dissection in MFS as compared to the TAV.
As fibrillin-1 is produced by VSMCs (28), a significant decrease (of 
structurally normal) fibrillin-1 is plausible in an aortic wall which constitutes 
less well differentiated VSMCs, also without apparent fibrillin-1 mutations. 
As described in this study, in both MFS and BAV the aortic wall is primarily 
less well differentiated which can explain the secondary decrease in the 
(structurally normal) expression of fibrillin-1. Besides a decreased amount 
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of fibrillin-1 in the aortic wall, in line with earlier research we found that the 
distribution and localization of fibrillin-1 was different in the MFS and BAV, 
with more accumulation within the VSMCs (7,29,30), whereas it was mostly 
seen extracellular in the TAVs. As earlier described by Nataatmadja et al. the 
few extracellular fibers observed in BAV and MFS were thick and short (7). 
Hollister et al. also found a deficiency in the amount of microfibrillar fibers, 
analyzed immunohistochemically (30), comparable with our results. 
As described above, cytolytic necrosis and VSMC apoptosis are observed 
in both MFS and TAV. However, VSMC apoptosis, which leads to cytolytic 
necrosis, seems to occur due to a different pathogenetic mechanism in MFS 
as compared to TAV. In TAV ageing, accompanied by an increased progerin 
expression, and atherosclerosis causes VSMC apoptosis (5,31), whereas as 
we have seen in this study in MFS these features are not apparent. In MFS 
the media of the aortic wall contains less well differentiated VSMCs similar to 
BAV. Therefore there must be a different pathway leading to cytolytic necrosis 
in MFS, which is on the one hand not related to cardiovascular ageing, but on 
the other hand can also not be associated directly to the immature state of 
the VSMCs as in BAV where cytolytic necrosisis scarce (5.24). 
VSMC apoptosis and subsequent cytolytic necrosis in MFS has earlier 
been described to occur at a much younger age as compared to the TAV 
and as a direct consequence of the fibrillin-1 mutation which leads to an 
increased Angiotensin II (AT2) receptors signaling and subsequently 
induction of TGFβ signalling (32-34). Two different pathologic pathways 
can thus be distinguished leading to aortic dissections. For clarification we 
have schematically hypothesized (Figure 4) how the various differentiation 
pathways and the involved gene pathways can lead to the observed 
histopathological similarities and differences we have seen between the 
investigated groups. In MFS there is thus a combination of immaturity of the 
aortic media and cytolytic necrosis, due to increased VSMC apoptosis, related 
to increased AT2 receptor signaling (31,32), rendering the aortic wall very 
weak. These observations could explain why angiotensin-receptor-blockers 
(ARBs), as Losartan, have been identified as a potentially therapeutic agent 
to prevent progressive dilation of the ascending aorta in MFS. ARBs reduce 
the signalling that occurs through both AT receptors, (AT1 and AT2 receptor). 
Many trials have emerged in recent years investigating the efficacy of ARB’s 
in human patients with MFS (12-18). The first results from these studies 
show reduced dilation of the aortic root in MFS with Losartan (17). 
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A similar positive effect has not been reported in a population of BAV patients 
that were treated with an angiotensin inhibitor (ACE inhibitor) (19) which can 
be understood on the basis of our current results. In BAV medical treatment 
is not effective because the aortic wall in BAVs is not characterized by 
apoptosis and cytolytic necrosis. In conclusion, comparison of the aortic 
wall samples in BAV, MFS and TAV demonstrates that aortic dissections in 
MFS have a different pathogenesis as compared to the TAV, explaining the 
higher incidence and the younger age of occurrence. These findings could 
be relevant for understanding why medical treatment to inhibit angiotensin 
are seemingly successful in MFS and less effective in TAV and BAV patients 
also being prone for aortic wall pathology. 
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Objective Patients with a bicuspid aortic valve (BAV) and patients with Marfan 
syndrome (MFS) have increased susceptibility for aortopathy. In the heart, 
epicardial cells expressing Wilms tumor suppressor protein (Wt1) are known 
to become activated after myocardial infarction. We hypothesize that the 
arterial epicardium might show a similar response in pathologic conditions. 
Furthermore, variability of Wt1 activity in BAV patients without dilation might 
aid in distinguishing patients susceptible for future aortopathy. 
Methods: Ascending aorta specimen of BAV (n=36) and tricuspid aortic valve 
(TAV) (n=23), non- and dilated (>45 mm) and non-dilated MFS specimen 
were investigated. The aorta was studied by immunohistochemistry, using 
Wt1, Retinaldehyde dehydrogenase-II (RALDH2), transcriptional activation of 
this enzyme is regulated by Wt1, and endothelial nitric oxide (eNOS), which 
regulates Wt1 expression.
Results: Endothelial cells, epicardial cells and VSMCs stained positive for 
Wt1, RALDH2 and eNOS. The endothelium did not show a difference in the 
ratio of positive compared to negative cells between the groups. In epicardial 
cells all groups exhibited Wt1 positive cells in a quiescent stage. Significantly 
increased Wt1 activity was observed in the epicardium and VSMCs of the 
dilated TAV group as compared to the dilated BAV group. Furthermore, a 
subset of non-dilated BAV patients showed a significantly increased Wt1 
expression in the VSMCs.  
Conclusion: In all non-dilated patients, a baseline activity of Wt1 is present 
in epicardial and VSMCs. In the TAD features of cardiovascular ageing as 
inflammation and increased progerin expression, which are not present in 
the BAD, lead to an increased Wt1 activity. In BAV, susceptibility for future 
aortopathy is probably associated to an increased MMP9 expression 
regulated by Wt1 through an eNOS mediated pathway.
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INTRODUCTION 
In the early 20th century thoracic aortic dilation in patients with a tricuspid aortic 
valve (TAV) had already been labelled as a degenerative disease, characterized 
by cytolytic necrosis (CN) (also termed medial degeneration) of unknown 
aetiology (1). Excessive medial degeneration thereby has been associated 
with destruction of the extracellular matrix (2) and loss of VSMCs (3), which 
can progressively weaken the aortic wall and ultimately lead to dilation. 
Patients with a bicuspid aortic valve (BAV) and patients with Marfan syndrome 
(MFS) carry an increased risk for aortic dilation as compared to TAV. Earlier 
research has shown that both syndromes have similarities in the aortic media 
architecture, characterized by immature VSMCs ((4), Marfan submitted). This 
is in contrast to the aortic wall in TAV, which harbours differentiated VSMCs (4). 
However, prevalence of aortic complication is higher in the MFS as compared 
to the BAV, as nearly 30% of all patients with BAV will never experience 
progressive dilation of the ascending aorta. A different pathobiological 
mechanism thus seems to underlie aortic wall pathology in BAV and MFS, 
probably superimposed on the immature state of the aortic media. In BAV 
we could identify markers possibly associated with an increased susceptibility 
future complications The markers included c-Kit, a marker for dedifferentiated 
VSMCs, and its phosphorylated state (pc-Kit) triggered by the presence of 
matrix metalloproteinase-9 (MMP9), Hypoxia-Inducible-Factor-1alpha (HIF1α) 
and endothelial nitric oxide (eNOS).  
The aortic wall in MFS did not show a similar expression of the susceptibility 
markers (Marfan submitted), on the contrary showed features of CN, which 
together with the immaturity could render the aortic media extremely weak 
and susceptible for aortic complications (Marfan submitted). We postulated 
earlier that the mechanism leading to CN is an increased angiotensin-receptor 
signaling due to the FBN1 mutation in MFS rather than an increased progerin 
expression as seen in TAV (Marfan submitted). These findings could have 
implications for the applied preventive treatment modalities in both syndromes, 
such as the administration of angiotensin-receptor blockers (Marfan submitted). 
However, some issues still remain unexplained, which we aim to address in 
the current paper. 
Firstly, most research on aortic dilation in BAV, TAV and MFS mainly approached 
the media or adventitia (5-17) of the vessel wall. The outermost covering of the 
ascending aorta, the arterial epicardium, has received hardly any attention 
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so far (18). In the heart, epicardial cells fulfill many important functions during 
embryogenesis and adult life (18;19). During the development of the heart, the 
epicardium undergoes a process called epithelial-to-mesenchymal transition. 
During epithelial-to-mesenchymal transition the morphologic appearance 
of the epicardial cells alters from squamous to cuboidal and the basement 
membrane delaminates. The epicardial cell delaminates becoming an 
epicardium derived cell (EPDC) which invades the subepicardial layer and 
subsequently migrates into the myocardium (20;21). EPDCs are mandatory 
for the development of the VSMCs of the coronary vasculature, contribute 
to the atrioventricular valves (reviewed: (18)). A large proportion of EPDCs 
differentiate into the cardiac interstitial fibroblasts of the heart, contributing to 
the fibrous skeleton. In adult life the epicardium and EPDCs are in a quiescent 
stage, but it has been shown that these inactive cells can become active in 
response to pathological processes such as myocardial ischemia (22). We 
postulate that a similar effect of the arterial epicardium is plausible, wherein 
aortic wall pathology might drive the activation of these cells. It has also 
been shown that endothelial nitric oxide (eNOS) regulates the expression of 
Wilms tumor suppressor protein (Wt1, which is an early epicardial marker for 
epithelial-to-mesenchymal transition (23)) and a deficiency of eNOS inhibits 
EPDC migration (24). Hence, we investigated the arterial epicardium on the 
expression of 1. Wt1; 2. Retinaldehyde dehydrogenase type II (RALDH2), Wt1 
controls retinoic acid signalling through transcriptional activation of the enzyme 
Raldh2 (25) and is a specific marker for the epicardium (26); and 3. eNOS. 
Another question which remained unexplained in our previous study was 
which trigger leads to an increased expression of MMP9 and thereby induces 
signaling of the pc-Kit cascade in the susceptible BAV group (27). It is known 
that Wt1 shuttles continuously between the nucleus, where it is active, to the 
cytoplasm, where it is in a quiescent stage (28). Marcet-Pollocios concluded 
that MMP9 expression is regulated by shuttling of Wt1 through a nitric oxide 
(NO) mediated pathway (29). Since all the identified susceptibility markers 
are found expressed in the aortic media, it is plausible that the marker which 
induces the expression of MMP9, might also be expressed by the VMSCs. 
However, the endothelial cells also express eNOS and Wt1 (13), and might 
be able to induce MMP9 expression paracrine. To address the missing link 
in the pc-Kit cascade, expression of Wt1, RALDH2 and eNOS was therefore 
also studied in the endothelial cells in the intimal layer and the VSMCs in the 
aortic media. 
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MATERIAL AND METHODS
Ethical approval and tissue samples
Ascending aortic wall samples were obtained from individuals with BAV and 
TAV, both with and without dilation and individuals with MFS, without dilation. 
Dilation was clinically defined by reaching an ascending aortic wall diameter 
of 45 mm and above (4;30). Sample collection and handling was carried 
out according to the official guidelines of the Medical Ethical Committee 
of the Leiden University Medical Centre (LUMC), Leiden, the Netherlands 
and the code of conduct of the Dutch federation of Biomedical Scientific 
Societies. The Heart Valve Bank, Thoraxcenter, Erasmus Medical Center 
(EMC), Rotterdam, provided 6 BAV samples without aortic dilation as these 
were not suitable for transplantation, as approved by their Scientific Advisory 
Board. Furthermore the Academic Medical Center (AMC) provided us with 8 
MFS biopsy specimen, with approval of the Medical Ethical Committee. The 
study population was divided in five groups: 1) TAV without ascending aorta 
dilation, termed TA 2) TAV with ascending aorta dilation, termed TAD 3) BAV 
without ascending aorta dilation, termed BA 4) BAV with ascending aorta 
dilation, termed BAD 5) MFS without ascending aorta dilation, termed MFS 
shown in table 1.  
Following excision, all specimen were fixed in 4% formalin for 24 hours, 
decalcified in Kristensen’s solution (a formic acid buffer) for 120 hrs. and 
subsequently embedded in paraffin. Transverse sections (5 µm) were 
mounted on pre-coated Starfrost slides (Klinipath B.V., 3057-1, Duiven, The 
Netherlands) to allow comparing different expression profiles on sequential 
sections.
Immunohistochemistry
Immunohistochemical staining was performed following the protocol for 
deparaffination, antigen retrieval and staining as described in our previous 
study (4). Primary antibodies applied to the slides were Wt1 1/300 (Product 
number CA1026, Calbiochem, Billerica, USA), RALDH2 1/100 (Product 
number ab75674, Abcam, Cambridge, UK) and eNOS 1/100 (Product 
number, PA1037, Thermo scientific, Rockford, USA). Secondary antibodies 
applied were: 1/200 goat-anti-rabbit-biotin (GAR), (Product number BA-100, 
Vector Laboratories, Burlingame, USA) and 1/66 normal goat serum (NGS), 
(Product number S1000, Vector Laboratories, Burlingame, USA). 




To detect co-expression, we performed double immunofluorescent stainings. 
Sections were deparaffinated, rehydrated and subjected to antigen retrieval 
as described. Tissue sections were incubated with primary antibodies 
Wt1 1/100, RALDH2 1/100 and eNOS 1/100 overnight (4°C), followed by 
incubation with secondary antibody Cy3 donkey anti mouse IgG (Product 
number 715-165-150 Jackson Immunoresearch, 715-165-150) for Wt1 and 
Alexa Fluor 647 donkey anti-rabbit IgG (Invitrogen, A-31573) for eNOS (1 
TA: tricuspid valve, without dilation; TAD: tricuspid valve, with dilation; BA: bicuspid valve, 
without dilation; BAD: bicuspid valve, with dilation; MFS: Marfan syndrome, without dilation; 
LUMC: Leiden University Medical Center, EMC: Erasmus Medical Center, AMC: Academic 
Medical Center. 
* data unavailable, clinically defined as non-dilated by pathologist. ** data unavailable for 5 
patients, clinically defined as non-dilated by pathologist. *** aortic root diameters unavailable 
Table 1 Patient characteristics are shown in table 1
Characteristic  TA TAD BA BAD  MFS 

























repair of a 






MFS MFS MFS MFS BAV 
Age (years) 64.5 ± 9.0 72.3 ± 11.2 55.8 ± 9.8 60.7 ± 7.8  34.1 ± 11.8 
Males (%) 54.5% 33.3% 70.1% 84.2% 62.5% 
Females (%) 45.5% 66.7% 29.4% 15.8% 37.5% 
Ascending aorta 
diameter (mean) 
* 55.0 ± 10.7 36.5 ± 7.4** 52.7 ± 6.2 28.4 ± 12.8 
Aortic root 
diameter (mean) 
*** *** *** *** 48.1 ± 3.0 
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hr, 20°C). Cy3 and Alexa Fluor 647 were preferred secondary antibodies, 
because of green autofluorescence of the elastic lamellae. Nuclei were 
visualized with 4’,6-diamidino-2-phenylindole (DAPI, Sigma-Aldrich). Finally, 
slides were mounted with ProlonGold (Invitrogen, P36930).
Morphometric analyses 
Sections were studied with a Leica BM5000 microscope equipped with plan 
achromatic objectives (Leica Microsystems, Wetzlar, Germany).
As handling during excision of aortic tissue can easily damage epicardial 
cells, we first identified Wt1 stained specimen in which the adventitia 
showed an intact monolayer of epicardial cells: TA n=4, TAD n= 4, BA n=4, 
BAD n=8 and MFS n=2. The number of MFS patients was to less to allow 
an adequate statistical analysis. Analysis of epicardial Wt1, RALDH2 and 
eNOS expression was therefore performed on the BA, BAD, TA and TAD 
group. In the MFS group, only the morphologic appearance of the epicardial 
cells could be described. To determine the level of expression of the Wt1, 
eNOS and RALDH2 markers in the aortic media, the number of positively 
stained nuclei (for Wt1 and eNOS) and cytoplasmic positive cells (for 
RALHD2) was counted using ImageJ on three predetermined locations (left, 
middle and right) of every section. These we refer to as ‘microscopic fields’ 
and maintained in evaluation of all sections. A threshold was applied to filter 
background noise. The total number of cells (positively stained and negative 
nuclei and cytoplasm) was not different in all specimens. In each microscopic 
field the number of cells positive for Wt1, RALDH2 and eNOS was therefore 
normalized to the total number of cells per 105 µm2. Finally, the number of 
normalized positive cells for each staining was averaged between the three 
microscopic fields. All specimens were re-evaluated by an independent, 
experienced histopathologist who was blinded to the clinical data.
Statistical Analysis
All numerical data are presented as mean ±SD of 3 fixed microscopic 
fields on each stained slide. Statistical differences were evaluated with the 
Mann-Whitney U-test for comparison between the groups. Significance 
was assumed when p<0.05 using SPSS 20.0 software program (SPSS Inc. 
Chicago, USA). We have performed a one, two and three way ANCOVA 
test to correct for age and gender. Graphpad software was used to create 
graphics of statistical analysis. 




Wt1, RALDH2 and eNOS expression pattern in the ascending aorta       
The aortic wall consists of three layers: the tunica intima, media and 
adventitia. Expression of Wt1, RALDH2 and eNOS was seen in all three 
layers, as will be presented in the next segments. Table 2 gives an overview 
of the stained markers in the endothelial cells, vascular smooth muscle cells 
and the epicardial cells (cytoplasmic and/or nuclear staining) 
Endothelium 
Endothelial cells lining the luminal surface of the tunica intima stained 
predominantly positive for Wt1 in the nucleus. Morphologic appearance of all 
Wt1 positive cells was similar, being squamous. We analysed the total Wt1 
positive population in each sample of the five groups and calculated the ratio 
of Wt1 positive compared to Wt1 negative cells. No significant difference was 
seen between the five groups (Table 2 and 3). 
All Wt1 positive endothelial cells also showed eNOS and RALDH2 expression, 
with no difference in the ratio of positive compared to negative cells between 
the five groups (Table 2 and 3). 
Media 
In the aorta a subset of VSMCs variably stained positive for Wt1 in the 
nucleus and/or cytoplasm. For analysis nuclear Wt1 level of expression was 
considered.  
The number of positively stained VSMCs in the aortic media was significantly 
highest in the TAD group. In the BAD however the VSMCs stained significantly 
less as compared to the TAD (p<0.0001), the expression was higher than in 
the BA group (p=0.015). Between the  BA, TA and MFS non-dilated aortic 
wall groups no significant difference was found in medial expression of 
Wt1 between the BA and TA group, whereas the MFS showed significantly 
less expression as compared to both BA and TA (p=0.0022 and p=0.0018 
respectively) (Fig. 1A, Table 2 and 3). All Wt1 positive VSMCs also stained 
cytoplasmic for RALDH2 (Fig. 1B, Table 2 and 3). 
Nuclear eNOS staining of the VSMCs was markedly seen in Wt1 and 
RALDH2 positive cells (Fig. 1A-G), however some cells stained positive for 
only eNOS. The number of eNOS positive cells was significantly higher in all 
TAVs (TA and TAD), as compared to all BAVs (BA and BAD) (p=0.0234 and 
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Wilms tumor suppressor protein (Wt1), Retinaldehyde dehydrogenase-II (RALDH2) and 
endothelial nitric oxide (eNOS), in the endothelial cells, vascular smooth muscle cells (VSMCs) 
and the epicardial cells. Positive and negative staining is indicated, either cytoplasmic or 
nuclear.
Table 2 overview of the stained markers
p=0.0353 respectively). In the MFS group, the number of eNOS positive cells 
was comparable to the BA group (p=0.1529) (Fig, 1A-C, Table 2,3).  
Adventitia and epicardial cells
The adventitial side of the vessel wall, bordering the pericardial cavity, is 
lined by arterial epicardial cells. Wt1 expression was variably present in the 
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nucleus and/or cytoplasm. An epicardial cell was identified as positive for Wt1 
if either the nucleus or cytoplasm stained positive. The epicardial cells could 
morphologically be distinguished in three types: Wt1 negative squamous, 
Wt1 positive squamous and Wt1 positive cuboidal phenotype. The Wt1 
positive cells were often found in epicardial invaginations/ inpocketings (Fig. 
2A, B). We first analysed the total Wt1 positive population (both squamous 
and cuboidal) in each sample and calculated the ratio of Wt1 positive 
compared to Wt1 negative cells. No significant difference was seen between 
the four groups (mean ratio 0.44). The Wt1 positive squamous epicardial 
cells represent an initial phase of epicardial activity, whereas cuboidal cells 
are prone for epithelial-to-mesenchymal transition. Therefore we assessed 
the epicardial activity, defined as the transition from an initial quiescent phase 
to active epicardium, by the ratio of Wt1 positive squamous and cuboidal 
epicardial cells. A significant increase in epicardial activity based on number 
of cuboid cells was seen in the TAD as compared to the TA (p=0.0286), 
and the epicardial activity was significantly greater in TAD compared to BAD 
(p<485) (G, Table 2 and 3). The epicardial cells of the ascending aorta of the 
MFS group were mostly squamous in appearance and showed minimal Wt1 
expression and when present only in the cytoplasm. In dilated specimen of 
Wilms tumor suppressor protein: Wt1, Retinaldehyde dehydrogenase-II: RALDH2, endothelial 
nitric oxide: eNOS. TA: tricuspid valve, without dilation; TAD: tricuspid valve, with dilation; BA: 
bicuspid valve, without dilation; BAD: bicuspid valve, with dilation; MFS: Marfan syndrome, 
without dilation. *: mean ratio positive/ negative cells; ** ratio positive squamous/ positive 
cuboidal cells; *** mean number of positive cells/ 105 µm2
Table 3 An overview of the results and the statistical significance.




Endothelial cells 0.54* 0.54* 0.54* 0.54* 0.54* ns 
Wt1, 
RALDH2 
Media (VSMCs) 346*** 1207*** 344*** 581*** 100*** TA-TAD and TAD-BAD: p<0.0001 
BA-BAD: p=0.015; TA-MFS: p=0.0018; 
BA-MFS: 0.0022 





Epicardial cells 0.73** 6.54** 1.05** 2.99** - TA-TAD: P=0.0286 
TAD-BAD: P=0.0485 
 
• * mean ratio postive/ negative cells 
• ** Ratio positive squamous/ positive cuboidal cells  
• *** mean number of positive cells/ 10^5 um^2 
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TAV invasion of epicardial cells into the subepicardial layer was also seen 
(not quantifi ed), demonstrating epithelial-to-mesenchymal transition resulting 
in EPDCs entering the adventitia, which was not prominent in BAV and MFS 
patients. Wt1 positive epicardial cells also stained positive cytoplasmic for its 
downstream mediator RALDH2 in all groups (Table 2). Moreover expression 
of eNOS was also observed in the same epicardial cells (Fig. 2C-F, Table 2). 
Figure 1 Expression of Wilms tumor suppressor protein (Wt1) (Graph A), Retinaldehyde 
dehydrogenase-II (RALDH2) (Graph B) and endothelial nitric oxide (eNOS) (Graph C) in the 
VSMCs of the aortic media. 
Transverse histologic sections of the aortic wall (D-G). Immunofl uorescent staining of Wt1 
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Medial expression of Wt1 in the BAsusceptible and BAnon-susceptible 
group
As shown in Figure 3, the group of patients prone for future aortopathy 
(BAsusceptible) showed an increased phosphorylation potential of c-Kit 
under influence of MMP9. Pc-Kit in turn led to an increase in HIF1α and 
eNOS expression as compared to the non-susceptible BA group. In this 
study we found that the expression of Wt1 was higher in the BA-susceptible 
as compared to the non-susceptible group (p<0.001) (Fig. 3).
DISCUSSION 
Thoracic aortic dilation is a relatively common medical problem. The fact 
that the first presentation can be life threatening in the form of dissection 
or rupture of the aortic wall makes it even more crucial to understand the 
underlying pathobiology. The results of this study provide evidence that an 
increased expression of Wt1 in the epicardial cells and VSMCs might be a 
marker of progressive pathology of the aortic wall. 
eNOS and Wt1 in the arterial endothelium 
We describe for the first time that Wt1 is expressed in the arterial endothelium, 
indicating that this marker is not specific for the epicardium (23). Functionality 
of Wt1 was confirmed by the co-expression of RALDH2 in the same cells.  
Kispert et al. have earlier shown that Wt1 is expressed in endogenous 
endothelium of the developing heart (31). It has however not been described 
in adult vasculature before. In our study we found that Wt1 is expressed in a 
similar fashion in the non-dilated aortic wall of BAV, TAV and MFS. 
Besides during normal development, an enhanced cardiac endothelial Wt1 
expression has also been described in pathologic conditions in a rat model 
(32). We however did not observe differences in Wt1 or RALDH2 expression 
in the endothelium of the dilated aortic walls of BAV, TAV and MFS as 
compared to the non-dilated aorta. 
We also studied the eNOS expression in the endothelial cells. The level of 
expression was not different between the non- and dilated groups of BAV 
and TAV, as described before (26). In this study we found that the endothelial 
eNOS expression in the MFS group was also similar. Expression of Wt1 and 
eNOS has been linked in the epicardial cells (33), however the observed co-
expression in the endothelium has not been described before. 
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Wt1 in the arterial epicardium
In the epicardium of the heart an increased Wt1 activity had been noted as 
a response to pathology. We hypothesized that the epicardial cells covering 
the aorta might show a similar mechanism. In the healthy adult heart, the 
epicardium always harbours some Wt1 activity. In this study we found 
that in all five groups the epicardial layer exhibited patches of quiescent 
epicardial cells alternating with cuboid epicardial cells that expressed Wt1 
and RALDH2. The dilated aortic specimens showed an increase of epicardial 
activity, possibly as a response to pathologic processes. This increase was 
significantly greater in the TAD as compared to the BAD.
Figure 2 Transverse histologic sections of the aortic wall. 
DAB staining (brown) of Wilms tumor suppressor protein (Wt1) is shown in the TAV group, 
with aortic dilation (TAD) and BAV, with aortic dilation (BAD). Immunofluorescent staining (C-
F) of Wt1 (red), endothelial nitric oxide (green) and DAPI (blue). Epicardial activity, defined as 
the ratio of Wt1 positive squamous and cuboidal epicardial cells, is shown in Graph G for TA: 
tricuspid valve, without dilation; TAD: tricuspid valve, with dilation; BA: bicuspid valve, without 
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The less apparent increase of Wt1 activity in BAD might be associated with 
the immaturity of the aortic wall and the lack of cardiovascular ageing. We 
base our assumption on the observation that the pathologic dilated aortic 
wall in TAD shows features of cardiovascular ageing as inflammation, 
atherosclerosis and an increased progerin expression. In the coronary 
vasculature comparable characteristics of cardiovascular ageing lead to 
myocardial ischemia (34) and subsequent activation of the epicardial Wt1 
(22). 
As the absolute diameters of the ascending aorta are somewhat similar in 
BAD and TAD, Wt1 expression in the epicardium is not likely to be associated 
with the degree of dilation, rather with the pathologic conditions leading to it.
As we performed our stainings on the complete vessel wall, we also found for 
the first time expression of eNOS in the epicardial cells. The epicardial cells 
which expressed Wt1 and RALDH2 were also positive for eNOS. Although in 
eNOS deficient mice an inhibition of EPDC migration has been noted (24), 
such prominent role of eNOS in the arterial epicardium of BAV cannot be 
concluded from this study. Future research should focus on arterial epicardial 
cells in BAV mouse models, to elucidate a possible role of eNOS related to 
the decreased Wt1 activity. 
Wt1, RALDH2 and eNOS in the aortic media
We describe in this study the co-expression of Wt1, RALDH2 and eNOS 
in the VSMCs of the aorta. As described for the endothelial and epicardial 
cells, co-localization of Wt1 with RALDH2 confirmed the functionality of Wt1 
in the VSMCs. Wt1 and RALDH2 positive cells were variably co-expressed 
with eNOS. VSMCs could on the other hand also only be positively stained 
for eNOS. 
In a previous study, we suggested that a subset of BAV patients without 
apparent ascending aorta dilation, but with an increased susceptibility for 
future aortic wall pathology can be identified on basis of a panel of markers 
(27). The identified markers could be linked to each other in a cascade, which 
was found active only in the BA susceptible group. MMP9 is an important 
regulator of the cascade as its presence triggers the phosphorylation of c-Kit. 
Pc-Kit in turn induces the expression of HIF1α, which then stimulates the 
expression of eNOS in the BA- susceptible group (Fig. 3) (27). 
In this study we found that the VSMCs expression of Wt1 is significantly 
higher in the BA-susceptible as compared to the non-susceptible group. 
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Figure 3 The observed differences in expression of molecular biologic markers are presented 
in a cascade.
In the bicuspid aortic valve group, without aortic dilation (BA) two subgroups are distinguishable: 
BAa and BAb. The non-susceptible group (BAa), which has a similar expression pattern as the 
MFS group (Marfan syndrome, without aortic dilation), showed significant higher expression 
of c-Kit as compared to the susceptible group (BAb), which has a similar expression pattern 
as the BAD (Bicuspid aortic valve, with aortic dilation). MMP9, scarcely expressed in the non-
susceptible group and abundantly in the susceptible, is involved in the phosphorylation of c-Kit. 
Lower expression of c-Kit in the susceptible group as shown in the cascade, could therefore 
be the result of its conversion to pc-Kit. Besides pc-Kit, HIF1α was richly expressed in the 
susceptible group, in contrast to the non-susceptible. HIF1α was only found co-expressed with 
pc-Kit. eNOS, regulated by HIF1α, is less expressed in the non-susceptible and significantly 
higher expressed. Wt1 showed a similar expression pattern of low expression in the non-
susceptible and significantly higher expression in the susceptible group.




BA susceptible BAD MFS
C-Kit +++ + + +++
Pc-Kit - ++ ++ -
HIF1α - ++ ++ -
eNOS - ++ ++ -
Wt1 - ++ ++ -
MMP9 - + + -
=
=
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This suggests a positive link between eNOS, Wt1 and MMP9 which has 
not been described before. It has earlier been shown however that Wt1 
regulates MMP9 through a nitric oxide (NO) mediated pathway (29). Wt1 
is a transcriptional factor that acts as a gene repressor (35-37), which can 
participate in transcriptional regulation of MMP9 too (29). NO is an important 
regulator of MMP9 (38-41). Mice with mutant inducible NOS (iNOS), produce 
significantly less MMP9 than wild-type mice (42;43). Also in human NO is 
shown to be an important up-regulator of MMP9 (29). Considering this, 
Marcet-Pollocios concluded that through a NO mediated pathway shuttling of 
Wt1 occurs: from the nucleus, where it is active, to the cytosol, where it loses 
its repression potential, leading to a de-repression (and thus an increase) of 
the MMP9 expression (29). These findings can be applied to the described 
panel of susceptibility markers as shown in Fig. 3, and previously by Grewal 
et al. (27). Expression of eNOS is significantly higher in the BA-susceptible 
as compared to the BA-non-susceptible and MFS, which can explain the 
shuttle of Wt1 from the nucleus to the cytoplasm in the susceptible group. As 
a consequence MMP9 expression was higher in the BA-susceptible and can 
lead to an increase in phosphorylation of c-Kit. 
Comparable to the epicardium we further see a difference in the VSMCs Wt1 
activity between the BAD and TAD. We postulate that that this difference, like 
in the epicardial cells, is based on the immature state of the vessel wall and 
the lack of degenerative features, like in the epicardial cells.
In this study we could thus complete the cascade by adding Wt1 to the panel 
of susceptibility markers. Further research is however needed to understand 
what triggers the activation of this cascade.
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SUMMARY AND FUTURE PERSPECTIVES
The prevalence of aortic dilation and related complications as rupture and 
dissection is higher in patients with a bicuspid aortic valve (BAV) as compared 
to patients with a tricuspid aortic valve (TAV), although not every individual 
carries an increased risk. It is therefore essential to identify those patients 
who are less susceptible for aortic wall pathology, as preventive ascending 
aortic surgery would not be necessary in this group. Since aortic diameter 
as a criterion for surgery is only decisive at population level, it would be very 
valuable to have tailored risk stratification at patient level.
The purpose of this thesis was therefore to investigate the possibility to 
identify patients with BAV, without apparent dilation, with an increased 
susceptibility for future complications as aortic dilation and dissection. 
Furthermore the biological mechanism underlying  aortic wall pathology in 
BAV was compared to a known genetically determined syndrome with an 
increased risk of aortopathy being Marfan syndrome. 
  
In Chapter 1 the development of BAV is described. An overview is provided 
of commonly observed complications in patients with a BAV. Also, the aim of 
this thesis is presented and an outline of the chapters is given. 
In Chapter 2 histological and molecular genetic aspects of the normal and 
abnormal development of the aortic wall and semilunar valves are discussed. 
In this review we describe how a defect during early embryogenesis can 
distort the contribution of neural crest cells and second heart field derived 
cells in the valvulogenesis and development of the ascending aortic wall. 
The genetic origin of syndromes associated with aortic dilation (including 
Marfan syndrome, Ehlers-Danlos syndrome, Smad3 mutations and Loeys-
Dietz syndrome) are discussed. The central role of  transforming growth 
factor β (TGFβ) is presented and linked to the embryonic development. 
We concluded that aortic wall pathology associated with BAV could be the 
result of a developmental defect during embryogenesis. These contributions 
alone, however, are not sufficient to explain the clinical heterogeneity seen 
in BAV patients, as not all individuals with BAV develop aortic complications 
during their life. To identify the patients susceptible for dilation, we first aimed 
for a more in-depth understanding of the pathobiology leading to aortopathy 
in BAV as compared to TAV, which is discussed in the next chapter. 
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In Chapter 3 differences in the histopathology of the aortic wall of patients 
with a BAV and TAV are described. Uniquely, not only dilated aortic wall 
specimen were investigated but also non-dilated specimen of both groups, 
representative for early lesions rather than of end-stage disease. The 
expression of vascular smooth muscle cell maturation markers, lamin A/C, 
which plays a pivotal role in vascular smooth muscle cell differentiation, and 
its splicing variant progerin indicative of aging, were studied. The results 
of this study show that the structure of the non-dilated and dilated aortic 
wall in bicuspidy and tricuspidy are intrinsically different. In bicuspidy lower 
lamin A/C expression is possibly linked with a defective smooth muscle cell 
differentiation, seen in these patients. This vessel wall immaturity, which can 
account for the increased weakness of the aortic wall, is encountered in all 
patients with BAV, including those who are less susceptible for future aortic 
complications. To identify the subset of patients which has an increased 
susceptibility for aortic complications we subsequently searched for markers, 
both clinical and immunohistochemical, predictive for aortic wall pathology in 
the non-dilated BAV patients. 
Chapter 4 concerns the recognition of BAV patients with an increased 
vulnerability for aortic wall pathology, based on clinical characteristics. 
A study population of 255 patients was evaluated. Analysis of patient 
characteristics, clinical course and echocardiographic parameters including 
valve morphology led to the identification of predictors for future complications. 
In this study a clinical risk stratification model is presented to detect patients 
with an increased susceptibility. This working model shows that males with 
a BAV with fusion of the right and left coronary cusp, a complete raphe, 
hypertension and no statin use exhibit the highest risk of complications and 
should be monitored more closely. 
Chapter 5 details the search for molecular biologic markers in identifying 
patients with an increased vulnerability for aortic complications, which 
can aid in patient selection for surgery. The aortic wall in patients with 
BAV and TAV, both dilated and non-dilated were studied. We studied a 
signaling pathway characteristic for cellular dedifferentiation, including the 
markers c-Kit, a marker for dedifferentiated vascular smooth muscle cells, 
and its phosphorylated state phosphorylated c-Kit (pc-Kit) triggered by the 
presence of matrix metalloproteinase-9 (MMP9), as well as the Hypoxia-
Inducible-Factor-1alpha (HIF1α) and endothelial nitric oxide (eNOS). We 
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found that this pathway was markedly expressed in the dilated BAV group 
and expression was completely comparable to only a subgroup of the non-
dilated BAV group. Whereas the remainder of the non-dilated BAV group was 
significantly distinct. This difference between the dilated BAV group and the 
susceptible non-dilated BAV group was further confirmed in the expression of 
TGFβ and phosphorylated Smad2. Next to the expression pattern, similarity 
in the dilated and the susceptible non- dilated BAV group was also noted 
clinically in the most common variant of commissure position and conjoined 
raphe of the BAV, being fusion of the right and left coronary cusp. This was in 
line with our findings described in Chapter 4. Based on these observations 
we considered the susceptible non-dilated BAV group a likely candidate for 
future dilation as opposed to the non-susceptible non-dilated BAV group. 
In this paper we also discussed the role of haemodynamic influences on 
development of aortic wall pathology in BAV by comparing expression of 
haemodynamic related markers in specimen obtained from the convex and 
concave side of the ascending aortic wall. A significant effect of shear stress 
on aortic complications in BAV was not observed.
In Chapter 6 we compared the aortic wall in BAV and TAV to a syndrome which 
is highly prone for aortic wall pathology, being Marfan syndrome. Mutations 
in the fibrillin-1 gene are found in 90-95% of all Marfan syndrome cases. In 
this study we investigated whether histopathological similarities are present 
between the aortic wall of BAV, TAV and Marfan syndrome, despite important 
clinical differences. We sought to identify an immunohistochemical explanation 
for the increased susceptibility for aortic dissections in Marfan syndrome, even 
in a non-dilated aortic wall, and at a younger age as compared to the BAV 
and TAV. The aortic media in Marfan syndrome showed a similar immature 
state of the vascular smooth muscle cells as in BAV. In both patient groups 
the level of expression of fibrillin-1 was also found decreased together with an 
altered distribution and localization of the protein as compared to the TAV. As 
fibrillin-1 is produced by vascular smooth muscle cells, a significant decrease 
of fibrillin-1 is plausible, also without apparent fibrillin-1 gene mutations, due to 
the less well differentiated vascular smooth muscle cells. 
The media in Marfan syndrome however also showed some histopathological 
resemblance with the dilated TAV group being significant cytolytic necrosis 
also referred to as medial necrosis, vascular smooth muscle cell apoptosis 
(programmed cell death) and degradation of the elastic lamellae. Vascular 
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smooth muscle cell apoptosis, which leads to cytolytic necrosis, however 
seems to occur due to a different pathogenetic mechanism in Marfan syndrome 
as compared to the dilated TAV group. In the dilated TAV ageing, accompanied 
by an increased progerin expression, and atherosclerosis causes vascular 
smooth muscle cell apoptosis, whereas these features were not apparent in 
the Marfan syndrome. In Marfan syndrome, vascular smooth cell apoptosis 
and subsequent cytolytic necrosis can occur as a direct consequence of the 
fibrillin-1 gene mutation which leads to an increased Angiotensin II receptor 
signaling in Marfan syndrome. This combination of immaturity of the aortic 
media and cytolytic necrosis, renders the aortic wall very weak. These 
observations could explain why angiotensin-receptor-blockers as losartan, 
which reduce signaling through Angiotensin II receptor, have been identified 
as a potentially therapeutic agent to prevent progressive dilation of the aorta in 
Marfan syndrome. In BAV such medical treatment is not as effective because 
the pathology in the aortic wall in BAVs is not characterized by cytolytic necrosis. 
In Chapter 7 we investigated the expression of Wilms tumor suppressor 
protein (Wt1), which has been found to become active in response to 
pathologic conditions in epicardial cells covering the myocardium of the heart. 
We hypothesized that the arterial epicardium might show a similar response 
in pathologic conditions. Wt1, retinaldehyde dehydrogenase-II (RALDH2), a 
downstream target of Wt1, and eNOS, which regulates Wt1 expression, were 
studied in the arterial epicardium in the BAV, TAV and Marfan syndrome. In 
search of the missing link between eNOS and matrix metalloproteinase (MMP9) 
in the phosphorylated c-Kit cascade described in Chapter 5, Wt1, RALDH2 
and eNOS were also studied in the endothelial cells and medial vascular 
smooth muscle cells. From this study we could conclude that in all non-dilated 
patients, a baseline activity of Wt1 is present in epicardial and vascular smooth 
muscle cells. In the dilated TAV group features of cardiovascular ageing as 
inflammation and increased progerin expression, which are not present in the 
dilated BAV group, lead to an increased Wt1 activity. 
We have shown earlier (Chapter 5) that within the non-dilated BAV group a 
subset of patients can be distinguished with an increased susceptibility for 
future aortic wall pathology on basis of the expression pattern of a panel 
of markers. The ‘susceptible group’ showed an increased expression of 
phosphorylated c-Kit, HIF1α, eNOS and MMP9. In this study we found that 
the Wt1 expression in the susceptible group is also significantly higher as 
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compared to the remainder of the non-dilated BAV group. Wt1 is a transcription 
factor that acts as a gene repressor, which can participate in transcriptional 
regulation of MMP9 too. It has been reported earlier that eNOS stimulates the 
shuttle of Wt1 from the nucleus (where it is active) to the cytoplasm (where it 
loses its repressor activity). It is therefore plausible that the increased eNOS 
expression in the susceptible group leads to an enhanced MMP9 expression 
in this group, which subsequently stimulates the phosphorylation of c-Kit. 
In this thesis we have added some new perspectives to the problem of decision 
making regarding patients with BAV  and associated aortic wall pathology. The 
recommending guidelines for surgery are up till now mainly based on aortic 
diameter, although already some exceptions for patients with BAV are made 
in practice (1). In this guideline a distinction between BAV patients with and 
without risk factors is made, eluding to the fact that not all BAV patients are 
equal. Our studies underline that exclusive use of aortic wall dimensions is not 
sufficient in selecting patients vulnerable for future aortic wall complications. 
It is however not possible as yet to make a direct extrapolation from our 
histopathology observations in a patient to the clinical practice. We should 
therefore, in future research, focus on the translation of the histopathology 
findings to 1) blood borne markers, 2) on site biopsy evaluation during 
surgery, as performed in research of malignancies, 3) refinement of imaging 
techniques, which can be applied in the clinical practice, to distinguish the 
susceptible from the non-susceptible cases with BAV. 
An important aspect which has not received sufficient attention in our current 
work is the follow up of patients after the aortic valve surgery. Several studies 
have indicated that in cases of an isolated aortic valve replacement the risk of 
postoperative ascending aortic dilation is minimized (2-5). Whereas Yasuda 
et al. indicated in their study that the aorta grows faster in BAV patients even 
after an aortic valve replacement has been performed (6).
Recent publications take the discussion on the role of haemodynamics in 
BAV patients in the development of aortic wall dilation to another level. This 
report focusses on a difference in dilation progress dependent on whether the 
diseased aortic valve was stenotic or regurgitant with concomitant root dilation 
(7) in the latter. It is argued that the aortic dilation in the “stenotic phenotype” 
is a functional haemodynamic induced problem, while the aortic wall problem 
in the “root phenotype” is genetically determined. We, however, do not 
completely agree on this differentiation into two main groups, as this cannot 
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be supported from a developmental point of view. All BAVs are intrinsically a 
congenital malformation and we have shown that this developmental disorder 
most probably also involves the wall of the ascending aorta independent of a 
stenotic or a root phenotype. From our studies we could also not divide our 
cases in pure stenotic and regurgitant phenotypes as in many cases both 
phenomena are encountered.  In future, besides a prospective clinical follow 
up of the study population after aortic valve replacement, it would thus also 
be valuable to expand the histopathology research subdivided on clinically 
well-defined stenotic and root phenotype patients. Thereby investigating in 
more detail the influence of the jet stream site using the opposite site of the 
aortic wall as a control. Most importantly this should include patients without 
an overt dilation as this category is not mentioned in the literature as yet. 
Haemodynamic markers should include shear stress responsive factors such 
as Krüppel like factor 4 ( KLF4) (8). 
These detailed studies might also shed more light on our consistent observation 
of diminished expression of maturation markers including alpha smooth actin 
both in the dilated and the non-dilated BAV aortic walls. This can confirm or 
exclude the possibility that shear stress, which is the frictional force acting in 
the direction of blood flow on the inner surface of blood vessels, is the cause 
of an inhibition of the expression of maturation vascular smooth muscle cell 
markers as has been observed in in vitro studies (9).
The localization of aortic wall dilation is typically different between patients 
with Marfan syndrome and BAV patients (10). Molecular biological research 
has shown that in Marfan syndrome fibrillin-1 mutations, typical for Marfan 
patients, lead to an increased Angiotensin II receptor signaling and 
subsequent induction of TGFβ signaling (11). In BAV patients a reduction of 
fibrillin-1 protein expression and rarely a mutation in the fibrillin-1 gene has 
also been described (Chapter 6, (12;13)). We, however, showed in our study 
that the expression level of TGFβ is significantly lower in the dilated BAVs 
as compared to controls, thus differentiating them from the Marfan patient 
with a fibrillin-1 mutation. It is therefore interesting to investigate whether the 
reported Angiotensin receptor increase in Marfan patients is also found in the 
wall of BAV patients or that this phenomenon is purely linked to the mutation 
and not to the observed diminished expression of fibrillin-1 protein as seen in 
both Marfan and BAV. The results might be relevant for the understanding of 
the difference in treatment results between Marfan and BAV patients after use 
of Angiotensin receptor blockers. 
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Bij patiënten met een bicuspide aortaklep (BAV), bestaat de klep uit twee 
klepblaadjes in plaats van drie (tricuspide aortaklep, TAV). Patiënten 
met BAV hebben vergeleken met TAV patiënten een verhoogd risico op 
complicaties van de aortaklep en van de grote lichaamsslagader, de aorta. 
Een veel voorkomende complicatie is een verwijding van het eerste deel 
van de aorta, de aorta ascendens, met bijbehorende vaak lethale problemen 
als een ruptuur of een dissectie (een scheur van de binnenste laag van de 
vaatwand). Bij een deel van de BAV patiënten wordt echter nooit pathologie 
van de aorta gezien. Het is daarom van essentieel belang om de patiënten 
die minder gevoelig zijn voor aorta pathologie te identificeren, aangezien 
een preventieve ingreep om de aorta te vervangen in deze groep patiënten 
niet noodzakelijk is. Tot op heden is de besluitvorming voor aortachirurgie 
gebaseerd op de maximale doorsnede van de aorta ascendens. Uit eerder 
onderzoek is echter gebleken dat alleen de diameter onvoldoende is om 
patiënten met een verhoogd risico te selecteren voor chirurgie. Het zou dus 
waardevol zijn als er patiënt specifieke criteria opgesteld kunnen worden 
voor de selectie van patiënten voor een (preventieve) operatieve ingreep 
van de aorta. 
Het doel van deze studie is het onderzoeken van klinische, morfologische en 
moleculair biologische factoren die BAV patiënten kunnen identificeren, met 
op dit moment een niet-gedilateerde aorta maar wel een verhoogd risico op 
aorta dilatatie in de toekomst. 
Daarnaast wordt het pathobiologische mechanisme dat leidt tot complicaties 
van de aorta vergeleken tussen BAV patiënten en patiënten met het Marfan 
syndroom (MFS), die ook een verhoogde kans hebben op aorta pathologie. 
In Hoofdstuk 1 wordt de ontwikkeling van BAV beschreven en een overzicht 
gegeven van veel voorkomende complicaties. Het doel van deze studie wordt 
verder toegelicht en de indeling van de hoofdstukken wordt weergeven. 
In Hoofdstuk 2 worden histologische en moleculair genetische aspecten 
van de normale en abnormale ontwikkeling van de aortawand en de 
aortaklep bediscussieerd. In dit review beschrijven we hoe een defect in 
de vroege ontwikkeling kan leiden tot een verstoring van de bijdrage van 
twee belangrijke embryonale cel populaties, namelijk de neurale lijst cellen 
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en cellen van het “second heart field”, aan de zich ontwikkelende klep en 
aortawand.
De genetische oorsprong van syndromen die geassocieerd zijn met aorta 
dilatatie (waaronder MFS, Ehlers-Danlos, Smad3 mutaties en Loeys-Dietz) 
wordt verder besproken. De centrale rol van TGFβ hierin wordt bediscussieerd 
en gekoppeld  aan de embryonale ontwikkeling. In dit review concluderen we 
dat BAV en de aorta pathologie die met deze klepafwijking geassocieerd is 
het gevolg kan zijn van een defect tijdens de embryonale ontwikkeling. Deze 
ontwikkelingsbiologische verklaring is echter niet voldoende om de klinische 
heterogeniteit in BAV te verklaren, aangezien niet alle BAV patiënten aorta 
complicaties ontwikkelen gedurende hun leven. Om de patiënten te kunnen 
identificeren die een verhoogd risico lopen op aortadilatatie, moeten we eerst 
de pathobiologie van de vaatwand die alle BAV patiënten gemeen hebben 
onderzoeken en vergelijken met de TAV patiënten. Dit wordt beschreven in 
het volgende hoofdstuk. 
In Hoofdstuk 3 worden verschillen in de aortawand beschreven tussen 
BAV en TAV patiënten. Biopten van de aortawand zijn onderzocht van zowel 
gedilateerde (BAD en TAD respectievelijk) als niet-gedilateerde (BA en TA 
respectievelijk) vaten. De vaatwanden werden onderzocht op de expressie 
van gedifferentieerde gladde spiercelmarkers, lamin A/C, dat een belangrijke 
rol speelt in de gladde spiercel differentiatie, en progerin, een marker indicatief 
voor cardiovasculaire veroudering. Uit dit onderzoek bleek dat de structuur 
van zowel de gedilateerde als de niet-gedilateerde aortawand intrinsiek 
anders is in de BAV vergeleken met de TAV. In the BAV is de gevonden 
lagere lamin A/C expressie mogelijk geassocieerd met een defecte gladde 
spierceldifferentiatie. Deze vaatwand immaturiteit, die de aortawand kan 
verzwakken, wordt dus in alle BAV patiënten gezien, inclusief de patiënten 
die minder gevoelig zijn voor aorta complicaties. Om de patiënten te 
kunnen identificeren die verhoogd kwetsbaar zijn voor pathologie van de 
aortawand, zijn we verder gaan zoeken naar voorspellende klinische en 
immunohistochemische markers. 
Hoofdstuk 4 richt zich op klinische kenmerken die kunnen bijdragen aan 
het identificeren van BAV patiënten met een verhoogde gevoeligheid 
voor pathologie van de aorta. Een studiepopulatie van 255 patiënten 
werd onderzocht op demografische kenmerken, het klinisch beloop en 
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echografische parameters, waaronder de morfologie van de aortaklep. In 
dit hoofdstuk wordt een klinisch risicomodel gepresenteerd om patiënten 
met een verhoogde gevoeligheid op complicaties te identificeren. Dit 
werkmodel laat zien dat mannen met een complete fusie van het rechter 
en linker coronaire klepblad,  met een hoge bloeddruk en zonder gebruik 
van cholesterolremmers het hoogste risico lopen en frequenter gemonitord 
moeten worden. 
Hoofdstuk 5 beschrijft de zoektocht naar moleculair biologische markers 
die gebruikt kunnen worden om patiënten met een verhoogde kans op 
aortacomplicaties te identificeren. Hiervoor werden niet- en gedilateerde 
ascenderende aortawand biopten van BAV en TAV patiënten onderzocht. 
De markers die geïdentificeerd werden konden gekoppeld worden in een 
signaleringscascade die kenmerkend is voor cellulaire de-differentiatie. De 
markers zijn: c-Kit, een marker voor ongedifferentieerde gladde spiercellen 
en de gefosforyleerde vorm gefosforyleerde-c-Kit (pc-Kit). De fosforylatie van 
c-Kit wordt aangedreven door de aanwezigheid van matrix metalloproteinase-9 
(MMP9).  Pc-Kit stuurt vervolgens de expressie van Hypoxia-Inducible-
Factor-1alpha (HIF1α) en endothelial nitric oxide (eNOS) aan. Deze cascade 
was geactiveerd in de gedilateerde BAV groep en de expressie was volledig 
vergelijkbaar met slechts een subgroep van de BA groep. Terwijl de rest van 
de BA groep een significant afwijkende expressiepatroon toonde. Dit verschil 
was ook te zien in de expressie van TGF-β en gefosforyleerde Smad2. Naast 
het expressiepatroon, waren overeenkomsten tussen de gedilateerde BAV 
groep en de subgroep van de niet-gedilateerde BAV groep ook duidelijk te 
zien in commissuur positie en de plaats van de raphe, namelijk een fusie 
tussen het rechter en linker coronair klepblad. Dit kwam overeen met onze 
bevindingen in  Hoofdstuk 4. Op grond van deze observaties beschouwen 
we de BAb groep in tegenstelling tot de BAa groep als mogelijke kandidaat 
voor aortadilatatie in de toekomst. 
In dit hoofdstuk beschrijven we ook de rol van hemodynamiek in de 
ontwikkeling van aorta pathologie. Hiervoor zijn biopten van de vaatwand 
onderzocht en vergeleken die verkregen waren van de convexe en concave 
zijde van de aorta. We hebben in de BAV patiënten geen significant effect 
van een veranderde hemodynamiek gevonden op het ontwikkelen van 
aortacomplicaties. 
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In Hoofdtuk 6 hebben we de aortawand van BAV en TAV patiënten 
vergeleken met een syndroom dat een zeer verhoogd risico op aortawand 
pathologie heeft, namelijk het MFS. Van alle MFS gevallen wordt 90-95% 
veroorzaakt door mutaties in het FBN1 (fibrilline-1) gen. In dit hoofdstuk 
werden de histopathologische overeenkomsten onderzocht tussen de aorta 
van de BAV, TAV en MFS patiënten. We hebben verder gezocht naar een 
immunohistochemische verklaring voor de verhoogde gevoeligheid van 
MFS patiënten voor het ontwikkelen van een aortadissectie, die zelfs gezien 
wordt in een niet gedilateerde aorta en op een jongere leeftijd vergeleken 
met de BAV en TAV patiënten. In MFS waren de gladde spiercellen in de 
media van de aorta, net als in de BAV, immatuur. In beide patiënten groepen 
was de expressie van fibrillin-1 ook verlaagd samen met een veranderde 
distributie en lokalisatie van het eiwit in vergelijking tot de TAV. Aangezien 
fibrillin-1 wordt geproduceerd door gladde spiercellen is het aannemelijk 
dat een verminderde expressie van fibrillin-1 ook kan voorkomen in minder 
gedifferentieerde vaten, terwijl er geen FBN1 mutatie is zoals in de BAV 
het geval is.  De MFS liet echter ook histopathologische overeenkomsten 
zien met de gedilateerde TAV zoals significante cytolytische necrose (CN) 
(verlies van gladde spiercelkernen in de media), gladde spiercel apoptose 
en degradatie van de elastische lamellen. De oorzaak van gladde spiercel 
apoptose, dat leidt tot CN, is echter anders in de MFS dan in de gedilateerde 
TAV groep. In de gedilateerde TAV veroorzaakt cardiovasculaire veroudering, 
met een verhoogde expressie van progerin, atherosclerose en inflammatie, 
terwijl deze verschijnselen in de MFS niet voorkomen, In MFS veroorzaakt de 
FBN1 mutatie direct gladde spiercel apoptose, via een verhoogde signalering 
van de Angiotensin II receptoren (AGTR). In MFS is er dus een combinatie 
van immaturiteit van de media en CN die de vaatwand extreem zwak maakt. 
Deze bevindingen verklaren ook waarom angiotensin-receptor-blokkers 
(ARBs) zoals losartan, die de signalering via de AGTRs verminderen, in MFS 
als preventief medicijn werken om dilatatie van de aorta tegen te gaan. In 
BAV werken deze medicijnen niet of nauwelijks omdat de aortwand in deze 
groep patiënten geen tekenen van CN laat zien. 
In Hoofdstuk 7 hebben we het expressiepatroon van Wilms tumor suppressor 
protein (Wt1) onderzocht, waarvan uit eerder onderzoek is gebleken dat 
het als reactie op pathologische omstandigheden geactiveerd wordt in de 
epicardcellen die het hart omgeven. Wij hypothetiseren dat de buitenste 
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cellaag van de ascenderende aorta, het arteriële epicard, een zelfde 
mechanisme vertoont onder pathologische omstandigheden. We hebben 
het arteriële epicard in BAV, TAV en MFS onderzocht op de expressie van 
Wt1, Retinaldehyde dehydrogenase-II (RALDH2), dat onder transcriptionele 
regulatie staat van Wt1 en eNOS, dat de Wt1 expressie reguleert. De 
expressie van deze drie markers werd ook in de endotheelcellen en de 
gladde spiercellen onderzocht, met als doel het kunnen linken van eNOS 
en MMP9 beschreven in de cascade in Hoofdstuk 5. In deze studie konden 
we concluderen dat in de epicardcellen en gladde spiercellen van alle niet-
gedilateerde vaten een basis Wt1 activiteit aanwezig is. In de gedilateerde 
TAV leiden kenmerken van cardiovasculaire veroudering zoals inflammatie en 
een verhoogde progerin expressie, die niet aanwezig zijn in de gedilateerde 
BAV groep, tot een significant hogere Wt1 activiteit.
We hebben eerder beschreven (Hoofdstuk 5) dat er binnen de niet-
gedilateerde BAV groep, op basis van het expressiepatroon van een 
moleculair biologisch pad, een subgroep geindentificeerd kan worden met 
een verhoogde kans op complicaties van de aorta. Deze groep vertoont een 
verhoogde expressie van pc-Kit, HIF1α, eNOS en MMP9. In deze studie 
hebben we aangetoond dat Wt1 expressie in de ‘ gevoelige patiënten’ 
ook significant hoger is vergeleken met de rest van de niet gedilateerde 
BAV groep. Wt1 is een trancriptiefactor dat een belangrijke rol speelt als 
onderdrukker van genexpressie, waaronder dat van MMP9. Daarnaast is 
eerder ook beschreven dat eNOS de verplaatsing van Wt1 uit de kern (waar 
Wt1 actief is) naar het cytoplasma (waar Wt1 de onderdrukkende functie 
verliest) stimuleert. Het is daarom aannemelijk dat de toegenomen eNOS 
expressie in de ‘gevoelige patiënten’ kan leiden tot een verhoogde MMP9 
expressie, dat vervolgens de fosforylering stimuleert van c-Kit. 
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LIST OF ABBREVIATIONS 
ACEinhibitor: Angiotensin-converting-enzyme inhibitor
ALK2:  Activin type I receptor
AMC:  Academic Medical Center
aPEO:  Arterial proepicardial organ
ARBs:  Angiotensin-receptor-blockers
αSMA:  α Smooth muscle actin
AT2 receptor: Angiotensin II receptor
AXIN1:  Axis Inhibitor 1
BA:  Bicuspid aortic valve without dilation
BAa:  Bicuspid aortic valve without dilation, non-susceptible   
  group
BAb:  Bicuspid aortic valve without dilation, susceptible group
BAD:   Bicuspid aortic valve with dilation
BAV:   Bicuspid aortic valve
BMP:  Bone morphogenetic protein
BSA:   Bovine serum albumin
CN:  Cytolytic necrosis
DAB:   Diaminobenzidine tetrachloride
DAPI:  4’,6-diamidino-2-phenylindole
EMC:  Erasmus Medical Center
eNOS:  Endothelial nitric oxide
FBN1:  Fibrillin-1
Fgf8:  Fibroblast growth factor 8
NO:  Nitric oxide
GAPDH:  Glyceraldehyde-3-phosphate dehydrogenase
GAR:  Goat-anti-rabbit-biotin
HAM:  Horse-anti-mouse-biotin
HE:  Hematoxylin-Eosin 
HIF1α:  Hypoxia-Inducible-Factor-1alpha
IgG:  Immunoglobulin G
LCC:  Left coronary cusp 
LUMC:  Leiden University Medical Center
MF:   Microscopic field
MFS:  Marfan syndrome
MMP9:  Matrix metalloproteinase-9
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NCC:  Non-coronary cusp
NGS:  Normal goat serum
NHS:   Normal horse serum
PBS:   Phosphate buffered saline
PBS-T:  Phosphate buffered saline with 0.05% Tween-20
pc-Kit:  Phosphorylated c-Kit
pSmad2: Phosphorylated Smad2
RALDH2: Retinaldehyde dehydrogenase-II
RAM-PO:  Peroxidase-conjugated rabbit anti-mouse
RCC:  right coronary cusp
RF:  Resorcin-Fuchsin
SD:  Standard deviation
SHF:  Second heart field 
SM22α:  Smooth muscle 22α
TA:   Tricuspid aortic valve without dilation
TAD:   Tricuspid aortic valve with dilation
TAV:   Tricuspid aortic valve
TGF-β: Transforming growth factor β 
Type 1 BAV: Fusion between the RCC and LCC
Type 2 BAV:  Fusion between the RCC and NCC
Type 3 BAV: Fusion between the LCC and NCC
VSMC:  Vascular smooth muscle cell
Wt1:  Wilms tumor suppressor protein
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